James Brooks Profile Stanford Profiles Stanford Profiles Menu Browse Schools Graduate School of Business Graduate School of Education School of Earth Energy and Environmental Sciences School of Engineering School of Humanities and Sciences School of Medicine Institutes Research Centers Freeman Spogli Institute for International Studies Institute for Computational and Mathematical Engineering ICME Institute for Artificial Intelligence HAI Institute for Stem Cell Biology and Regenerative Medicine Precourt Institute for Energy SLAC National Accelerator Laboratory Stanford Stanford Institute for Economic Policy Research SIEPR Stanford PULSE Institute Stanford Woods Institute for the Environment Wu Tsai Neurosciences Institute Administration Office of External Relations Office of VP for University Human Resources Office of Vice President for Business Affairs and Chief Financial Officer Stanford University Libraries Vice Provost and Dean of Research Vice Provost for Student Affairs Vice Provost for Undergraduate Education Sign In Edit My Profile James Brooks Keith and Jan Hurlbut Professor in the Stanford University School of Medicine Urology Practices at Stanford Hospital and Clinics Print Profile Email Profile View Profile Tab Menu Bio Research Scholarship Teaching Publications Clinical Focus Cancer Urologic Oncology Prostate cancer screening Prostate cancer localized Prostate cancer active surveillance Urology Academic Appointments Professor Urology Member Member Maternal Child Health Research Institute MCHRI Member Stanford Cancer Institute Administrative Appointments Molecular and Cellular Characterization Centers NCI 2015 2017 Nominating Committee Society of Basic Urologic Research 2015 2017 Vice Chair Department of Urology 2014 Present Associate Dean Academic Affairs Stanford University School of Medicine 2013 2019 Chief Urologic Oncology Department of Urology 2012 Present Acting Chair Department of Urology 2012 2012 Editorial Board Andrology 2011 Present Associate Chair Prostate Cancer Working Group EDRN 2010 2015 Editorial Board Prostate Cancer 2010 2015 The Open Prostate Cancer Journal 2008 2015 Membership Committee Society for Basic Urologic Research 2004 2008 Editorial Board The Prostate 2000 Present Honors Awards Dornier Research Scholar American Foundation for Urologic Disease Clinician Scientist Award Doris Duke Foundation Eugene Schonfeld Medical Research Award Kidney Cancer Association Faculty Scholar Stanford University School of Medicine Best Doctors in America Best Doctors Listing in Guide to America Top Surgeons Consumers Research Council 2010 Keith and Jan Hurlbut Professor Stanford University 2012 Professional Education Medical Education Stanford University School of Medicine 1988 CA Residency Johns Hopkins University Surgery Program 1990 MD Internship Johns Hopkins University Surgery Program 1989 MD Fellowship Johns Hopkins University School of Medicine 1997 MD Residency Johns Hopkins University School of Medicine 1994 MD Board Recertification Urology American Board of Urology 2017 Board Certification American Board of Urology Urology 2000 A University of Chicago Biology 1982 Contact Academic University Faculty Department nbspUrology Divisions Position Professor GRANT S287 Stanford California Clinical Clinic 875 Blake Wilbur Dr Clinic E MC 6513 Stanford CA 94305 650 office 650 fax Additional Info Mail Code 5118 Links Stanford Center for Urologic Genomics Current Research and Scholarly Interests Our interest is in developing diagnostic and prognostic markers for urological diseases Our work spans discovery measurement methodologies and clinical validation of candidate biomarkers We have primarily used genomic and proteomic approaches for biomarker discovery While our primary focus has been in prostate cancer we have also worked in kidney cancer and other malignancies We are also working to characterize the functional roles of several of the candidate biomarkers in cancer In the past several years our work has expanded into benign urologic diseases including benign prostatic hyperplasia obstructive nephropathy and androgen insensitivity syndrome In collaboration with bioengineers and radiologists we have active research in molecular imaging and protein and nucleotide detection on biological samples We also participate in several large clinical trials for development validation and implementation of clinical biomarkers in prostate cancer Clinical Trials Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma Recruiting This pilot clinical trial studies perfusion computed tomography CT in predicting response to treatment in patients with advanced kidney cancer Comparing results of diagnostic procedures done before during and after targeted therapy may help doctors predict a patient response to treatment and help plan the best treatment View full details Prostate Active Surveillance Study Recruiting The Prostate Active Surveillance Study PASS is a research study for men who have chosen active surveillance as a management plan for their prostate cancer Active surveillance is defined as close monitoring of prostate cancer with the offer of treatment if there are changes in test results This study seeks to discover markers that will identify cancers that are more aggressive from those tumors that grow slowly View full details Prostate Cancer Upgrading Reference Set Recruiting Research repository designed to establish prostate cancer upgrading reference set and development of a risk prediction tool Repository will include clinical information and biologics on a cohort of 240 men to predict presence of high grade cancer at time of prostatectomy removal of prostate among patients with a low grade cancer diagnosis at time of biopsy View full details Quality of Life Following Radical Prostatectomy Recruiting This study will utilize the Expanded Prostate Cancer Index Composite questionnaire to learn what impact the surgery has upon the participant sense of health sexual and urinary quality of life View full details A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer Not Recruiting Pilot study to evaluate the ability of BR55 to identify prostate cancer lesions with Gleason Score by ultrasound molecular imaging on the basis of a visual score in comparison with histopathology results Stanford is currently not accepting patients for this trial For more information please contact Phuong Pham View full details Hypofractionated Radiotherapy for Localized Prostate Cancer With CyberKnife or With IMRT Not Recruiting To demonstrate that a course of radiotherapy ie an accelerated radiotherapy course where fewer but larger doses of radiotherapy are given is both safe and effective in the treatment of localized prostate cancer Stanford is currently not accepting patients for this trial For more information please contact Gillian McFarlane 650 721 2034 View full details Imaging During Surgery in Diagnosing Patients With Prostate Bladder or Kidney Cancer Not Recruiting This pilot clinical trial studies imaging during surgery in diagnosing patients with prostate bladder or kidney cancer New diagnostic imaging procedures may find prostate bladder or kidney cancer Stanford is currently not accepting patients for this trial For more information please contact Mark Gonzalgo View full details Microarray Analysis of Gene Expression in Prostate Tissues Not Recruiting The purpose of this study is to investigate gene expression profiles and biologic features of prostate tissue and how they relate to prostate cancer development and growth Stanford is currently not accepting patients for this trial For more information please contact Cancer Clinical Trials Office View full details Photoacoustic Imaging PAI of the Prostate A Clinical Feasibility Study Not Recruiting The purpose of our study is to image human prostate tissue using a transrectal photoacoustic imaging probe Stanford is currently not accepting patients for this trial For more information please contact Kothapalli View full details Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia Not Recruiting The purpose of this study is to evaluate improvement of symptoms from benign prostatic hyperplasia BPH as assessed by the International Prostate Symptom Score IPSS for prostatic artery embolization PAE using Embosphere Microspheres compared to conventional transurethral resection of the prostate TURP Stanford is currently not accepting patients for this trial For more information please contact Denise Haas View full details Courses Independent Studies 5 Directed Reading in UrologyUROL 299 Aut Win Spr Sum Early Clinical Experience in UrologyUROL 280 Aut Win Spr Sum Graduate ResearchUROL 399 Aut Win Spr Sum Medical Scholars ResearchUROL 370 Aut Win Spr Sum Undergraduate ResearchUROL 199 Aut Win Spr Sum Stanford Advisees Postdoctoral Faculty Sponsor okyaz Eminaga Ru Wen Postdoctoral Research Mentor okyaz Eminaga Ru Wen Graduate and Fellowship Programs Cancer Biology Phd Program All Publications association study of survival with prostate cancer Cancer Sohlberg Thomas Yang Kapphahn Velaer Goldstein Wagner Chertow Brooks Patel Desai Leppert 2020 Abstract BACKGROUND Estimates of overall patient health are essential to inform treatment decisions for patients diagnosed with cancer The authors applied XWAS methods herein referred to as association study LWAS to evaluate associations between routinely collected laboratory tests and survival in veterans with prostate The authors identified patients who were diagnosed with prostate cancer between 2000 and 2013 in the Veterans Health Administration using any laboratory tests collected within 6 months of diagnosis results Using the LWAS framework the rate was used to test the association between multiple laboratory tests and survival and these results were validated using training testing and validation A total of 31 laboratory tests associated with survival met stringent LWAS criteria LWAS confirmed markers of prostate cancer biology antigen hazard ratio HR 95 confidence interval 95 CI and alkaline phosphatase HR 95 CI as well laboratory tests of general health eg serum albumin HR 95 CI and creatinine HR 95 CI and inflammation leukocyte count HR 95 CI and erythrocyte sedimentation rate HR 95 CI In addition the authors derived and validated separate models for patients with localized and advanced disease identifying 28 laboratory markers and 15 laboratory markers respectively in each The authors identified routinely collected laboratory data associated with survival for patients with prostate cancer using LWAS methodologies including markers of prostate cancer biology overall health and inflammation Broadening consideration of determinants of survival beyond those related to cancer itself could help to inform the design of clinical trials and aid in shared decision SUMMARY This article examined routine laboratory tests associated with survival among veterans with prostate cancer Using association studies the authors identified 31 laboratory tests associated with survival that can be used to inform the design of clinical trials and aid patients in shared decision making View details for DOI View details for PubMedID 33237577 Sprr2f protects against renal injury by decreasing the level of reactive oxygen species in female mice American journal of physiology Renal physiology Huynh Wong Wu Horschman Zhao Brooks 2020 Abstract Renal injury leads to chronic kidney disease for which women are not only more likely to be diagnosed with than men but have poorer outcomes as well We have previously shown that expression of Sprr2f a member of the Small Proline Rich Region Sprr gene family is increased several after renal injury using a unilateral ureteral obstruction UUO mouse model To better understand the role of Sprr2f in renal injury we generated a Sprr2f knockout mouse model using technology female mice showed greater renal damage after UUO compared to wild type animals evidenced by higher hydroxyproline levels and denser collagen staining indicating a protective role of Sprr2f during renal injury Gene expression profiling by identified 162 genes whose expression levels were significantly different between day 0 and day 5 after UUO in mice Out of the 162 genes 121 were upregulated after UUO and enriched with those involved in a phenomenon not observed in wild type animals suggesting a protective role of Sprr2f in UUO through defense against oxidative damage Consistently bilateral ischemia reperfusion injury resulted in higher serum blood urea nitrogen level and higher tissue reactive oxygen species ROS in compared to female mice Moreover cultured renal epithelial cells from female mice showed lower viability after oxidative damage induced by menadione compared to cells that could be rescued by supplementation with reduced glutathione suggesting that Sprr2f induction after renal damage acts as a defense against ROS View details for DOI View details for PubMedID 33017192 Tailoring Intensity of Active Surveillance for Prostate Cancer Based on Individualized Prediction of Risk Stability JAMA oncology Cooperberg Zheng Faino Newcomb Zhu Cowan Brooks Dash Gleave Martin Morgan Nelson Thompson Wagner A Carroll Lin 2020 e203187 Abstract Importance Active surveillance is increasingly recognized as the preferred standard of care for men with prostate cancer However active surveillance requires repeated assessments including antigen tests and biopsies that may increase anxiety risk of complications and To identify and validate clinical parameters that can identify men who can safely defer prostate cancer Setting and Participants The Canary Prostate Active Surveillance Study PASS is a multicenter prospective active surveillance cohort study initiated in July 2008 with ongoing accrual and a median period of years Men with prostate cancer managed with active surveillance from 9 North American academic medical centers were enrolled Blood tests and biopsies were conducted on a defined schedule for least 5 years after enrollment Model validation was performed among men at the University of California San Francisco UCSF who did not enroll in PASS Men with Gleason grade group 1 prostate cancer diagnosed since 2003 and enrolled in PASS before 2017 with at least 1 confirmatory biopsy after diagnosis were included A total of 850 men met these criteria and had adequate For the UCSF validation study 533 active surveillance patients meeting the same criteria were identified Exclusion criteria were treatment within 6 months of diagnosis diagnosis before 2003 Gleason grade score of at least 2 at diagnosis or first surveillance biopsy no surveillance biopsy or missing Active surveillance for prostate Outcomes and Measures Time from confirmatory biopsy to reclassification defined as Gleason grade group 2 or higher on subsequent A total of 850 men median interquartile range age 64 years 774 91 White were included in the PASS cohort A total of 533 men median interquartile range age 61 years 422 79 White were included in the UCSF cohort Parameters predictive of reclassification on multivariable analysis included maximum percent positive cores hazard ratio HR 95 CI history of any negative biopsy after diagnosis 1 vs 0 HR 95 CI P and vs 0 HR 95 CI P time since diagnosis HR 95 CI P body mass index HR 95 CI P prostate size HR 95 CI P antigen at diagnosis HR 95 CI and antigen kinetics HR 95 CI P For prediction of nonreclassification at 4 years the area under the receiver operating curve was for the PASS cohort and for the UCSF validation cohort This model achieved a negative predictive value of 95 CI for those in the bottom 25th percentile of risk and of 95 CI for those in the bottom 10th and Relevance In this study among men with prostate cancer heterogeneity prevailed in risk of subsequent disease reclassification These findings suggest that active surveillance intensity can be modulated based on an individual risk parameters and that many men may be safely monitored with a substantially less intensive surveillance regimen View details for DOI View details for PubMedID 32852532 AZGP1 Protein Expression in Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy Diagnostics Basel Switzerland Winther Kristensen Stroomberg Berg Toft Brooks Brasso Roder A 2020 10 8 Abstract Biomarkers for predicting the risk of prostate cancer CRPC in men treated with primary androgen deprivation therapy ADT are lacking We investigated whether 2 glycoprotein AZGP1 expression in the diagnostic biopsies of men with prostate cancer PCa undergoing primary ADT was predictive of the development of CRPC and mortality The study included 191 patients who commenced ADT from 2000 to 2011 The AZGP1 expression was evaluated using immunohistochemistry and scored as high or low expression The risks of CRPC and mortality were analyzed using stratified cumulative incidences and a COX regression analysis for competing risk assessment The median time was IQR years In total 94 and 97 patients presented with low and high AZGP1 expression respectively A low AZGP1 expression was found to be associated with a shorter time to CRPC when compared to patients with a high AZGP1 expression HR 95 CI p However the multivariable analysis demonstrated no added benefit by adding the AZGP1 expression to prediction models for CRPC No differences for mortality between the AZGP1 groups were observed In conclusion a low AZGP1 expression was associated with a shorter time to CRPC for PCa patients treated with ADT but did not add any predictive information besides clinicopathological variables View details for DOI View details for PubMedID 32726925 Phenotyping severity of outcomes using clinical notes A prostate cancer use case LEARNING HEALTH SYSTEMS Bozkurt Paul Coquet Sun Banerjee Brooks 2020 View details for DOI View details for Web of Science ID 000548944700001 Life expectancy estimates for patients diagnosed with prostate cancer in the Veterans Health Administration Urologic oncology Sohlberg Thomas Yang Kapphahn Daskivich Skolarus Shelton J Makarov Bergman Bang Goldstein Wagner Brooks Desai Leppert 2020 Abstract PURPOSE Accurate life expectancy estimates are required to inform prostate cancer treatment decisions However few models are specific to the population served or easily implemented in a clinical setting We sought to create life expectancy estimates specific to Veterans diagnosed with prostate AND METHODS Using national Veterans Health Administration electronic health records we identified Veterans diagnosed with prostate cancer between 2000 and 2015 We abstracted demographics comorbidities oncologic staging and treatment information We fit Cox Proportional Hazards models to determine the impact of age comorbidity cancer risk and race on survival We stratified life expectancy estimates by age comorbidity and cancer Our analytic cohort included patients Survival modeling demonstrated the importance of age and comorbidity across all cancer risk categories Life expectancy estimates generated from age and comorbidity data were predictive of overall survival 95 CI and visualized using plots and heatmaps stratified by age and comorbidity Separate life expectancy estimates were generated for patients with localized or advanced disease These life expectancy estimates calibrate well across prostate cancer risk Life expectancy estimates are essential to providing prostate cancer care We developed accessible life expectancy estimation tools for Veterans diagnosed with prostate cancer that can be used in routine clinical practice to inform making View details for DOI View details for PubMedID 32674954 Registration of MRI and histopathology images from radical prostatectomy via RAPSODI Medical physics Rusu Shao Kunder Wang J Soerensen Teslovich Sood Chen Fan Ghanouni Brooks Sonn A 2020 Abstract PURPOSE Magnetic resonance imaging MRI has great potential to improve prostate cancer diagnosis however subtle differences between cancer and confounding conditions render prostate MRI interpretation challenging The tissue collected from patients who undergo radical prostatectomy provides a unique opportunity to correlate histopathology images of the prostate with MRI to accurately map the extent of cancer from histopathology images onto MRI We seek to develop an platform to align MRI and histopathology images of resected prostates in patients who underwent radical prostatectomy to create accurate cancer labels on Here we introduce RAdiology Pathology Spatial Integration RAPSODI the first framework for the registration of radiology and pathology images RAPSODI relies on three steps First it creates a 3D reconstruction of the histopathology specimen as a digital representation of the tissue before gross sectioning Second RAPSODI registers corresponding histopathology and MRI slices Third the optimized transforms are applied to the cancer regions outlined on the histopathology images to project those labels onto the We tested RAPSODI in a phantom study where we simulated various conditions tissue shrinkage during fixation Our experiments showed that RAPSODI can reliably correct multiple artifacts We also evaluated RAPSODI in 157 patients from three institutions that underwent radical prostatectomy and have very different pathology processing and scanning RAPSODI was evaluated in 907 corresponding slices and achieved a Dice coefficient of for the prostate a Hausdorff distance of mm for the prostate boundary a urethra deviation of mm and a landmark deviation of mm between registered histopathology images and Our robust framework successfully mapped the extent of cancer from histopathology slices onto MRI providing labels from training machine learning methods to detect cancer on MRI View details for DOI View details for PubMedID 32564359 Association of renal cell carcinoma subtypes with and comorbid medical conditions Lichtensztajn Hofer Leppert Brooks Chung Shah DeRouen Gomez Cheng AMER ASSOC CANCER RESEARCH 2020 View details for DOI View details for Web of Science ID 000580647800537 Testicular cancer in Hispanics Incidence of subtypes over time according to neighborhood sociodemographic factors in California DeRouen McKinley Shah Borno Aoki Lichtensztajn Leppert Brooks Chung Gomez Cheng AMER ASSOC CANCER RESEARCH 2020 View details for DOI View details for Web of Science ID 000580647800288 Testicular cancer in Hispanics incidence of subtypes over time according to neighborhood sociodemographic factors in California Cancer causes control CCC DeRouen McKinley Shah Borno Aoki Lichtensztajn Leppert Brooks Chung Gomez Cheng I 2020 Abstract PURPOSE Hispanic men in the USA experience the incidence rate of testicular germ cell tumors TGCTs behind NH White men and have experienced steep increases in TGCT in recent decades It is unknown whether increases in incidence differ according to neighborhood sociodemographic We conducted a study of Hispanic and NH White men total diagnosed with TGCT in California during the three most recent pericensal periods We calculated incidence rates according to neighborhood socioeconomic status nSES and among Hispanics according to ethnic enclave We calculated incidence rate ratios to compare rates across nSES and ethnic enclave and to examine changes in rates over pericensal time periods according to these neighborhood factors for major histologic types seminoma and nonseminoma Hispanic men residing in high SES compared to low SES neighborhoods had greater incidence of seminoma and nonseminoma testicular cancer across pericensal periods as did Hispanic men in low enclave less ethnic compared to high enclave neighborhoods Between the periods and Hispanic men residing in low SES neighborhoods experienced a 39 increased incidence of seminoma while those residing in low and middle SES neighborhoods experienced 87 and 48 increased incidence of nonseminoma While TGCT incidence has increased among all Hispanic men incidence increases appear to be driven disproportionately by those residing in lower SES and lower enclave neighborhoods particularly for nonseminoma View details for DOI View details for PubMedID 32440828 Detection of prostate cancer and determination of its significance using explainable artificial intelligence Eminaga Loening Lu Brooks Rubin AMER SOC CLINICAL ONCOLOGY 2020 View details for Web of Science ID 000560368302398 Four distinct outcome PRO trajectories in longitudinal responses collected before during and after chemotherapy Blayney Azad Yilmaz Bozkurt Brooks AMER SOC CLINICAL ONCOLOGY 2020 View details for Web of Science ID 000560368301127 The Human Tumor Atlas Network Charting Tumor Transitions across Space and Time at Resolution Cell Regev Oberdoerffer Nawy Hupalowska Rood Ashenberg Cerami Coffey Demir Ding Esplin Ford Goecks Ghosh Gray Guinney Hanlon Hughes Hwang Johnson Lau Lively Mazzilli Santagata Shalek Schapiro Snyder Sorger Spira Srivastava Tan West Williams Human Tumor Atlas Network Aberle Achilefu Ademuyiwa Adey Aft Agarwal Aguilar Alikarami Allaj Amos Anders Angelo Anton Ashenberg Aster Babur Bahmani Balsubramani Barrett Beane Bender Bernt Berry Betts Bletz Blise Boire Boland Borowsky Bosse Bott Boyden Brooks Bueno Burlingame Cai Campbell Caravan Cerami Chaib Chan Chang Chatterjee Chaudhary Chen A Chen Chen Chen Chen Chen Chheda Chin Chiu Chu Chuaqui Chun Cisneros Coffey Colditz Cole Collins Contrepois Coussens Creason Crichton Curtis Davidsen Davies de Bruijn Dellostritto De Marzo Demir DeNardo Diep Ding Diskin Doan Drewes Dubinett Dyer Egger Eng Engelhardt Erwin Esplin Esserman Felmeister Feiler Fields Fisher Flaherty Flournoy Ford Fortunato Frangieh Frye Fulton Galipeau Gan Gao Gao Gao Gao Geiger George Getz Ghosh Giannakis Gibbs Gillanders Goecks Goedegebuure Gould Gowers Gray Greenleaf Gresham Guerriero Guha Guimaraes Guinney Gutman Hacohen Hanlon Hansen Harismendy Harris Hata Hayashi Heiser Helvie Herndon Hirst Hodi Hollmann Horning Hsieh Hughes Huh Hunger Hwang Ijaz Izar Jacobson Janes Jayasinghe Jiang Johnson Johnson Ju Kadara Kaestner Kagan Kalinke Keith Khan Kibbe Kim Kim Kim Kolodzie Kopytra Kotler Krueger Krysan Kundaje Ladabaum Lake B Lam Laquindanum Lau Laughney Lee Lenburg Leonard Leshchiner Levy Li Lian Lim Lin Lin Liu Liu Lively Longabaugh Longacre Ma Macedonia Madison Maher Maitra Makinen Makowski Maley Maliga Mallo Maris Markham Marks Martinez Mashl Masilionais Mason Massague Massion Mattar Mazurchuk Mazutis Mazzilli McKinley McMichael Merrick Meyerson Miessner Mills Mills Mondal Mori Mori Moses Mosse Muhlich Murphy Navin Nawy Nederlof Ness Nevins Nikolov Nirmal Nolan Novikov Oberdoerffer Offin Oh Olson Ooms Ossandon Owzar Parmar Patel Patti Peng Persson Petty Pfister Polyak Pourfarhangi Puram Qiu Raj Rashid Reeb Regev Reid Resnick Reynolds Riesterer Rodig Roland Rosenfield Rotem Roy Rudin Ryser Santagata Sato Schapiro Schrag Schultz Sears Sears Sen Sen Shalek Sheng Sheng Shoghi Shrubsole Shyr Sibley A Siex Simmons Singer Sivagnanam Slyper Snyder Sokolov Song Sorger Spira Srivastava Stein Storm Stover Strand Su Sudar Sullivan Surrey Suva Tan Terekhanova Ternes Thammavong Thibault Thomas Thorsson Todres Tran Tyler Uzun Vachani Van Allen Vandekar Veis Vigneau Vossough Waanders Wagle Wang Wendl West Williams Wu Wu Wu Wyczalkowski Xie Yang Yapp Yu Yuan Zhang Zhang Zhang Zhang Zhang Zhao Zhou Zhou Zhu Zhu Zhu Zhu Zhuang X 2020 181 2 Abstract Crucial transitions in tumor initiation local expansion metastasis and therapeutic complex interactions between cells within the dynamic tumor ecosystem Transformative genomics technologies and spatial multiplex in situ methods now provide an opportunity to interrogate this complexity at unprecedented resolution The Human Tumor Atlas Network HTAN part of the National Cancer Institute NCI Cancer Moonshot Initiative will establish a clinical experimental computational and organizational framework to generate informative and accessible atlases of cancer transitions for a diverse set of tumor types This effort complements both ongoing efforts to map healthy organs and previous cancer genomics approaches focused on bulk sequencing at a single point in time Generating multiparametric longitudinal atlases and integrating them with clinical outcomes should help identify novel predictive biomarkers and features as well as therapeutically relevant cell types cell states and cellular interactions across transitions The resulting tumor atlases should have a profound impact on our understanding of cancer biology and have the potential to improve cancer detection prevention and therapeutic discovery for better treatments of cancer patients and those at risk for cancer View details for DOI View details for PubMedID 32302568 MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING AND RECLASSIFICATION FROM ACTIVE SURVEILLANCE Magnani Bievre Erdogdu Baker Brooks LIPPINCOTT WILLIAMS WILKINS 2020 View details for Web of Science ID 000527010301653 The Urine Ratio and Kidney Function after Nephrectomy The Journal of urology Sun Thomas Velaer Ganesan Song Pao Wagner Brooks Chertow Leppert 2020 101097JU0000000000001005 Abstract BACKGROUND Patients with kidney cancer are at risk of developing chronic kidney disease CKD after radical and partial nephrectomy We sought to determine if the urine ratio UACR is independently associated with progressive CKD after We performed a cohort study based within a large integrated health care system We identified patients who underwent radical or partial nephrectomy from 2004 to 2014 with UACR measured in the 12 months prior to surgery We fit multivariable models to determine if the UACR was associated with the time to CKD progression defined as reaching stage 4 or 5 CKD eGFR 30 We performed a parallel analysis measuring the time to stage 3b 4 or 5 CKD eGFR 45 among patients with normal or preoperative kidney function eGFR m2 We also examined the association between UACR and 1930 patients underwent radical or partial nephrectomy and had preoperative UACR and and eGFR Of these 658 34 and 157 8 had moderate UACR or severe albuminuria UACR respectively Albuminuria severity was independently associated with progressive CKD after radical moderate albuminuria HR 95 CI severe albuminuria HR 95 CI and partial nephrectomy moderate albuminuria HR 95 CI severe albuminuria HR 95 CI Albuminuria was also associated with survival following radical and partial In patients undergoing radical or partial nephrectomy the severity of albuminuria can stratify risk of progressive CKD View details for DOI View details for PubMedID 32125227 Leveraging Digital Data to Inform and Improve Quality Cancer Care Cancer epidemiology biomarkers prevention a publication of the American Association for Cancer Research cosponsored by the American Society of Preventive Oncology Blayney Brooks 2020 Abstract BACKGROUND Efficient capture of routine clinical care and patient outcomes are needed at a as is evidence on important side effects and their effect on and clinical outcomes The increasing availability of electronic health records EHRs offers new opportunities to generate evidence on oncological care that can better guide treatment decisions and This study includes patients seeking care at an academic medical center Digital data sources are combined to address missingness inaccuracy and noise common to EHR data Clinical concepts were identified and extracted from EHR unstructured data using natural language processing NLP and learning techniques All models are trained tested and validated on independent data samples using standard We provide use cases for using EHR data to assess guideline adherence and quality measurements among cancer patients Pretreatment assessment was evaluated by guideline adherence and quality metrics for cancer staging metrics Patient outcomes included and Advanced technologies applied to EHRs present opportunities to advance quality assessment to learn from routinely collected clinical data for personalized treatment and to augment epidemiological and population health studies The effective use of digital data can inform care quality initiatives and policy A comprehensive set of health data analyzed with advanced technologies results in a unique resource that facilitates innovative and impactful research on prostate cancer This work demonstrates novel use of EHRs and technology to advance epidemiological studies and benefit oncological care View details for DOI View details for PubMedID 32066619 Discovery of PTN as a biomarker of prostate cancer British journal of cancer Liu Shen Hsu Zhang Nolley Koul Rice Aslan Pitteri Massie George Brooks Gnanapragasam Stoyanova 2020 Abstract Distinguishing clinically significant from indolent prostate cancer PC is a major clinical challenge We utilised targeted protein biomarker discovery approach to identify biomarkers specific for PC Serum samples from the group Cambridge Prognostic Group 1 CPG1 low risk CPG5 high risk and metastatic disease were analysed using Olink Proteomics panels Tissue validation was performed by immunohistochemistry in a radical prostatectomy cohort n 234 We discovered that nine proteins pleiotrophin PTN MK PVRL4 EPHA2 hK11 SYND1 ANGPT2 and hK14 were elevated in metastatic PC patients when compared to other groups PTN levels were increased in serum from men with CPG5 compared to benign and CPG1 High tissue PTN level was an independent predictor of biochemical recurrence and metastatic progression in and disease These findings suggest that PTN may represent a novel biomarker for the presence of poor prognosis local disease with the potential to metastasise warranting further investigation View details for DOI View details for PubMedID 33288843 The m6A RNA demethylase FTO is a synthetic lethal partner with the VHL tumor suppressor Proceedings of the National Academy of Sciences of the United States of America Xiao Thakkar Zhao Broughton Li Seoane J Diep Metzner von Eyben Dill Brooks Curtis Leppert Ye Peehl Giaccia Sinha Rankin B 2020 Abstract Loss of the von VHL tumor suppressor is a hallmark feature of renal clear cell carcinoma VHL inactivation results in the constitutive activation of the factors HIFs and and their downstream targets including the proangiogenic factors VEGF and PDGF However antiangiogenic agents and inhibitors have limited efficacy in cancer therapy due to the development of resistance Here we employed an innovative computational platform Mining of Synthetic Lethals MiSL to identify synthetic lethal interactions with the loss of VHL through analysis of primary tumor genomic and transcriptomic data Using this approach we identified a synthetic lethal interaction between VHL and the m6A RNA demethylase FTO in renal cell carcinoma MiSL identified FTO as a synthetic lethal partner of VHL because deletions of FTO are mutually exclusive with VHL loss in pan cancer datasets Moreover FTO expression is increased in ccRCC tumors compared to normal adjacent tissue Genetic inactivation of FTO using multiple orthogonal approaches revealed that FTO inhibition selectively reduces the growth and survival of cells in vitro and in vivo Notably FTO inhibition reduced the survival of both HIF wild type and tumors identifying FTO as an vulnerability of cancers Integrated analysis of and analysis identified the glutamine transporter SLC1A5 as an FTO target that promotes metabolic reprogramming and survival of ccRCC cells These findings identify FTO as a potential therapeutic target for the treatment of renal cell carcinoma View details for DOI View details for PubMedID 32817424 Cardiorespiratory Fitness and Risk of Prostate Cancer Cancer epidemiology biomarkers prevention a publication of the American Association for Cancer Research cosponsored by the American Society of Preventive Oncology Crump Stattin Brooks Stocks Sundquist Sieh Sundquist 2020 Abstract Adolescence is a period of rapid prostatic growth yet is understudied for susceptibility for future risk of prostate cancer PC We examined cardiorespiratory fitness CRF in late adolescence in relation to PC cohort study was conducted of all Swedish military conscripts during of men in relation to risk of PC overall aggressive PC and PC mortality during ages years CRF was measured by maximal aerobic workload and PC was ascertained using the National Prostate Cancer Register Muscle strength was examined as a secondary million of men were diagnosed with PC Adjusting for sociodemographic factors height weight and family history of PC high CRF was associated with a slightly increased risk of any PC highest lowest quintile incidence rate ratio IRR 95 CI but was not significantly associated with aggressive PC nor PC mortality High muscle strength also was associated with a modestly increased risk of any PC highest lowest quintile IRR 95 CI P but not aggressive PC nor PC mortality CRF or muscle strength in late adolescence was associated with slightly increased future risk of PC possibly related to increased screening but not risk of aggressive PC nor PC findings illustrate the importance of distinguishing aggressive from indolent PC and assessing for potential detection bias View details for DOI View details for PubMedID 32856610 Clinical Documentation to Predict Factors Associated with Urinary Incontinence Following Prostatectomy for Prostate Cancer RESEARCH AND REPORTS IN UROLOGY Li Banerjee Magnani Blayney Brooks 2020 12 View details for DOI View details for Web of Science ID 000512137700001 Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1 Proceedings of the National Academy of Sciences of the United States of America Hsu Rice Bermudez Marques Aslan Liu Ghoochani Zhang Chen Zlitni Kumar Nolley Habte Shen Koul Peehl Zoubeidi Gambhir Kunder Pitteri Brooks Stoyanova 2020 Abstract Resistance to androgen deprivation therapy or prostate cancer CRPC is often accompanied by metastasis and is currently the ultimate cause of prostate deaths in men Recently secondary hormonal therapies have led to an increase of neuroendocrine prostate cancer NEPC a highly aggressive variant of CRPC Here we identify that high levels of cell surface receptor Trop2 are predictive of recurrence of localized prostate cancer Moreover Trop2 is significantly elevated in CRPC and NEPC drives prostate cancer growth and induces neuroendocrine phenotype Overexpression of Trop2 induces tumor growth and metastasis while loss of Trop2 suppresses these abilities in vivo NEPC displays a significant of PARP1 and PARP inhibitors significantly delay tumor growth and metastatic colonization and reverse neuroendocrine features in NEPC Our findings establish Trop2 as a driver and therapeutic target for metastatic prostate cancer with neuroendocrine phenotype and suggest that high Trop2 levels could identify cancers that are sensitive to therapies and PARP1 inhibition View details for DOI View details for PubMedID 31932422 Magnetic Resonance Imaging for the Detection of Cancer in the Canary Prostate Active Surveillance Study The Journal of urology Liss Newcomb Zheng Garcia Filson Boyer Brooks Carroll Cooperberg Ellis Gleave Martin Morgan Nelson Wagner A Thompson Lin 2020 101097JU0000000000001088 Abstract We investigated the ability of prostate MRI to detect Gleason Grade Group GG cancer in a standardized active surveillance evaluated men enrolled in Canary Prostate Active Surveillance Study PASS with GG 2 and who underwent a biopsy within 12 months of a multiparametric MRI Our primary outcome was biopsy reclassification to GG2 or greater We evaluated the performance of MRI PIRADS score and clinical factors Multivariable logistic regression models were fit with MRI and clinical factors and used to perform receiver operating curve were 361 participants with 395 prostate MRIs with a median of IQR years Overall 27 biopsies showed reclassification Defining positive MRI as PIRADS the NPV and PPV for detecting GG cancer was 83 95 CI and 31 95 CI respectively PIRADS was significantly associated with reclassification PIRADS 5 versus 1 and 2 OR 95 CI p in a multivariable model but did not improve upon a model with only clinical factors AUC versus In 194 fusion biopsies higher grade cancer was found in targeted cores in 21 11 instances while 25 13 had higher grade cancer found in the systematic study adds the largest cohort data to the body of literature for MRI in active surveillance recommending systematic biopsy in patients with a negative MRI and the inclusion of systematic biopsy in patients with a positive MRI View details for DOI View details for PubMedID 32343189 Clinical Trial Outcomes in Urology Assessing Early Discontinuation Results Reporting and Publication in Registrations The Journal of urology Magnani Steinberg Harmange Zhang Driscoll Bell Larson You Weeks Turner Brooks 2020 101097JU0000000000001432 Abstract Clinical trials require significant resources but benefits are only realized after trial completion and dissemination of results We comprehensively assessed early discontinuation registry results reporting and publication by trial sponsor and subspecialty in urology assessed trial registrations from on and publication data from Associations between sponsor or subspecialty with early discontinuation were assessed using Cox Proportional Hazards and results reporting or publication with logistic regression at three years after trials were completed while 999 were discontinued of completed trials reported results and were published Sponsors included Academic institutions Industry or US Government adjusted hazard ratio aHR 95 Confidence Interval CI and trials 95 p were less likely than Industry to discontinue early trials were more likely to report adjusted odds ratio aOR 95 and publish 95 were less likely to report but more likely to publish 95 p These outcomes were similar across subspecialties however endourology was more likely to discontinue early 95 p general urology more likely to report results 95 and andrology less likely to publish 95 type is significantly associated with trial completion and dissemination trials had the best performance while Industry and lagged in trial completion and results reporting respectively Subspecialty played a lesser role Lack of dissemination remains a problem for urology trials View details for DOI View details for PubMedID 33079618 Phenotyping severity of outcomes using clinical notes A prostate cancer use case Learning health systems Bozkurt Paul Coquet Sun Banerjee Brooks 2020 4 4 e10237 Abstract A learning health system LHS must improve care in ways that are meaningful to patients integrating outcomes PCOs into core infrastructure PCOs are common following cancer treatment such as urinary incontinence UI following prostatectomy However PCOs are not systematically recorded because they can only be described by the patient are subjective and captured as unstructured text in the electronic health record EHR Therefore PCOs pose significant challenges for phenotyping patients Here we present a natural language processing NLP approach for phenotyping patients with UI to classify their disease into severity subtypes which can increase opportunities to provide therapy and promote a delivery undergoing prostate cancer treatment from 2008 to 2018 were identified at an academic medical center Using a hybrid NLP pipeline that combines and deep learning methodologies we classified positive UI cases as mild moderate and severe by mining clinical model accurately classified UI into disease severity categories accuracy which outperformed the deep learning model accuracy In the deep learning model the recall rates for mild and moderate group were higher than the precision rate and respectively A hybrid model that combined both methods did not improve the accuracy of the model but did outperform the deep learning model accuracy patients based on indication and severity of PCOs is essential to advance a patient centered LHS EHRs contain valuable information on PCOs and by using NLP methods it is feasible to accurately and efficiently phenotype PCO severity Phenotyping must extend beyond the identification of disease to provide classification of disease severity that can be used to guide treatment and inform shared Our methods demonstrate a path to a patient centered LHS that could advance precision medicine View details for DOI View details for PubMedID 33083539 View details for PubMedCentralID PMC7556418 Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study PASS Cohort Journal of clinical oncology official journal of the American Society of Clinical Oncology Lin Zheng McKenney Brown Lu Crager Boyer Tretiakova Brooks Dash Fabrizio Gleave Kolb Liss Morgan Thompson Wagner A Tsiatis Pingitore Nelson Newcomb 2020 JCO1902267 Abstract The Oncotype DX Genomic Prostate Score GPS test predicts adverse pathology AP in patients with prostate cancer treated with immediate surgery We evaluated the GPS test as a predictor of outcomes in a multicenter active surveillance biopsy tissue was obtained from men enrolled at 8 sites in the Canary Prostate Active Surveillance Study The primary endpoint was AP Gleason Grade Group GG 3 pT3a in men who underwent radical prostatectomy RP after initial surveillance Multivariable regression models for data were used to evaluate the association between AP and GPS Inverse probability of censoring weighting was applied to adjust for informative censoring Predictiveness curves were used to evaluate how models stratified risk of AP Association between GPS and time to upgrade on surveillance biopsy was evaluated using Cox proportional hazards results were obtained for 432 men median years 101 underwent RP after a median years of surveillance and 52 had AP A total of 167 men 39 upgraded at a subsequent biopsy GPS was significantly associated with AP when adjusted for diagnostic GG hazards ratio HR GPS units 95 CI to P but not when also adjusted for antigen density PSAD HR 95 CI to P Models containing PSAD and GG or PSAD GG and GPS may stratify risk better than a model with GPS and GG No association was observed between GPS and subsequent biopsy upgrade P our study the independent association of GPS with AP after initial active surveillance was not statistically significant and there was no association with upgrading in surveillance biopsy Adding GPS to a model containing PSAD and diagnostic GG did not significantly improve stratification of risk for AP over the clinical variables alone View details for DOI View details for PubMedID 32130059 Development of a DNA Diagnostic Signature to Distinguish Benign Oncocytoma From Renal Cell Carcinoma JCO precision oncology Brennan Metzner Kao Massie Stewart Haile Brooks Hitchins Leppert Gevaert O 2020 4 Abstract A challenge in the diagnosis of renal cell carcinoma RCC is to distinguish chromophobe RCC chRCC from benign renal oncocytoma because these tumor types are histologically and morphologically similar yet they require different clinical management Molecular biomarkers could provide a way of distinguishing oncocytoma from chRCC which could prevent unnecessary treatment of oncocytoma Such biomarkers could also be applied to preoperative biopsy specimens such as needle core biopsy specimens to avoid unnecessary surgery of profiled DNA methylation in oncocytoma and chRCC tumors and adjacent normal tissue and used machine learning to identify a signature of differentially methylated sites CpGs that robustly distinguish oncocytoma from clustering of Stanford and preexisting RCC data from The Cancer Genome Atlas TCGA revealed that of all RCC subtypes oncocytoma is most similar to chRCC Unexpectedly however oncocytoma features more extensive overall abnormal methylation than does chRCC We identified 79 CpGs with large methylation differences between oncocytoma and chRCC A diagnostic model trained on 30 CpGs could distinguish oncocytoma from chRCC in area under the receiver operating curve AUC 95 CI to and could distinguish TCGA chRCCs from an independent set of oncocytomas from a previous study AUC This signature also separated oncocytoma from other RCC subtypes and normal tissue revealing it as a standalone diagnostic biomarker for CpG signature could be developed as a clinical biomarker to support differential diagnosis of oncocytoma and chRCC in surgical samples With improved biopsy techniques this signature could be applied to preoperative biopsy specimens View details for DOI View details for PubMedID 33015531 View details for PubMedCentralID PMC7529536 Sudden PSA rise to and prostate cancer diagnosis in the United States A study The Prostate Vilson Li Brooks Eisenberg 2020 Abstract While antigen PSA screening protocols vary many clinicians have anecdotes of screened men with low PSA levels that rise significantly and are associated with prostate cancer PC We sought to better understand the frequency of cases that appear suddenly in a screened utilized data from a Commercial and Medicare advantage claims database to identify all US men ages 50 and above undergoing PSA screening who then had a sudden interval rise in PSA PSA 20 and diagnosis of PC We determined associations with age race screening intensity and baseline PSA all men met entry criteria with an average age of and of years As the baseline PSA increased the rate of PC increased from persons among men with the lowest baseline PSA 1 to among men with a baseline PSA 5 Moreover as a man age at baseline PSA increased the rate of PC also increased In contrast the incidence of PC did not vary significantly by More screening PSAs and shorter intervals between PSA screenings were associated with a lower incidence of incidence of PC in a screened population is low Our findings suggest that systematic screening can not eliminate all PC deaths and provide an estimate for the risk of the rapid development of cancers that is comparable to that observed in active surveillance populations View details for DOI View details for PubMedID 32956488 Association between emails and overall survival in cancer patients undergoing chemotherapy Evidence from the setting Cancer medicine Coquet Blayney Brooks 2020 Abstract Prior studies suggest email communication between patients and providers may improve patient engagement and health outcomes The purpose of this study was to determine whether emails are associated with overall survival benefits among cancer patients undergoing identified emails through the patient portal in electronic health records EHR among 9900 cancer patients receiving chemotherapy between 2013 and 2018 Email users were defined as patients who sent at least one email 12 months before to 2 months after chemotherapy started A propensity cohort analysis was carried out to reduce bias due to confounding age primary cancer type gender insurance payor ethnicity race stage income Charlson score county of residence The cohort included 3223 email users and 3223 users The primary outcome was overall survival stratified by email use Secondary outcomes included number of visits prescriptions and telephone calls The healthcare teams response to emails and other forms of communication was also investigated Finally a quality measure related to inpatient and emergency department visits was survival was higher in patients who were email users with an adjusted hazard ratio of 95 CI p Email users had higher rates of healthcare utilization including visits 63 50 p drug prescriptions 28 21 p and phone calls 18 16 p Clinical quality outcome measure of inpatient use was better among email users p emails are associated with a survival benefit among cancer patients receiving chemotherapy and may be a proxy for patient engagement As payment models emphasize incorporating the patients voice into their care email communications could serve as a novel source of data View details for DOI View details for PubMedID 32986931 Reply by Authors The Journal of urology Schenk Newcomb Zheng Faino Zhu Nyame Y Brooks Carroll Cooperberg Dash Filson Gleave Liss Martin Morgan Nelson Thompson Wagner A Lin 2020 101097JU000000000000062102 View details for DOI View details for PubMedID 31951502 Identification of Diagnostic Metabolic Signatures in Clear Cell Renal Cell Carcinoma Using Mass Spectrometry Imaging International journal of cancer Vijayalakshmi Shankar Bain Nolley Sonn Kao Zhao Tibshirani Zare Brooks 2019 Abstract Clear cell renal cell carcinoma ccRCC is the most common and lethal subtype of kidney cancer Intraoperative frozen section IFS analysis is used to confirm the diagnosis during partial nephrectomy PN However surgical margin evaluation using IFS analysis is time consuming and unreliable leading to relatively low utilization In this study we demonstrated the use of desorption electrospray ionization mass spectrometry imaging as a molecular diagnostic and prognostic tool for ccRCC was conducted on 23 paired nephrectomy specimens of ccRCC An independent validation cohort of 17 pairs were analyzed provides molecular images of tissues with mass spectra representing small metabolites fatty acids and lipids These tissues were subjected to histopathologic evaluation A set of metabolites that distinguish ccRCC from normal kidney were identified by performing least absolute shrinkage and selection operator Lasso and Lasso analysis Lasso analysis with cross validation selected 57 peaks from over metabolic features across pixels obtained using of ccRCC and normal tissues Baseline Lasso of metabolites predicted the class of each tissue to be normal or cancerous tissue with an accuracy of 94 and 76 respectively Combining the baseline Lasso with the ratio of glucose to arachidonic acid could potentially reduce scan time and improve accuracy to identify normal 82 and ccRCC 88 tissue allows rapid detection of metabolites associated with normal and ccRCC with high accuracy As this technology advances it could be used for rapid intraoperative assessment of surgical margin status This article is protected by copyright All rights reserved View details for DOI View details for PubMedID 31863456 Editorial Comment The Journal of urology Brooks 2019 10109701JU00006126127033813 View details for DOI View details for PubMedID 31674872 African American Race is Not Associated with Risk of Reclassification during Active Surveillance Results from the Canary Prostate Cancer Active Surveillance Study PASS The Journal of urology Schenk Newcomb Zheng Faino Zhu Nyame Y Brooks Carroll Cooperberg Dash Filson Gleave Liss Martin Morgan Nelson Thompson Wagner A Lin 2019 101097JU0000000000000621 Abstract OBJECTIVE To evaluate whether African American AA men are at higher risk of reclassification in a large prospective active surveillance AS The Canary Prostate Active Surveillance Study PASS is a active surveillance cohort with antigen PSA and surveillance biopsies regimen Men included in this study had Gleason Grade Group 1 or 2 at diagnosis 5 years between diagnosis and enrollment and had undergone 1 surveillance biopsy Risk of reclassification defined as an increase in Gleason score on subsequent biopsy was compared between AA and CA using cox proportional hazards models For the subset of men undergoing delayed prostatectomy rates of adverse pathology defined as pT3a or greater or Gleason Grade Group 3 or greater were compared for AA and Of men there were 89 7 AA and 93 CA There were no differences in the rate of treatment for AA and CA In multivariate models AA race was not associated with the risk of reclassification 95 CI Among 441 men who had a prostatectomy after a period of AS rate of adverse pathology was similar for AA and CA 46 vs 47 Among men on AS who follow a standardized protocol of regular PSA and biopsy AA men were not at increased risk of pathologic reclassification on AS or adverse pathology at prostatectomy AS appears to be an appropriate management strategy for AA men with favorable risk prostate cancer View details for DOI View details for PubMedID 31651227 S100A10 is a critical mediator of angiogenesis in renal cell carcinoma Cancer research Xiao Zhao Tian Nolley Diep Ernst Fuh Miao von Eyben Leppert Brooks Peehl Giaccia Rankin B 2019 Abstract Angiogenesis is a hallmark of cancer that promotes tumor progression and metastasis However antiangiogenic agents have limited efficacy in cancer therapy due to the development of resistance In clear cell renal cell carcinoma ccRCC AXL expression is associated with antiangiogenic resistance and poor survival Here we establish a role for signaling in promoting the angiogenic potential of ccRCC cells through the regulation of the plasminogen receptor S100A10 Genetic and therapeutic inhibition of AXL signaling in ccRCC tumor xenografts reduced tumor vessel density and growth under the renal capsule signaling activated the expression of S100A10 through SRC to promote plasmin production endothelial cell invasion and angiogenesis Importantly treatment with the small molecule AXL inhibitor cabozantinib or an affinity soluble AXL Fc fusion decoy receptor sAXL reduced the growth of a ccRCC xenograft Moreover the combination of sAXL synergized with pazopanib and axitinib to reduce ccRCC xenograft growth and vessel density These findings highlight a role for signaling in mediating the angiogenic potential of ccRCC cells and support the combination of AXL inhibitors with antiangiogenic agents for advanced ccRCC View details for DOI View details for PubMedID 31585940 Performance of PCA3 and TMPRSS2 ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study PASS PROSTATE CANCER AND PROSTATIC DISEASES Newcomb Zheng Faino Cooperberg Brown Brooks Dash Fabrizio Gleave Liss Morgan Thompson Wagner A Carroll Nelson Lin 2019 22 3 View details for DOI View details for Web of Science ID 000480651400011 Simultaneous transrectal ultrasound and photoacoustic human prostate imaging Science translational medicine Kothapalli Sonn Choe Nikoozadeh Bhuyan Park Cristman Fan Moini Lee Wu Carver Trivedi Shiiba Steinberg Huland Rasmussen Liao Brooks Gambhir 2019 11 507 Abstract Imaging technologies that simultaneously provide anatomical functional and molecular information are emerging as an attractive choice for disease screening and management Since the 1980s transrectal ultrasound TRUS has been routinely used to visualize prostatic anatomy and guide needle biopsy despite limited specificity Photoacoustic imaging PAI provides functional and molecular information at ultrasonic resolution based on optical absorption Combining the strengths of TRUS and PAI approaches we report the development and translation of an integrated TRUS and photoacoustic TRUSPA device TRUSPA uses a miniaturized capacitive micromachined ultrasonic transducer array for simultaneous imaging of anatomical and molecular optical contrasts intrinsic hemoglobin extrinsic intravenous indocyanine green ICG of the human prostate Hemoglobin absorption mapped vascularity of the prostate and surroundings whereas ICG absorption enhanced the intraprostatic photoacoustic contrast Future work using the TRUSPA device for molecular imaging may enable a fundamentally new approach to prostate cancer diagnosis prognostication and therapeutic monitoring View details for DOI View details for PubMedID 31462508 Extracting Outcomes from Clinical Notes in Electronic Health Records Assessment of Urinary Incontinence After Radical Prostatectomy EGEMS Washington DC Gori Banerjee Chung Ferrari Rucci Blayney Brooks 2019 7 1 43 Abstract Objective To assess documentation of urinary incontinence UI in prostatectomy patients using unstructured clinical notes from Electronic Health Records EHRs We developed a natural language processing tool to extract assessments as recorded in unstructured text notes of UI before and after radical prostatectomy in a single academic practice across multiple clinicians Validation was carried out using a subset of patients who completed surveys before and after surgery The prevalence of UI as assessed by EHR and was compared using ANOVA The agreement of reported UI between EHR and was evaluated using Cohen Kappa A total of 4870 patients and 716 surveys were included Preoperative prevalence of UI was percent Postoperative prevalence was percent at 3 months percent at 6 months and and at 12 and 24 months respectively Similar rates were recorded by physicians in the EHR particularly for early For all time points the agreement between and the EHR was moderate all p and ranged from percent agreement at baseline Kappa to percent agreement at 24 months postoperative Kappa We have developed a tool to assess documentation of UI after prostatectomy using EHR clinical notes Our results suggest such a tool can facilitate unbiased measurement of important PCOs using data which are routinely recorded in EHR unstructured clinician notes Integrating PCO information into clinical decision support can help guide shared treatment decisions and promote care View details for DOI View details for PubMedID 31497615 Regulates Invasion Gene Expression and Predicts Overall Survival in Patients with Clear Cell Renal Cell Carcinoma Kidney cancer Gong Zhao Saar Peehl Brooks 2019 3 2 Abstract Background Clear cell renal cell carcinoma ccRCC is molecularly diverse and distinct molecular subtypes show different clinical outcomes MicroRNAs miRNAs are essential components of gene regulatory networks and play a crucial role in progression of many cancer types including Identify prognostic miRNAs and determine the role of in Hierarchical clustering was done in R using gene expression profiles of over 450 ccRCC cases in The Cancer Genome Atlas TCGA analysis was performed to identify prognostic miRNAs in the TCGA dataset was performed to identify target genes in primary ccRCC cells and Matrigel invasion assay was performed to assess the effects of overexpression on cell Hierarchical clustering analysis using prognostic genes previously identified by our group demonstrated that ccRCC patients with longer overall survival expressed lower levels of genes promoting proliferation or immune responses while better maintaining gene expression associated with cortical differentiation and cell adhesion Targets of 26 miRNAs were significantly enriched in the prognostic genes and these miRNAs were prognostic by themselves was associated with poor overall survival in the TCGA dataset Overexpression of promoted invasion of primary ccRCC cells in vitro and modulated transcriptional programs implicated in cancer progression including DNA repair cell proliferation and Our results suggest that ccRCCs with differential clinical outcomes have distinct transcriptomes for which miRNAs could serve as master regulators as a master regulator promotes ccRCC progression at least in part by enhancing cell invasion View details for DOI View details for PubMedID 31763513 Early detection of unilateral ureteral obstruction by desorption electrospray ionization mass spectrometry Scientific reports Banerjee Wong Yan Wu Zhao Tibshirani Zare Brooks 2019 9 1 11007 Abstract Desorption electrospray ionization mass spectrometry is an emerging analytical tool for rapid in situ assessment of metabolomic profiles on tissue sections without tissue pretreatment or labeling We applied to identify candidate metabolic biomarkers associated with kidney injury at the early stage was performed on sections of kidneys from 80 mice over a time course following unilateral ureteral obstruction UUO and compared to sham controls A predictive model of renal damage was constructed using the LASSO least absolute shrinkage and selection operator method Levels of lipid and small metabolites were significantly altered and glycerophospholipids comprised a significant fraction of altered species These changes correlate with altered expression of lipid metabolic genes with most genes showing decreased expression However rapid upregulation of PG level appeared to be a hitherto unknown feature of the metabolic shift observed in UUO Using LASSO and SAM significance analysis of microarrays we identified a set of metabolites that accurately predicted renal damage that was detectable by 12h after UUO prior to apparent histological changes Thus could serve as a useful adjunct to histology in identifying renal damage and demonstrates early and broad changes in membrane associated lipids View details for DOI View details for PubMedID 31358807 Predictive value of AZGP1 following radical prostatectomy for prostate cancer a cohort study and Journal of clinical pathology Kristensen Berg Toft Stroomberg Nolley Brooks Brasso Roder A 2019 Abstract AIMS AZGP1 is a promising tissue biomarker to predict outcomes in men undergoing treatment for localised prostate cancer PCa We aimed to examine the association between AZGP1 expression and the endpoints risk of biochemical failure BF initiating treatment developing PCa CRPC and mortality following radical prostatectomy RP The study included a prospective cohort of 302 patients who underwent RP for PCa from 2002 to 2005 AZGP1 expression was analysed using immunohistochemistry on tissue microarray RP specimens and was scored semiquantitively as low or high expression Risk of all endpoints was analysed using stratified cumulative incidences and Cox regression and validated with receiver operating curves calibration and discrimination in analyses A was performed including previous studies investigating AZGP1 expression and risk of BF following Median time of was years The cumulative incidence of all endpoints was significantly higher in patients with low AZGP1 expression compared with patients with high AZGP1 expression p In a multivariate analysis low AZGP1 expression increases the risk of BF HR 95 CI to p treatment HR 95 CI to and CRPC HR 95 CI to Validation showed a low risk of prediction error and a high model performance for all endpoints In a low AZGP1 was associated with BF HR 95 CI to Low AZGP1 expression is associated with the risk of aggressive outcomes in men undergoing RP for localised PCa View details for DOI View details for PubMedID 31331953 Prostate Magnetic Resonance Imaging Interpretation Varies Substantially Across Radiologists EUROPEAN UROLOGY FOCUS Sonn Fan Ghanouni Wang Brooks Loening Daniel To o Thong Leppert 2019 5 4 View details for DOI View details for Web of Science ID 000486156800014 Comparison of orthogonal NLP methods for clinical phenotyping and assessment of bone scan utilization among prostate cancer patients JOURNAL OF BIOMEDICAL INFORMATICS Coquet Bozkurt Kan Ferrari Blayney Brooks 2019 94 View details for DOI View details for Web of Science ID 000525692600015 AUTOMATED DETECTION OF PROSTATE CANCER ON MULTIPARAMETRIC MRI USING DEEP NEURAL NETWORKS TRAINED ON SPATIAL COORDINATES AND PATHOLOGY OF BIOPSY CORES Chen Bien Fan Cheong Rajpurkar Thong Wang Ahmadi Rusu Brooks Ng Sonn LIPPINCOTT WILLIAMS WILKINS 2019 E1098 View details for Web of Science ID 000473345203470 Vasectomy and the risk of prostate cancer in a prospective US Cohort Data from the Diet and Health Study ANDROLOGY Davenport Zhang Leppert Brooks Eisenberg 2019 7 2 View details for DOI View details for Web of Science ID 000461886700007 Utilization of Prostate Cancer Quality Metrics for Research and Quality Improvement A Structured Review JOINT COMMISSION JOURNAL ON QUALITY AND PATIENT SAFETY Gori Dulal Blayney Brooks Fantini McDonald 2019 45 3 Abstract The shift toward care in the United States emphasizes the role of quality measures in payment models Many diseases such as prostate cancer have a proliferation of quality measures resulting in resource burden and physician burnout This study aimed to identify and summarize proposed prostate cancer quality measures and describe their frequency and use in PubMed database was used to identify quality measures relevant to prostate cancer care and included articles in English through April 2018 A gray literature search for other documents was also conducted After the selection process of the pertinent articles measure characteristics were abstracted and uses were summarized for the 10 most frequently utilized measures in the total of 26 articles were identified for review Of the 71 proposed prostate cancer quality measures only 47 were used and less than 10 of these were endorsed by the National Quality Forum Process measures were most frequently reported Only 6 outcome measures were of which were among the most frequently a high number of proposed prostate cancer quality measures are reported in the literature few were assessed and the majority of these were process measures Process measures were most commonly assessed outcome measures were rarely evaluated In a step to close the quality chasm a top 5 core set of quality measures for prostate cancer care including structure process and outcomes measures is suggested Future studies should consider this comprehensive set of quality measures View details for DOI View details for Web of Science ID 000461797400013 View details for PubMedID 30236510 Performance of the genomic prostate score test in men with prostate cancer PCa managed with active surveillance AS Results from the Canary Prostate Active Surveillance Study PASS Lin Zheng McKenney Brown Lu Crager Boyer Brooks Dash Fabrizio Gleave Liss Morgan Thompson Wagner Tsiatis Pingatore Lawrence Nelson Newcomb AMER SOC CLINICAL ONCOLOGY 2019 View details for DOI View details for Web of Science ID 000489108800303 Continued 5 Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS JOURNAL OF UROLOGY Kearns Faino Schenk Newcomb Brooks Carroll Dash Ellis Fabrizio Gleave Morgan Nelson Thompson Wagner Zheng Lin 2019 201 1 Abstract Outcomes in patients who enroll in active surveillance programs for prostate cancer while receiving inhibitors have not been well defined We sought to determine the association of inhibitor use with the risk of reclassification in the PASS Canary Prostate Active Surveillance Study in the multicenter PASS were enrolled between 2008 and 2016 Study inclusion criteria were current or never inhibitors use Gleason score 3 4 or less prostate cancer at diagnosis less than a 34 core involvement ratio at diagnosis and 1 or more surveillance biopsies Included in study were men including 107 on inhibitors and 902 who had never received inhibitors Reclassification was defined as increase in the Gleason score an increase to 34 or greater in the ratio of biopsy cores positive for cancer Adverse pathology at prostatectomy was defined as Gleason 4 3 or greater nonorgan confined disease pT3 or N1 multivariable analysis there was no difference in reclassification between men who had received and those who had never received inhibitors HR p Patients who had received inhibitors were less likely to undergo radical prostatectomy 8 vs 18 p or any definitive treatment 19 vs 24 p In the 167 participants who underwent radical prostatectomy there was no suggestion of a difference in the rate of adverse pathology findings at prostatectomy between inhibitor users and inhibitor use after an initial diagnosis of prostate cancer was not associated with the risk of reclassification on active surveillance in men in the PASS cohort View details for PubMedID 30076904 Framework for the of MRI and Histology Images in Prostate Cancer Patients with Radical Prostatectomy Rusu Kunder Fan Ghanouni West Sonn Brooks Angelini Landman B SOC OPTICAL ENGINEERING 2019 View details for DOI View details for Web of Science ID 000483012700057 Improved detection of prostate cancer using a assay for serum circulating autoantibodies PloS one Xu Lee Hao Ling X Brooks Wang Gambhir 2019 14 8 e0221051 Abstract PURPOSE To develop a MNS based multiplex assay to measure protein and autoantibody biomarkers from human serum for prostate cancer CaP AND METHODS A MNS autoantibody assay and a MNS protein assay were developed and optimized in our labs Using these assays serum concentration of six biomarkers including antigen PSA protein PSA ratio as well as four autoantibodies against Parkinson disease 7 PARK7 TAR protein 43 TARDBP Talin 1 TLN1 and Caldesmon 1 CALD1 and were analyzed Human serum samples from 99 patients 50 with and 49 with clinically localized CaP were The MNS assay showed excellent performance characteristics and no All autoantibody assays showed a statistically significant difference between CaP and samples except for PARK7 The most significant difference was the combination of the four autoantibodies as a panel in addition to the PSA ratio This combination had the highest area under the curve AUC in ROC Our results suggest that this autoantibody panel along with PSA and free PSA have potential to segregate patients without cancer from those with prostate cancer with higher sensitivity and specificity than PSA alone View details for DOI View details for PubMedID 31404106 Machine Learning Approaches for Extracting Stage from Pathology Reports in Prostate Cancer Studies in health technology and informatics Lenain Seneviratne Bozkurt Blayney Brooks 2019 264 Abstract Clinical and pathological stage are defining parameters in oncology which direct a patient treatment options and prognosis Pathology reports contain a wealth of staging information that is not stored in structured form in most electronic health records EHRs Therefore we evaluated three supervised machine learning methods Support Vector Machine Decision Trees Gradient Boosting to classify pathology reports for prostate cancer into T N and M stage groups View details for DOI View details for PubMedID 31438212 Weakly supervised natural language processing for assessing outcome following prostate cancer treatment JAMIA open Banerjee Li Seneviratne Ferrari Seto Brooks Rubin 2019 2 1 Abstract The assessment of outcomes PCOs has been limited by the efficient and accurate collection of these data Natural language processing NLP pipelines can determine whether a clinical note within an electronic medical record contains evidence on these data We present and demonstrate the accuracy of an NLP pipeline that targets to assess the presence absence or risk discussion of two important PCOs following prostate cancer treatment urinary incontinence UI and bowel dysfunction BD propose a weakly supervised NLP approach which annotates electronic medical record clinical notes without requiring manual chart review A weighted function of neural word embedding was used to create a vector representation of relevant expressions extracted from the clinical notes Sentence vectors were used as input for a multinomial logistic model with output being either presence absence or risk discussion of The classifier was trained based on automated sentence annotation depending only on dictionaries weak supervision model achieved an average F1 score of for the classification task in both UI and BD The model also outperformed a model for annotation of UI with significant demonstrate a machine learning method to categorize clinical notes based on important PCOs that trains a classifier on sentence vector representations labeled with a dictionary which eliminates the need for manual engineering of linguistic rules or manual chart review for extracting the PCOs The weakly supervised NLP pipeline showed promising sensitivity and specificity for identifying important PCOs in unstructured clinical text notes compared to algorithms View details for PubMedID 31032481 Genomic analysis of benign prostatic hyperplasia implicates cellular in disease pathogenesis JCI insight Middleton Shen Varma Pollack Gong Zhu Zhu Foley Vennam Sweeney Tu Biscocho Eminaga Nolley Tibshirani Brooks West Pollack 2019 5 Abstract Benign prostatic hyperplasia BPH is the most common cause of lower urinary tract symptoms in men Current treatments target prostate physiology rather than BPH pathophysiology and are only partially effective Here we applied sequencing to gain new insight into BPH By RNAseq we uncovered transcriptional heterogeneity among BPH cases where a BPH stromal signature correlated with symptom severity Stromal signaling molecules BMP5 and CXCL13 were enriched in BPH while estrogen regulated pathways were depleted Notably BMP5 addition to cultured prostatic myofibroblasts altered their expression profile towards a BPH profile that included the BPH stromal signature RNAseq also suggested an altered cellular milieu in BPH which we verified by immunohistochemistry and RNAseq In particular BPH tissues exhibited enrichment of myofibroblast subsets whilst depletion of neuroendocrine cells and an estrogen receptor ESR1 fibroblast cell type residing near epithelium By sequencing we uncovered somatic variants SNVs in BPH of uncertain pathogenic significance but indicative of clonal cell expansions Thus genomic characterization of BPH has identified a stromal signature and new candidate disease pathways including a likely role for BMP5 signaling and reveals BPH to be not merely a hyperplasia but rather a fundamental of cell types View details for DOI View details for PubMedID 31094703 Is it possible to automatically assess pretreatment digital rectal examination documentation using natural language processing A retrospective study BMJ open Bozkurt Kan Ferrari Rubin Blayney Brooks 2019 9 7 e027182 Abstract To develop and test a method for automatic assessment of a quality metric pretreatment digital rectal examination DRE using the outputs of a natural language processing NLP electronic health records EHR prostate cancer data warehouse was used to identify patients and associated clinical notes from 1 January 2005 to 31 December 2017 Using a previously developed natural language processing pipeline we classified DRE assessment as documented currently or historically performed deferred or suggested as a future examination and investigated the quality metric performance documentation 6 months before treatment and identified patient and clinical factors associated with metric cohort included 7215 patients with prostate cancer and 426 227 unique clinical notes associated with pretreatment encounters DREs of 5958 patients were documented and 1257 of patients did not have a DRE documented in the EHR A total of 3742 patient DREs were documented within 6 months prior to treatment meeting the quality metric Patients with private insurance had a higher rate of DRE 6 months prior to starting treatment as compared with or payors Patients undergoing chemotherapy radiation therapy or surgery as the first line of treatment were more likely to have a documented DRE 6 months prior to contain valuable unstructured information and with NLP it is feasible to accurately and efficiently identify quality metrics with current documentation clinician workflow View details for DOI View details for PubMedID 31324681 PSA Testing Use and Prostate Cancer Diagnostic Stage After the 2012 Preventive Services Task Force Guideline Changes Journal of the National Comprehensive Cancer Network JNCCN Magnani Li Seto McDonald Blayney Brooks 2019 17 7 Abstract Most patients with prostate cancer are diagnosed with localized disease and may not require definitive treatment In 2012 the Preventive Services Task Force USPSTF recommended against prostate cancer screening to address overdetection and overtreatment This study sought to determine the effect of guideline changes on antigen PSA screening and initial diagnostic stage for prostate analysis was conducted to compare changes in PSA screening exposure relative to cholesterol testing control after the 2012 USPSTF guideline changes and test was used to determine whether there was a subsequent decrease in prostate cancer diagnoses Data were derived from a tertiary academic medical center electronic health records a national commercial insurance database OptumLabs and the SEER database for men aged years before and after the guideline both the academic center and insurance databases PSA testing significantly decreased for all men compared with the control The greatest decrease was among men aged 55 to 74 years at the academic center and among those aged years in the commercial database The proportion of prostate cancer diagnoses View details for DOI View details for PubMedID 31319390 Applying the PRECISION approach in biopsy nave and previously negative prostate biopsy patients Urologic oncology Wang Teslovich Fan Ghanouni Leppert Brooks Ahmadi Sonn A 2019 Abstract The PRECISION trial provides level 1 evidence supporting prebiopsy multiparametric magnetic resonance imaging mpMRI followed by targeted biopsy only when mpMRI is abnormal 1 This approach reduced of cancer while increasing detection of clinically significant cancer CSC Still important questions remain regarding the reproducibility of these findings outside of a clinical trial and quantifying missed CSC diagnoses using this approach To address these issues we retrospectively applied the PRECISION strategy in men who each underwent prebiopsy mpMRI followed by systematic and targeted imaging and pathology data were prospectively collected from 358 biopsy nave men and 202 men with previous negative biopsies To apply the PRECISION approach a retrospective analysis was done comparing the cancer yield from 2 diagnostic strategies 1 mpMRI followed by targeted biopsy alone for men with Prostate Imaging Reporting and Data System 3 lesions and 2 systematic biopsy alone for all men Primary outcomes were biopsies avoided and the proportion of CSC cancer Grade Group and Grade Group 1 biopsy nave patients the mpMRI diagnostic strategy would have avoided 19 of biopsies while detecting more CSC and 12 less P Thirteen percent 9 of men with normal mpMRI had CSC on systematic biopsy For previous negative biopsy patients the mpMRI diagnostic strategy avoided 21 of biopsies while detecting more CSC and 13 less P Seven percent 3 of men with normal mpMRI had CSC on systematic results provide external validation of the PRECISION finding that mpMRI followed by targeted biopsy of suspicious lesions reduces biopsies and of cancer Unlike PRECISION we did not find increased diagnosis of CSC This was true in both biopsy nave and previously negative biopsy cohorts We have incorporated this information into shared decision making which has led some men to choose to avoid biopsy However we continue to recommend targeted and systematic biopsy in men with abnormal MRI View details for DOI View details for PubMedID 31151788 Analysis of Released and Glycopeptide Profiling of Prostate Cancer Tissue Totten Bermudez Guerrero Yan Jones Brooks Pitteri OXFORD UNIV PRESS 2018 1056 View details for Web of Science ID 000452746700137 Multiregion Quantification of Extracellular Kinase Activity in Renal Cell Carcinoma European urology oncology Hoerner Massoudi Metzner Stell Kong Liliental Brooks Sabatti Leppert Fan 2018 Abstract To personalize treatment for renal cell carcinoma RCC it would be ideal to confirm the activity of druggable protein pathways within individual tumors We have developed a nanoimmunoassay NIA to measure protein activity with high precision in scant specimens eg fine needle aspirates FNAs Here we used NIA to determine whether protein activation varied in different regions of RCC tumors Since most RCC therapies target angiogenesis by inhibiting the vascular endothelial growth factor VEGF receptor we quantified phosphorylation of extracellular kinase ERK a downstream effector of the VEGF signaling pathway In 90 ex vivo FNA biopsies sampled from multiple regions of 38 primary clear cell RCC tumors ERK phosphorylation differed among patients In contrast within individual patients we found limited intratumoral heterogeneity of ERK phosphorylation Our results suggest that measuring ERK in a single FNA may be representative of ERK activity in different regions of the same tumor As diagnostic and therapeutic protein biomarkers are being sought NIA measurements of protein signaling may increase the clinical utility of renal mass biopsy and allow for the application of precision oncology for patients with localized and advanced RCC PATIENT SUMMARY In this report we applied a new approach to measure the activity of extracellular kinase ERK a key cancer signaling protein in different areas within kidney cancers We found that ERK activity varied between patients but that different regions within individual kidney tumors showed similar ERK activity This suggests that a single biopsy of renal cell carcinoma may be sufficient to measure protein signaling activity to aid in precision oncology approaches View details for DOI View details for PubMedID 31412000 Undertreatment of Localized Prostate Cancer in the California Latino Population Journal of the National Comprehensive Cancer Network JNCCN Lichtensztajn Leppert Brooks Shah Sieh Chung Gomez Cheng I 2018 16 11 Abstract Background The NCCN Clinical Practice Guidelines in Oncology recommend definitive therapy for all men with localized prostate cancer PCa who have a life expectancy 5 years or who are symptomatic However the application of these guidelines may vary among ethnic groups We compared receipt of treatment between Latino and white men in California Methods California Cancer Registry data were used to identify Latino and white men diagnosed with localized PCa from 2010 through 2014 The association of clinical and sociodemographic factors with definitive treatment was examined using logistic regression overall and by ethnicity Results Latinos were less likely than whites to receive definitive treatment before odds ratio OR 95 CI and after adjusting for age and tumor characteristics OR 95 CI Additional adjustment for sociodemographic factors eliminated the disparity However the association with treatment differed by ethnicity for several factors Latino men with no health insurance were considerably less likely to receive definitive treatment relative to insured Latino men OR 95 CI an association that was more pronounced than among whites OR 95 CI disease was associated with lower odds of definitive treatment in Latinos OR 95 CI but not whites Younger age and care at Cancer Centers were significantly associated with receipt of definitive treatment in whites but not in Latinos Conclusions California Latino men diagnosed with localized PCa are at increased risk for undertreatment The observed treatment disparity is largely explained by sociodemographic factors suggesting it may be ameliorated through targeted outreach such as that aimed at younger and underinsured Latino men View details for PubMedID 30442735 Elevated urinary and monocyte chemoattractant levels in children with congenital ureteropelvic junction obstruction Journal of pediatric urology Yu Zhou Li Li Luo Zhang Wu Brooks Sun 2018 Abstract INTRODUCTION In children with congenital ureteropelvic junction obstruction UPJO urinary biomarkers could assist in the diagnosis of renal damage or kidneys at risk for damage Urinary levels of IL6 neutrophil lipocalin LCN2 monocyte chemoattractant MCP1 and transforming growth TGFB1 proteins have been correlated with renal damage in several contexts Whether they might be useful biomarkers of obstructive nephropathy due to unilateral and bilateral congenital UPJO was AND METHODS A cohort study was performed at People Hospital of Xinjiang Uygur Autonomous Region in China Bladder urine samples from 17 patients with UPJO were obtained before surgical intervention and from 17 healthy controls Levels of IL6 LCN2 MCP1 and TGFB1 were determined by immunosorbent assay and normalized to urinary creatinine Levels of urinary LCN2 MCP1 and IL6 were significantly elevated in the urine from individuals with UPJO compared with controls and respectively Children with bilateral UPJO showed significantly higher levels of IL6 LCN2 and MCP1 protein in their urine compared with controls or those with unilateral UPJO P and respectively Combining LCN2 and MCP1 slightly improved biomarker Urinary biomarkers could be used in obstructed patients to monitor for renal damage and might find particular utility on patients with bilateral UPJO Monitoring urinary biomarkers and imaging features in untreated patients could provide insights into the natural history of renal damage due to obstruction and will be necessary to test their performance characteristics as Urinary levels of LCN2 and MCP1 protein are promising biomarkers monitoring children with UPJO particularly in those with bilateral disease View details for PubMedID 30420258 James Brooks prostate cancer screening awaits optimization to reduce inappropriate treatment TRANSLATIONAL ANDROLOGY AND UROLOGY Li Brooks 2018 7 5 View details for DOI View details for Web of Science ID 000447937100015 Refined Analysis of Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes EUROPEAN UROLOGY Cooperberg Brooks Faino Newcomb Kearns Carroll Dash Etzioni Fabrizio Gleave Morgan Nelson Thompson Wagner A Lin Zheng Y 2018 74 2 Abstract For men on active surveillance for prostate cancer utility of antigen PSA kinetics PSAk in predicting pathologic reclassification remains develop prediction methods for utilizing serial PSA and evaluate frequency of were collected from men enrolled in the multicenter Canary Prostate Active Surveillance Study for whom PSA data were measured and biopsies performed on prespecified schedules We developed a PSAk parameter based on a linear model LMEM that accounted for serial PSA association of diagnostic PSA PSAk with time to reclassification increase in cancer grade volume was evaluated using multivariable Cox proportional hazards total of 851 men met the study criteria 255 30 had a reclassification event within 5 yr Median was After adjusting for prostate size time since diagnosis biopsy parameters and diagnostic PSA PSAk was a significant predictor of reclassification hazard ratio for each increase in 95 confidence interval p The PSAk model improved stratification of risk prediction for the top and bottom deciles of risk over a model without PSAk Model performance was essentially identical using PSA data measured every 6 mo to those measured every 3 mo The major limitation is the reliability of reclassification as an end point although it drives most treatment calculated using an LMEM statistically significantly predicts biopsy reclassification Models that use repeat PSA measurements outperform a model incorporating only diagnostic PSA Model performance is similar using PSA assessed every 3 or 6 mo If validated these results should inform optimal incorporation of PSA trends into active surveillance protocols and risk this report we looked at whether repeat antigen PSA measurements or PSA kinetics improve prediction of biopsy outcomes in men using active surveillance to manage localized prostate cancer We found that in a large multicenter active surveillance cohort PSA kinetics improves the prediction of surveillance biopsy outcome View details for PubMedID 29433975 Methionine aminopeptidase II MetAP2 activated in situ of probes for imaging prostate cancer Xie Rice Cheng Song Kunder Brooks Stoyanova Rao AMER ASSOC CANCER RESEARCH 2018 View details for Web of Science ID 000441803800181 Defining new drivers of resistant prostate cancer Hsu Rice Nolley Bermudez Huang Peehl Kunder Pitteri Brooks Stoyanova AMER ASSOC CANCER RESEARCH 2018 90 View details for Web of Science ID 000441803800135 The Role of DNA Methylation in Renal Cell Carcinoma MOLECULAR DIAGNOSIS THERAPY Lasseigne Brooks 2018 22 4 Abstract Renal cell carcinoma RCC is the most common kidney cancer and includes several molecular and histological subtypes with different clinical characteristics While survival rates are high if RCC is diagnosed when still confined to the kidney and treated definitively there are no specific diagnostic screening tests available and symptoms are rare in early stages of the disease Management of advanced RCC has changed significantly with the advent of targeted therapies yet survival is usually increased by months due to acquired resistance to these therapies DNA methylation the covalent addition of a methyl group to a cytosine is essential for normal development and transcriptional regulation but becomes altered commonly in cancer These alterations result in broad transcriptional changes including in tumor suppressor genes Because DNA methylation is one of the earliest molecular changes in cancer and is both widespread and stable its role in cancer biology including RCC has been extensively studied In this review we examine the role of DNA methylation in RCC disease etiology and progression the preclinical use of DNA methylation alterations as diagnostic prognostic and predictive biomarkers and the potential for DNA therapies View details for PubMedID 29777398 Trends in Incidence and Mortality in Men With Newly Diagnosed Metastatic Prostate Analysis of 2 National Cohorts CANCER Helgstrand Roder Klemann Toft Lichtensztajn Brooks Brasso Vainer Iversen 2018 124 14 Abstract Early detection has increased prostate cancer PCa incidence Randomized trials have demonstrated that early detection reduces the incidence of de novo metastatic PCa Concurrently treatments have been introduced for patients with advanced PCa On a level the authors analyzed whether early detection and improved treatments changed the incidence and mortality of men with de novo metastatic diagnosed with PCa during the periods 1980 to 2011 and 1995 to 2011 were identified in the US Surveillance Epidemiology and End Results SEER program and the Danish Prostate Cancer Registry DaPCaR respectively and stratified according to period of diagnosis incidence rates were calculated mortality rates for de novo metastatic PCa were analyzed using competing risk of and men were identified in SEER and DaPCaR respectively Of these and 6874 had de novo metastatic PCa The incidence of de novo metastatic PCa decreased from to per men in the SEER cohort whereas it increased from to per men in the DaPCaR cohort PCa mortality in the SEER cohort was stable for men diagnosed with de novo metastatic PCa from 1980 to 1994 and increased slightly in the latest periods studied P whereas it decreased by P in the DaPCaR earlier detection de novo metastatic PCa remains associated with a high risk of mortality The reduced PCa mortality in the Danish cohort is largely explained by Early detection strategies do indeed decrease the incidence of de novo metastatic PCa as observed in the SEER cohort This achievement however must be weighed against the unsolved issue of overdetection and overtreatment of indolent PCa Cancer 2018 2018 American Cancer Society View details for PubMedID 29723398 Re Brandon Mahal David Yang Natalie Wang et al Clinical and Genomic Characterization of Antigen Prostate Cancer Eur Urol In press https European urology Leppert Brooks 2018 View details for PubMedID 30017399 glycosylation site mapping in prostate cancer and matched normal tissue Defining glycan microheterogeneity Totten Tanimoto Bermudez Hembree Brooks Pitteri AMER ASSOC CANCER RESEARCH 2018 View details for DOI View details for Web of Science ID 000468819505079 Architecture and Implementation of a Clinical Research Data Warehouse for Prostate Cancer EGEMS Washington DC Seneviratne Seto Blayney Brooks 2018 6 1 13 Abstract Background Electronic health record EHR based research in oncology can be limited by missing data and a lack of structured data elements Clinical research data warehouses for specific cancer types can enable the creation of more robust research We linked data from the Stanford University EHR with the Stanford Cancer Institute Research Database SCIRDB and the California Cancer Registry CCR to create a research data warehouse for prostate cancer The database was supplemented with information from clinical trials natural language processing of clinical notes and surveys on unique prostate cancer patients were identified in the Stanford EHR of which were matched to the Stanford cancer registry and 6153 in the CCR 7158 patients with EHR data and at least one of SCIRDB and CCR data were initially included in the A clinical research data warehouse combining multiple data sources can facilitate secondary data use and enhance observational research in oncology View details for PubMedID 30094285 Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification Results from the Canary Prostate Active Surveillance Study EUROPEAN UROLOGY Kearns Faino Newcomb Brooks Carroll Dash Ellis Fabrizio Gleave Morgan Nelson Thompson Wagner A Zheng Lin 2018 73 5 Abstract Many patients who are on active surveillance AS for prostate cancer will have surveillance prostate needle biopsies PNBs without any cancer define the association between negative surveillance PNBs and risk of reclassification on men were enrolled in the Canary Prostate Active Surveillance Study PASS between 2008 and 2016 Men were included if they had Gleason prostate cancer and 34 core involvement ratio at diagnosis Men were prescribed surveillance PNBs at 12 and 24 mo after diagnosis and then every 24 was defined as an increase in Gleason grade an increase in the ratio of biopsy cores to cancer to PNB outcomes were defined as follows 1 no cancer on biopsy 2 cancer without reclassification or 3 reclassification and Cox proportional hazard models were performed to assess the risk of total of 657 men met inclusion criteria On first surveillance PNB 214 32 had no cancer 282 43 had cancer but no reclassification and 161 25 reclassified Among those who did not reclassify 313 had a second PNB On second PNB 120 38 had no cancer 139 44 had cancer but no reclassification and 54 17 reclassified In a multivariable analysis significant predictors of decreased future reclassification after the first PNB were no cancer on PNB hazard ratio HR lower serum antigen larger prostate size and lower body mass index A finding of no cancer on the second PNB was also associated with significantly decreased future reclassification in a multivariable analysis regardless of the first PNB result The major limitation of this study is a relatively small number of patients with who have a surveillance PNB with no evidence of cancer are significantly less likely to reclassify on AS in the PASS cohort These findings have implications for tailoring AS on active surveillance for prostate cancer who have a biopsy showing no cancer are at a decreased risk of having worse disease in the future This may have an impact on how frequently biopsies are required to be performed in the future View details for PubMedID 29433973 The Research Implications of PSA Registry Errors Data from the Veterans Health Administration The Journal of urology Guo Thomas Mittakanti Shelton J Makarov Skolarus Cooperberg Sonn Chung Brooks Leppert 2018 Abstract INTRODUCTION We sought to characterize the effects of PSA registry errors on clinical research by comparing cohorts based on cancer registry PSA values with those based directly on results in the electronic health We defined example cohorts of men with prostate cancer using data from the Veterans Health Administration those with a PSA values less than to to and to We compared the composition of each cohort and overall patient survival when using PSA values from either the VA Central Cancer Registry versus the gold standard electronic health record laboratory file There was limited agreement between cohorts defined using either the cancer registry PSA values versus the laboratory file of the electronic health record The least agreement was seen in patients with PSA values 58 and greatest among patients with PSA values between and 89 In each cohort patients assigned to a cohort based only on the cancer registry PSA value had significantly different overall survival when compared with patients assigned based on both the registry and laboratory file PSA Cohorts based exclusively on cancer registry PSA values may have high rates of misclassification that can introduce concerning differences in key characteristics and result in measurable differences in clinical outcomes View details for PubMedID 29630980 The CPC Risk Calculator A New App to Predict Antigen Recurrence During After Radical Prostatectomy European urology focus Roder Berg Loft Thomsen Ferrari Kurbegovic Rytgaard Gruschy Brasso Gerds Kjar Brooks Iversen 2018 4 3 Abstract BACKGROUND It can be challenging to predict the risk of biochemical recurrence BR during after radical prostatectomy RP in men who have undetectable antigen PSA even years after To establish and validate a contemporary nomogram that predicts the absolute risk of BR every year after RP in men with undetectable PSA while accounting for competing risks of SETTING AND PARTICIPANTS A total of 3746 patients from Rigshospitalet Copenhagen Denmark and Stanford Urology Stanford CA USA who underwent RP between 1995 and 2013 were MEASUREMENTS AND STATISTICAL ANALYSIS Time to BR was defined as the first PSA result BR risk was computed using multiple Cox regression including preoperative PSA pT category RP Gleason score GS and surgical margin R status Death without BR was considered a competing event The nomogram presents the future risk of BR for a man who is alive and without BR at the time of Validation assessed the discrimination and accuracy using area under the curve and Brier AND LIMITATIONS The nomogram predicts risk of BR up to 12 yr after RP at an individual level As example the risk of BR for a man with pT3a GS 3 4 and preoperative PSA followed for 5 yr with undetectable PSA is 18 for the next 5 yr External validation demonstrated both high accuracy and discrimination The CPC Risk Calculator is available as a free Android and iOS App Declining discrimination and accuracy after 7 yr of is the main This nomogram can be used as a tool to inform men with undetectable PSA during after RP about their future risk of BR and may aid in decisions on the necessity for further The nomogram is the first to be available as a free SUMMARY We developed an easily interpretable nomogram to evaluate the risk of antigen elevation cancer recurrence following complete removal of the prostate radical prostatectomy The tool can aid both physicians and patients in evaluating the future risk of cancer recurrence during after surgery The model is available as a free mobile app that can be downloaded from the App Store View details for PubMedID 28753827 PREOPERATIVE KIDNEY FUNCTION TRENDS IMPROVING ESTIMATES OF BASELINE KIDNEY FUNCTION PRIOR TO KIDNEY CANCER SURGERY Sun Thomas Ganesan Sylman Pao Wagner Brooks Chertow Leppert ELSEVIER SCIENCE 2018 E362 View details for Web of Science ID 000429166601066 Identification of transcripts associated with renal damage due to ureteral obstruction as candidate urinary biomarkers American journal of physiology Renal physiology Wu Gong Kennedy Brooks 2018 Abstract Renal obstruction is a common cause of renal failure in adults and children and is suspected when hydronephrosis is detected on imaging Since not all cases of hydronephrosis are associated with renal damage biomarkers are needed to guide intervention to relieve obstruction We performed gene expression profiling on the kidneys from adult mice over a detailed time course after obstruction and compared these data to a neonatal model of bilateral high grade obstruction induced by conditional deletion of the calcineurin SS1 Cnb1 gene Having identified a set of 143 transcripts modulated in both adult and neonatal obstruction we tested their expression in a model of obstruction 1 day where renal damage is transient and reversible and obstruction 5 days where significant renal damage is permanent A significantly number of transcripts increased early after obstruction and later normalized while 26 transcripts remained elevated 10 and 28 days after relief of 5 days of ureteral obstruction Using QPCR elevated levels of several of these candidate RNA biomarkers of renal damage were detected in urine from obstructed mice In addition several of these candidate RNA biomarkers of damage due to obstruction were detectable in catheterized urine samples from children undergoing surgery for ureteropelvic junction obstruction UPJO Measurement of urinary transcripts modulated in response to renal obstruction could serve as biomarkers of renal damage with important clinical applications View details for PubMedID 29488389 Male infertility is associated with altered treatment course of men with cancer Andrology Eminaga Li Baker Brooks Eisenberg 2018 Abstract This study aims to evaluate whether cancer treatments differ in infertile men compared to men who have undergone vasectomy and controls We analyzed subjects from the Truven Health MarketScan Claims database from 2001 to 2009 Infertile men were identified through diagnosis and treatment codes Comparison groups included vasectomized men and an cohort who were not infertile and had not undergone vasectomy We considered cancer types previously associated with infertility that were diagnosed after the diagnosis of infertility The treatment regimens were determined based on the presence of claims with CPT codes for chemotherapy CTX radiation RTX or surgical treatment ST for each entity in all study groups Cases with multimodal treatments were also identified As a result CTX was similarly distributed among the infertile vasectomized and control groups In contrast RTX treatment length was shorter in infertile men The frequency of multimodal treatment radiation and chemotherapy was twofold lower in men with infertility compared to other men By focusing on treatment patterns for each cancer type among these groups the duration of RTX and CTX was shorter in infertile men diagnosed with NHL compared to controls We conclude that Infertile men diagnosed with cancer and specific cancer types experience different treatment courses with shorter RTX and less combined compared to fertile and vasectomized men These differences could reflect differences in stage at presentation biological behavior or treatment responses in infertile men View details for PubMedID 29457365 Affinity Chromatography and Quantitative Proteomic Analysis Reveal Differential Glycoform Levels between Prostate Cancer and Benign Prostatic Hyperplasia Sera Scientific reports Totten Adusumilli Kullolli Tanimoto Brooks Mallick Pitteri J 2018 8 1 6509 Abstract Currently antigen is used for prostate cancer PCa screening however it lacks the necessary specificity for differentiating PCa from other diseases of the prostate such as benign prostatic hyperplasia BPH presenting a clinical need to distinguish these cases at the molecular level Protein glycosylation plays an important role in a number of cellular processes involved in neoplastic progression and is aberrant in PCa In this study we systematically interrogate the alterations in the circulating levels of hundreds of serum proteins and their glycoforms in PCa and BPH samples using affinity chromatography and quantitative mass proteomics Specific lectins AAL and were used to target and chromatographically separate and protein glycoforms for analysis as differential expression of these glycan types have been previously associated with PCa Global levels of CD5L CFP C8A BST1 and C7 were significantly increased in the PCa samples Notable alterations between BPH and PCa were identified among proteins CD163 C4A and ATRN in the fraction and among C4BPB and AZGP1 glycoforms in the AAL fraction Despite these modest differences substantial similarities in glycoproteomic profiles were observed between PCa and BPH sera View details for PubMedID 29695737 Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer Oncotarget Sahoo Wei Auman Carroll Fazli Gleave Lin Nelson Simko Thompson Leach Troyer True McKenney Feng Brooks 2018 9 5 Abstract The introduction of serum Prostate Specific Antigen PSA testing nearly 30 years ago has been associated with a significant shift towards localized disease and decreased deaths due to prostate cancer Recognition that PSA testing has caused over diagnosis and over treatment of prostate cancer has generated considerable controversy over its value and has spurred efforts to identify prognostic biomarkers to distinguish patients who need treatment from those that can be observed Recent studies show that cancer is heterogeneous and forms a hierarchy of tumor cell populations We developed a method of identifying prostate cancer differentiation states related to androgen signaling using Boolean logic Using gene expression data we identified two markers CD38 and ARG2 that group prostate cancer into three differentiation states Cancers with expression patterns corresponding to an undifferentiated state had significantly lower survival compared to the most differentiated group We carried out immunohistochemical IHC staining for these two markers in a single institution Stanford n 234 and Canary n 1326 cohorts IHC staining for CD38 and ARG2 in the Stanford cohort demonstrated that combined expression of CD38 and ARG2 was prognostic In the Canary cohort low CD38 protein expression by IHC was significantly associated with survival RFS seminal vesicle invasion SVI extension ECE in univariable analysis In multivariable analysis ARG2 and CD38 IHC staining results were not independently associated with RFS overall survival or survival after adjusting for other factors including SVI ECE Gleason score PSA and surgical margins View details for PubMedID 29464091 Performance of multiparametric MRI appears better when measured in patients who undergo radical prostatectomy Research and reports in urology Wang Fan Leppert Ghanouni Kunder Brooks Chung Sonn A 2018 10 Abstract Utilization of multiparametric MRI mpMRI is increasing To optimize the usefulness of mpMRI physicians should accurately quote patients a numerical risk of cancer based on their MRI The Prostate Imaging Reporting and Data System PIRADS standardizes interpretation of mpMRI however reported rates of clinically significant prostate cancer CSC stratified by PIRADS score vary widely While some publications use radical prostatectomy RP specimens as gold standard others use biopsy We hypothesized that much of the variation in CSC stems from differences in cancer prevalence in RP cohorts 100 prevalence vs biopsy cohorts To quantify the impact of this selection bias on cancer yield according to PIRADS score we analyzed data from 614 men with 854 lesions who underwent targeted biopsy from 2014 to 2018 Of these 125 men underwent RP We compared the PIRADS detection rates of CSC Gleason on targeted biopsy between the and RP cohorts For all PIRADS scores CSC yield was much greater in patients who underwent RP For example CSC was found in 30 of PIRADS 3 lesions in men who underwent RP vs in men who underwent biopsy Our results show that mpMRI performance appears to be better in men who undergo RP compared with those who only receive biopsy Physicians should understand the effect of this selection bias and its magnitude when discussing mpMRI results with patients considering biopsy and take great caution in quoting CSC yields from publications using RP as gold standard View details for PubMedID 30538970 Distribution of global health measures from routinely collected PROMIS surveys in patients with breast cancer or prostate cancer Cancer Seneviratne Bozkurt Patel Seto Brooks Blayney Kurian 2018 Abstract The collection of outcomes PROs is an emerging priority internationally guiding clinical care quality improvement projects and research studies After the deployment of Outcomes Measurement Information System PROMIS surveys in routine outpatient workflows at an academic cancer center electronic health record data were used to evaluate survey completion rates and global health measures across 2 tumor types breast and prostate study retrospectively analyzed PROMIS surveys from patients with breast cancer and 4411 surveys from patients with prostate cancer and it calculated survey completion rates and global physical health GPH and global mental health GMH scores between 2013 and total of of eligible patients with breast cancer and of patients with prostate cancer completed at least 1 survey with completion rates lower among black patients for both tumor types P The mean T scores calibrated to a general population mean of 50 for GPH were 9 for breast cancer and 9 for prostate cancer and the GMH scores were 8 and 9 respectively GPH and GMH were frequently lower among ethnic minorities patients without private health insurance and those with advanced analysis provides important baseline data on global health in breast and prostate cancer Demonstrating that PROs can be integrated into clinical workflows this study shows that supportive efforts may be needed to improve PRO collection and global health endpoints in vulnerable populations View details for PubMedID 30512191 Identifying Cases of Metastatic Prostate Cancer Using Machine Learning on Electronic Health Records AMIA Annual Symposium proceedings AMIA Symposium Seneviratne Banda Brooks Shah 2018 2018 Abstract Cancer stage is rarely captured in structured form in the electronic health record EHR We evaluate the performance of a classifier trained on structured EHR data in identifying prostate cancer patients with metastatic disease Using EHR data for a cohort of prostate cancer patients mapped to the Observational Health Data Sciences and Informatics OHDSI data model we constructed feature vectors containing frequency counts of conditions procedures medications observations and laboratory values Staging information from the California Cancer Registry was used as the For identifying patients with metastatic disease a random forest model achieved precision and recall of using data within 12 months of diagnosis This compared to precision recall for an ICD query classifiers using hundreds of structured data elements significantly outperform ICD queries and may assist in identifying cohorts for observational research or clinical trial matching View details for PubMedID 30815195 An Automated Feature Engineering for Digital Rectal Examination Documentation using Natural Language Processing AMIA Annual Symposium proceedings AMIA Symposium Bozkurt Park Kan Ferrari Rubin Brooks 2018 2018 Abstract Digital rectal examination DRE is considered a quality metric for prostate cancer care However much of the DRE related rich information is documented as in clinical narratives Therefore we aimed to develop a natural language processing NLP pipeline for automatic documentation of DRE in clinical notes using a dictionary created by clinical experts and an extended version of the same dictionary learned by clinical notes using distributional semantics algorithms The proposed pipeline was compared to a baseline NLP algorithm and the results of the proposed pipeline were found superior in terms of precision and recall for documentation of DRE We believe the NLP pipeline enriched with terms learned from the whole corpus can provide accurate and efficient identification of this quality metric View details for PubMedID 30815067 Comparative rates of upstaging and upgrading in Caucasian and Korean prostate cancer patients eligible for active surveillance PLOS ONE Jeon Yoo Jeong Seo Jeon Choi Lee Ferrari Brooks Chung I 2017 12 11 View details for DOI View details for Web of Science ID 000415121200003 Temporal Trends in Clinical and Pathological Characteristics for Men Undergoing Radical Prostatectomy Between 1995 and 2013 at Rigshospitalet Copenhagen Denmark and Stanford University Hospital United States Clinical genitourinary cancer Loft Berg Kjaer Iversen Ferrari Zhang Brasso Brooks Roder A 2017 Abstract PURPOSE To analyze how antigen PSA screening and practice patterns has affected trends in tumor characteristics in men undergoing radical prostatectomy RP in the United States and Denmark Unlike in the United States PSA screening has not been recommended in AND METHODS We performed an observational register study using and postoperative data on 2168 Danish patients from Rigshospitalet Copenhagen Denmark and 2236 patients from Stanford University Hospital Stanford CA who underwent RP between 1995 and 2013 Patients were stratified according to Cancer of the Prostate Risk risk groups and risk classification and were clustered into 4 time periods and Temporal trends in the proportions of patients of a given variable at the 2 institutions were evaluated with test for trends and A total of 4404 patients were included Temporal changes in preoperative PSA age grade and stage was found in both cohorts Median preoperative PSA declined in both cohorts while median age increased with the Danish cohort showing the greatest changes in both PSA and age In both cohorts there was a trend for preoperative features before RP over time In and of the patients were in the group at Copenhagen and Stanford Despite recommendation against PSA screening in Denmark Danish men undergoing RP at Rigshospitalet to a considerable extent now resemble American men undergoing RP at Stanford At both sites there is continued trend to reduce the number of men undergoing RP for prostate cancer View details for PubMedID 28988695 NUSAP1 promotes invasion and metastasis of prostate cancer ONCOTARGET Gordon Gong Ganesh Brooks 2017 8 18 Abstract We have previously identified nucleolar and spindle associated protein 1 NUSAP1 as a prognostic biomarker in early stage prostate cancer To better understand the role of NUSAP1 in prostate cancer progression we tested the effects of increased and decreased NUSAP1 expression in cell lines in vivo models and patient samples NUSAP1 promotes invasion migration and metastasis possibly by modulating family with sequence similarity 101 member B FAM101B a transforming growth factor beta 1 TGF1 signaling effector involved in the epithelial to mesenchymal transition Our findings provide insights into the importance of NUSAP1 in prostate cancer progression and provide a rationale for further study of NUSAP1 function regulation and clinical utility View details for DOI View details for Web of Science ID 000400456200032 View details for PubMedID 28404898 DNA methylation measurements in prostate tissues uncovers novel prostate cancer diagnostic biomarkers and transcription factor binding patterns BMC CANCER Kirby Ramaker Roberts Lasseigne Gunther Burwell Davis Gulzar Absher Cooper Brooks Myers 2017 17 Abstract Current diagnostic tools for prostate cancer lack specificity and sensitivity for detecting very early lesions DNA methylation is a stable genomic modification that is detectable in peripheral patient fluids such as urine and blood plasma that could serve as a diagnostic biomarker for prostate measured DNA methylation patterns in 73 clinically annotated prostate cancers and 63 prostate tissues using the Illumina Infinium HumanMethylation450 BeadChip array We overlaid the most significantly differentially methylated sites in the genome with transcription factor binding sites measured by the Encyclopedia of DNA Elements consortium We used logistic regression and receiver operating characteristic curves to assess the performance of candidate diagnostic identified methylation patterns that have a high predictive power for distinguishing malignant prostate tissue from prostate tissue and these methylation signatures were validated using data from The Cancer Genome Atlas Project Furthermore by overlaying ENCODE transcription factor binding data we observed an enrichment of enhancer of zeste homolog 2 binding in gene regulatory regions with higher DNA methylation in malignant prostate methylation patterns are greatly altered in prostate cancer tissue in comparison to tissue We have discovered patterns of DNA methylation marks that can distinguish prostate cancers with high specificity and sensitivity in multiple patient tissue cohorts and we have identified transcription factors binding in these differentially methylated regions that may play important roles in prostate cancer development View details for DOI View details for Web of Science ID 000399668700002 View details for PubMedID 28412973 View details for PubMedCentralID PMC5392915 Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy Results from the Canary Prostate Cancer Active Surveillance Study JOURNAL OF UROLOGY Macleod Ellis Newcomb Zheng Brooks Carroll Gleave Lance Nelson Thompson Wagner A Wei Lin 2017 197 4 View details for DOI View details for Web of Science ID 000398050600025 HETEROGENEITY IN RENAL CELL CARCINOMA IMPLICATIONS FOR PROTEOMIC ANALYSIS OF RENAL MASS BIOPSIES Massoudi Hoerner Metzner Curtis Stell Sabatti Brooks Fan Leppert ELSEVIER SCIENCE 2017 View details for DOI View details for Web of Science ID 000398276602070 Diagnosis of prostate cancer by desorption electrospray ionization mass spectrometric imaging of small metabolites and lipids PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA Banerjee Zare Tibshirani Kunder Nolley Fan Brooks Sonn A 2017 114 13 Abstract Accurate identification of prostate cancer in frozen sections at the time of surgery can be challenging limiting the surgeon ability to best determine resection margins during prostatectomy We performed desorption electrospray ionization mass spectrometry imaging on 54 banked human cancerous and normal prostate tissue specimens to investigate the spatial distribution of a wide variety of small metabolites carbohydrates and lipids In contrast to several previous studies our method included Krebs cycle intermediates 200 which we found to be highly informative in distinguishing cancer from benign tissue Malignant prostate cells showed marked metabolic derangements compared with their benign counterparts Using the Least absolute shrinkage and selection operator Lasso we analyzed all metabolites from the data and identified parsimonious sets of metabolic profiles for distinguishing between cancer and normal tissue In an independent set of samples we could use these models to classify prostate cancer from benign specimens with nearly 90 accuracy per patient Based on previous work in prostate cancer showing that glucose levels are high while citrate is low we found that measurement of the ion signal ratio accurately predicted cancer when this ratio exceeds and normal prostate when the ratio is less than After brief tissue preparation the ratio can be recorded on a tissue sample in 1 min or less which is in sharp contrast to the 20 min or more required by histopathological examination of frozen tissue specimens View details for DOI View details for Web of Science ID 000397607300049 View details for PubMedID 28292895 View details for PubMedCentralID PMC5380053 Novel lincRNA SLINKY is a prognostic biomarker in kidney cancer ONCOTARGET Gong Siprashvili Eminaga Shen Sato Kume Homma Ogawa Khavari Pollack Brooks 2017 8 12 Abstract Clear cell renal cell carcinomas ccRCC show a broad range of clinical behavior and prognostic biomarkers are needed to stratify patients for appropriate management We sought to determine whether long intergenic RNAs lincRNAs might predict patient survival Candidate prognostic lincRNAs were identified by mining The Cancer Genome Atlas TCGA transcriptome data on 466 ccRCC cases randomized into discovery and validation sets annotated for lncRNAs A previously uncharacterized lincRNA SLINKY LINcRNA in KidneY cancer was the prognostic lincRNA and validated in an independent University of Tokyo cohort In multivariable analysis SLINKY expression predicted overall survival independent of tumor stage and grade TCGA CI P Tokyo CI P and by decision tree ROC and decision curve analysis added independent prognostic value In ccRCC cell lines SLINKY knockdown reduced cancer cell proliferation with G1 arrest and induced transcriptome changes enriched for cell proliferation and survival processes Notably the genes affected by SLINKY knockdown in cell lines were themselves prognostic and correlated with SLINKY expression in the ccRCC patient samples From a screen for binding partners we identified direct binding of SLINKY to Heterogeneous Nuclear Ribonucleoprotein K HNRNPK whose knockdown recapitulated SLINKY knockdown phenotypes Thus SLINKY is a robust prognostic biomarker in ccRCC where it functions possibly together with HNRNPK in cancer cell proliferation View details for PubMedID 28423633 Contemporary Use of Partial Nephrectomy Are Older Patients With Impaired Kidney Function Being Left Behind UROLOGY Leppert Mittakanti Thomas Lamberts Sonn Chung Skinner Wagner Chertow Brooks 2017 100 View details for DOI View details for Web of Science ID 000397168900017 Incident CKD after Radical or Partial Nephrectomy Journal of the American Society of Nephrology JASN Leppert Lamberts Thomas Chung Sonn Skinner Wagner Chertow Brooks 2017 Abstract The comparative effectiveness of partial nephrectomy versus radical nephrectomy to preserve kidney function has not been well established We determined the risk of clinically significant stage 4 and higher CKD after radical or partial nephrectomy among veterans treated for kidney cancer in the Veterans Health Administration Among patients with preoperative per m 2 the incidence of CKD stage 4 or higher after radical or partial nephrectomy was overall The median time to stage 4 or higher CKD after surgery was 5 months after which few patients progressed In propensity cohorts partial nephrectomy associated with a significantly lower relative risk of incident CKD stage 4 or higher hazard ratio 95 confidence interval 95 CI to versus radical nephrectomy In a parallel analysis of patients with normal or preoperative kidney function per m 2 partial nephrectomy was also associated with a significantly lower relative risk of incident CKD stage 3b or higher hazard ratio 95 CI to versus radical nephrectomy in propensity cohorts Competing risk regression models produced consistent results Finally patients treated with a partial nephrectomy had reduced risk of mortality hazard ratio 95 CI to In conclusion compared with radical nephrectomy partial nephrectomy was associated with a marked reduction in the incidence of clinically significant CKD and with enhanced survival Postoperative decline in kidney function occurred mainly in the first year after surgery and appeared stable over time View details for PubMedID 29018140 Comparative rates of upstaging and upgrading in Caucasian and Korean prostate cancer patients eligible for active surveillance PloS one Jeon Yoo Jeong Seo Jeon Choi Lee Ferrari Brooks Chung I 2017 12 11 e0186026 Abstract To investigate the impact of race on the risk of pathological upgrading and upstaging at radical prostatectomy RP in an Asian Korean and Western Caucasian cohort eligible for active surveillance AS performed a retrospective cohort study of 854 patients eligible for AS who underwent RP in United States n 261 and Korea n 593 between 2006 and 2015 After adjusting for age PSA level and prostate volume we utilized multivariate logistic regression analysis to assess the effect of race on upgrading or were significant differences between Caucasian and Korean patients in terms of age at surgery PSA density and mean number of positive cores but not in preoperative PSA values The rate of upstaging from cT1 or cT2 to pT3 or higher was not significantly different between the two cohorts P However there were higher rates of upgrading to cancer Gleason or higher in Korean patients when compared to Caucasian counterparts P Multivariate logistic regression analysis showed that age OR P and smaller prostate volume OR P but not race were significantly associated with upstaging or were no differences in rates of upgrading or upstaging between Caucasian and Korean men eligible for active surveillance View details for PubMedID 29136019 Mining Electronic Health Records to Extract Outcomes Following Prostate Cancer Treatment AMIA Annual Symposium proceedings AMIA Symposium Kourdis Seto Ferrari Blayney Rubin Brooks 2017 2017 Abstract The clinical granular data in electronic health record EHR systems provide opportunities to improve patient care using informatics retrieval methods However it is well known that many methodological obstacles exist in accessing data within EHRs In particular clinical notes routinely stored in EHR are composed from narrative highly unstructured and heterogeneous biomedical text This inherent complexity hinders the ability to perform automated medical knowledge extraction tasks without the use of computational linguistics methods The aim of this work was to develop and validate a Natural Language Processing NLP pipeline to detect important outcomes PCOs as interpreted and documented by clinicians in their dictated notes for male patients receiving treatment for localized prostate cancer at an academic medical center View details for PubMedID 29854154 A diagnosis of prostate cancer and pursuit of active surveillance is not followed by weight loss potential for a teachable moment PROSTATE CANCER AND PROSTATIC DISEASES Liss Schenk Faino NEWCOMB Boyer Brooks Carroll Dash Fabrizio Gleave Nelson Neuhouser Wei Zheng Wright Lin THOMPSON 2016 19 4 Abstract Obesity is a risk factor for incident prostate cancer PC as well as risk of disease progression and mortality We hypothesized that men diagnosed with PC and who elected active surveillance AS for their cancer management would likely initiate lifestyle changes that lead to weight were enrolled in the Prostate Active Surveillance Study PASS a multicenter prospective biomarker discovery and validation study of men who have chosen AS for their PC Data from 442 men diagnosed with PC within 1 year of study entry who completed a standard of care visit were analyzed We examined the change in weight and body mass index BMI over the first year of study 1 year on AS of patients had lost 5 or more of their weight The proportion of men who lost 5 or more weight was similar across categories of baseline BMI 8 overweight 6 and obese 10  2 test The results were similar for patients enrolled in the study 1 year or 6 months after diagnosis By contrast after 1 year of patients had gained 5 of their of men with PC enrolled in AS lost a modest amount of weight after diagnosis Given that obesity is related to PC progression and mortality targeted lifestyle interventions may be effective at this moment as men begin AS for PC View details for DOI View details for PubMedID 27431498 Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of Prostate Cancer in Men in the Canary Prostate Active Surveillance Study European urology Lin Newcomb Brown Sjoberg Dong Brooks Carroll Cooperberg Dash Ellis Fabrizio Gleave Morgan Nelson Thompson Wagner A Zheng Y 2016 Abstract Diagnosis of Gleason 6 prostate cancer can leave uncertainty about the presence of undetected aggressive evaluate the utility of a four kallikrein 4K panel in predicting the presence of cancer in men on active collected before the first and subsequent surveillance biopsies was assessed for 718 men prospectively enrolled in the Canary PASS trial Biopsy data were split into training and test sets We developed statistical models that included clinical information and either the 4Kpanel or serum antigen PSA endpoint was reclassification to Gleason We used receiver operating characteristic ROC curve analyses and area under the curve AUC to assess discriminatory capacity and decision curve analysis DCA to report clinical net predictors for reclassification were 4Kpanel odds ratio OR 95 confidence interval CI or PSA OR 95 CI cores positive OR 95 CI two or more prior negative biopsies OR 95 CI prostate volume OR 95 CI and body mass index OR 95 CI ROC curve analysis comparing 4K and base models indicated that the 4Kpanel improved accuracy for predicting reclassification AUC vs at the first surveillance biopsy Both models performed comparably for prediction of reclassification at subsequent biopsies AUC vs In DCA both models showed higher net benefit compared to and strategies Limitations include the single cohort nature of the study and the small numbers results should be validated in another cohort before clinical 4Kpanel provided incremental value over routine clinical information in predicting cancer in the first biopsy after diagnosis The 4Kpanel did not add predictive value to the base model at subsequent surveillance surveillance is a management strategy for many prostate cancers Repeat biopsies monitor for previously undetected cancer We show that a model with clinical variables including a panel of four kallikreins indicates the presence of cancer before a biopsy is performed View details for DOI View details for PubMedID 27889277 MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer A Study PLOS ONE Eminaga Wei Hawley Auman Newcomb Simko Troyer Carroll Gleave Lin Nelson Thompson True McKenney Feng Fazli Brooks 2016 11 11 Abstract The uncertainties inherent in clinical measures of prostate cancer CaP aggressiveness endorse the investigation of clinically validated tissue biomarkers MUC1 expression has been previously reported to independently predict aggressive localized prostate cancer We used a large cohort to validate whether MUC1 protein levels measured by immunohistochemistry IHC predict aggressive cancer recurrence and survival outcomes after radical prostatectomy independent of clinical and pathological IHC was performed on a tissue microarray TMA resource including men with a median of 5 years Associations with clinical and pathological parameters were tested by the test and the Wilcoxon rank sum test Relationships with outcome were assessed with univariable and multivariable Cox proportional hazard models and the presence of MUC1 expression was significantly associated with extracapsular extension and higher Gleason score but not with seminal vesicle invasion age positive surgical margins or serum PSA levels In univariable analyses positive MUC1 staining was significantly associated with a worse recurrence free survival RFS HR CI P although not with disease specific survival DSS P On multivariable analyses the presence of positive surgical margins extracapsular extension seminal vesicle invasion as well as higher PSA and increasing Gleason score were independently associated with RFS while MUC1 expression was not Positive MUC1 expression was not independently associated with disease specific survival DSS but was weakly associated with overall survival OS our large rigorously designed validation cohort MUC1 protein expression was associated with adverse pathological features although it was not an independent predictor of outcome after radical prostatectomy View details for DOI View details for PubMedID 27846218 Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Radical Prostatectomy Cohort Prostate Brooks Wei Pollack West Shin Sunwoo J Hawley Auman Newcomb Simko Troyer Carroll Gleave Lin Nelson Thompson True McKenney Feng Fazli 2016 76 15 Abstract Given the uncertainties inherent in clinical measures of prostate cancer aggressiveness clinically validated tissue biomarkers are needed We tested whether 1 AZGP1 protein levels measured by immunohistochemistry and RNA expression by RNA in situ hybridization RISH predict recurrence after radical prostatectomy independent of clinical and pathological IHC and RISH were performed on a large tissue microarray resource including men with 5 year median The relationship between IHC and RISH expression levels was assessed using the Kappa analysis Associations with clinical and pathological parameters were tested by the test and the Wilcoxon rank sum test Relationships with outcome were assessed with univariable and multivariable Cox proportional hazards models and the or weak expression of AZGP1 protein was associated with worse recurrence free survival RFS disease specific survival and overall survival after radical prostatectomy in univariable analysis AZGP1 protein expression along with serum PSA levels surgical margin status seminal vesicle invasion extracapsular extension and Gleason score predicted RFS on multivariable analysis Similarly absent or low AZGP1 RNA expression by RISH predicted worse RFS after prostatectomy in univariable and multivariable our large rigorously designed validation cohort loss of AZGP1 expression predicts RFS after radical prostatectomy independent of clinical and pathological variables Prostate 2016 Wiley Periodicals View details for DOI View details for PubMedID 27325561 Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy Results from the Canary Prostate Cancer Active Surveillance Study journal of urology Macleod Ellis Newcomb Zheng Brooks Carroll Gleave Lance Nelson Thompson Wagner A Wei Lin 2016 Abstract During active surveillance for localized prostate cancer the timing of the first surveillance biopsy varies We analyzed the Canary PASS Prostate Cancer Active Surveillance Study to determine biopsy timing influence on rates of prostate cancer adverse reclassification at the first active surveillance participants in PASS 421 had fewer than 34 of cores involved with cancer and Gleason sum 6 or less and thereafter underwent active surveillance biopsy Reclassification was defined as an increase in Gleason sum 34 or more of cores with prostate cancer First active surveillance biopsy reclassification rates were categorized as less than 8 8 to 13 and greater than 13 months after diagnosis Multivariable logistic regression determined association between reclassification and first biopsy 421 men 89 experienced reclassification at the first active surveillance biopsy Median time from prostate cancer diagnosis to first active surveillance biopsy was 11 months IQR Reclassification rates at less than 8 8 to 13 and greater than 13 months were 24 19 and 22 p On multivariable analysis compared to men biopsied at less than 8 months the OR of reclassification at 8 to 13 and greater than 13 months were 95 CI and 95 CI respectively Prostate specific antigen density or greater referent less than OR 95 CI and body mass index 35 2 or greater referent less than 25 2 OR 95 CI were associated with increased odds of of the first active surveillance biopsy was not associated with increased adverse reclassification but prostate specific antigen density and body mass index were In low risk patients on active surveillance it may be reasonable to perform the first active surveillance biopsy at a later time reducing the overall cost and morbidity of active surveillance View details for DOI View details for PubMedID 27810448 Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort AMERICAN JOURNAL OF SURGICAL PATHOLOGY McKenney Wei Hawley Auman Newcomb Boyer Fazli Simko Troyer Tretiakova Carroll Cooperberg Gleave Lance Lin Nelson Thompson True Feng Brooks 2016 40 11 Abstract Histologic grading remains the gold standard for prognosis in prostate cancer and assessment of Gleason score plays a critical role in active surveillance management We sought to optimize the prognostic stratification of grading and developed a method of recording and studying individual architectural patterns by light microscopic evaluation that is independent of standard Gleason grade Some of the evaluated patterns are not assessed by current Gleason grading eg reactive stromal response Individual histologic patterns were correlated with survival in a retrospective postradical prostatectomy cohort of 1275 patients represented by the foci of carcinoma in tissue microarrays In univariable analysis fibromucinous rupture with varied epithelial complexity had a significantly lower relative risk of survival in cases graded as Cases having focal poorly formed glands which could be designated as pattern had lower risk than cribriform patterns with either small cribriform glands or expansile cribriform growth In separate multivariable Cox proportional hazard analyses of both Gleason score and carcinomas reactive stromal patterns were associated with worse survival Decision tree models demonstrate potential regrouping of architectural patterns into categories with similar risk In summary we argue that Gleason score assignment by current consensus guidelines are not entirely optimized for clinical use including active surveillance Our data suggest that focal poorly formed gland and cribriform patterns currently classified as Gleason pattern 4 should be in separate prognostic groups as the latter is associated with worse outcome Patterns with extravasated mucin are likely overgraded in a subset of cases with more complex epithelial bridges whereas stromogenic cancers have a worse outcome than conveyed by Gleason grade alone These findings serve as a foundation to facilitate optimization of histologic grading and strongly support incorporating reactive stroma into routine assessment View details for PubMedID 27635949 Contemporary Use of Partial Nephrectomy Are Older Patients With Impaired Kidney Function Being Left Behind Urology Leppert Mittakanti Thomas Lamberts Sonn Chung Skinner Wagner Chertow Brooks 2016 Abstract To assess whether patient factors such as age and preoperative kidney function were associated with receipt of partial nephrectomy in a national integrated healthcare identified patients treated with a radical or partial nephrectomy from 2002 to 2014 in the Veterans Health Administration We examined associations among patient age sex race or ethnicity multimorbidity baseline kidney function tumor characteristics and receipt of partial nephrectomy We estimated the odds of receiving a partial nephrectomy and assessed interactions between covariates and the year of surgery to explore whether patient factors associated with partial nephrectomy changed over our cohort of patients 4508 received a partial nephrectomy Use of partial nephrectomy increased from 17 in 2002 to 32 in 2008 and to 38 in 2014 Patient race or ethnicity age tumor stage and year of surgery were independently associated with receipt of partial nephrectomy Black veterans had significantly increased odds of receipt of partial nephrectomy whereas older patients had significantly reduced odds Partial nephrectomy utilization increased for all groups over time but older patients and patients with worse baseline kidney function showed the least increase in odds of partial the utilization of partial nephrectomy increased for all groups the greatest increase occurred in the youngest patients and those with the highest baseline kidney function These trends warrant further investigation to ensure that patients at the highest risk of impaired kidney function are considered for partial nephrectomy whenever possible View details for DOI View details for PubMedID 27634733 Prognostic value of Ki67 in localized prostate carcinoma a study of 1000 prostatectomies PROSTATE CANCER AND PROSTATIC DISEASES Tretiakova Wei Boyer NEWCOMB Hawley Auman McKenney Fazli Simko Troyer Thompson Carroll Ellis Gleave Nelson Lin True Feng Brooks 2016 19 3 Abstract Expanding interest in and use of active surveillance for early state prostate cancer PC has increased need for prognostic biomarkers Using a tissue microarray resource including over 1000 radical prostatectomy samples we sought to correlate Ki67 expression captured by an automated image analysis system with clinicopathological features and validate its utility as a clinical grade test in predicting immunostaining the Ki67 proliferation index PI of tumor areas of each core three cancer was analyzed using a nuclear quantification algorithm Aperio We assessed whether Ki67 PI was associated with clinicopathological factors and survival RFS including biochemical recurrence metastasis or PC death median 1004 PCs tissue cores Ki67 PI showed significantly higher than variation Ki67 PI was associated with stage P seminal vesicle invasion SVI extracapsular extension ECE P and Gleason score GS P Ki67 PI as a continuous variable significantly correlated with overall and survival by multivariable Cox proportional hazard model hazards ratio HR High Ki67 score defined as was significantly associated with worse RFS and worse overall survival localized PC treated by radical prostatectomy higher Ki67 PI assessed using a clinical grade automated algorithm is strongly associated with a higher GS stage SVI and ECE and greater probability of Cancer and Prostatic Diseases advance online publication 3 May 2016 View details for DOI View details for PubMedID 27136741 Overall Survival in Patients with Localized Prostate Cancer in the US Veterans Health Administration Is PIVOT Generalizable EUROPEAN UROLOGY Barbosa Thomas Srinivas Buyyounouski Chung Chertow Asch Wagner Brooks Leppert 2016 70 2 Abstract A better understanding of overall survival among patients with clinically localized prostate cancer PCa in the US Veterans Health Administration VHA is critical to inform PCa treatment decisions especially in light of data from the Prostate Intervention Versus Observation Trial PIVOT We sought to describe patterns of survival for all patients with clinically localized PCa treated by the VHA We created an analytic cohort of 35 954 patients with clinically localized PCa diagnosed from 1995 to 2001 approximating the PIVOT inclusion criteria age of diagnosis yr and clinical stage T2 or lower Mean patient age was yr and median was 161 mo Overall of patients were treated with surgery were treated with radiotherapy and were treated with androgen deprivation Median survival of the entire cohort was 14 yr 25th 75th percentiles range yr Among patients who received treatment with curative intent median survival was yr following surgery and yr following radiotherapy of patients died within 10 yr of diagnosis compared with nearly half of the participants in PIVOT This finding sounds a note of caution when generalizing the mortality data from PIVOT to VHA patients and those in the than of patients diagnosed with clinically localized prostate cancer treated through the US Veterans Health Administration from 1995 to 2001 died within 10 yr of their diagnosis Caution should be used when generalizing the estimates of competing mortality data from PIVOT View details for DOI View details for PubMedID 26948397 Analytic validation of a PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH MODERN PATHOLOGY Lotan Wei Ludkovski Morais Guedes Jamaspishvili Lopez Hawley Feng Fazli McKenney Simko Carroll Gleave Lin Nelson Thompson True Brooks Lance Troyer Squire J A 2016 29 8 Abstract PTEN loss is a promising prognostic and predictive biomarker in prostate cancer Because it occurs most commonly via PTEN gene deletion we developed a automated and inexpensive immunohistochemical assay to detect PTEN loss We studied the sensitivity and specificity of PTEN immunohistochemistry relative to fluorescence in situ hybridization FISH for detection of PTEN gene deletion in a cohort of 731 primary prostate tumors Intact PTEN immunostaining was 91 specific for the absence of PTEN gene deletion tumors with two copies of the PTEN gene by FISH showed intact expression of PTEN by immunohistochemistry and 97 sensitive for the presence of homozygous PTEN gene deletion absent PTEN protein expression by immunohistochemistry in tumors with homozygous deletion PTEN immunohistochemistry was 65 sensitive for the presence of hemizygous PTEN gene deletion with protein loss in hemizygous tumors We reviewed the 53 cases where immunohistochemistry showed PTEN protein loss and FISH showed two intact copies of the PTEN gene On there was ambiguous immunohistochemistry loss in 6 and failure to analyze the same tumor area by both methods in 34 Of the remaining discordant cases 41 revealed hemizygous or homozygous PTEN gene deletion that was focal in most cases The remaining 19 cases had two copies of the PTEN gene detected by FISH representing truly discordant cases Our automated PTEN immunohistochemistry assay is a sensitive method for detection of homozygous PTEN gene deletions Immunohistochemistry screening is particularly useful to identify cases with heterogeneous PTEN gene deletion in a subset of tumor glands Mutations small insertions or deletions epigenetic or mechanisms may lead to PTEN protein loss in tumors with normal or hemizygous PTEN gene copy Pathology advance online publication 13 May 2016 View details for DOI View details for Web of Science ID 000380821400012 View details for PubMedID 27174589 The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial EUROPEAN RADIOLOGY Jamshidi Jonasch Zapala Korn Brooks Ljungberg Kuo 2016 26 8 Abstract To characterize a radiogenomic risk score RRS a previously defined biomarker and to evaluate its potential for stratifying radiological survival rPFS in patients with metastatic renal cell carcinoma mRCC undergoing treatment with this study prospective imaging analysis of the RRS was performed on phase II clinical trial data of mRCC patients n 41 evaluating whether patient stratification according to the RRS resulted in groups more or less likely to have a rPFS to bevacizumab prior to cytoreductive nephrectomy Survival times of RRS subgroups were analyzed using survival RRS is enriched in diverse molecular processes including drug response stress response protein kinase regulation and signal transduction pathways P The RRS successfully stratified rPFS to bevacizumab based on computed tomography imaging with a median survival of 6 versus 25 months P and overall survival of 25 versus 37 months in the high and low RRS groups P respectively Conventional prognostic predictors including the Motzer and Heng criteria were not predictive in this cohort P RRS stratifies rPFS to bevacizumab in patients from a phase II clinical trial with mRCC undergoing cytoreductive nephrectomy and The RRS SOMA stratifies patient outcomes in a phase II clinical trial RRS stratifies subjects into prognostic groups in a discrete or continuous fashion RRS is biologically enriched in diverse processes including drug response programs View details for DOI View details for Web of Science ID 000379192500043 View details for PubMedID 26560727 PTEN Loss as Determined by Immunohistochemistry Assay Is Associated with Worse Survival in Prostate Cancer European urology focus Lotan Wei Morais Hawley Fazli Troyer McKenney Simko Carroll Gleave Lance Lin Nelson Thompson True Feng Brooks 2016 2 2 Abstract PTEN is the most commonly deleted tumor suppressor gene in primary prostate cancer PCa and its loss is associated with poor clinical outcomes and ERG gene tested whether PTEN loss is associated with shorter survival RFS in surgically treated PCa patients with known ERG genetically validated automated PTEN immunohistochemistry IHC protocol was used for 1275 primary prostate tumors from the Canary Foundation retrospective PCa tissue microarray cohort to assess homogeneous in all tumor tissue sampled or heterogeneous in a subset of tumor tissue sampled PTEN loss ERG status as determined by a genetically validated IHC assay was available for a subset of 938 between PTEN and ERG status were assessed using Fisher exact test and multivariate weighted Cox proportional models for RFS were compared to intact PTEN homogeneous hazard ratio HR p but not heterogeneous HR p PTEN loss was significantly associated with shorter RFS in multivariate models Among tumors homogeneous HR p but not heterogeneous HR p PTEN loss was significantly associated with shorter RFS Among tumors PTEN did not reach significance for inclusion in the final multivariate models The interaction term for PTEN and ERG status with respect to RFS did not reach statistical significance p for the current sample data suggest that PTEN is a useful prognostic biomarker and that there is no statistically significant interaction between PTEN and ERG status for found that loss of the PTEN tumor suppressor gene in prostate tumors as assessed by tissue staining is correlated with shorter time to prostate cancer recurrence after radical prostatectomy View details for PubMedID 27617307 PROSTATE CANCER YIELD IN MRI LESIONS VARIES ACROSS RADIOLOGISTS Sonn Fan Li Ghanouni Loening Daniel To o Gill Chung Brooks ELSEVIER SCIENCE 2016 E42 View details for DOI View details for Web of Science ID 000375278600096 GSTP1 Loss Results in Accumulation of Oxidative DNA Base Damage and Promotes Prostate Cancer Cell Survival Following Exposure to Protracted Oxidative Stress PROSTATE Mian Khattab Hedayati Coulter Schwaninger Veeraswamy Brooks Hopkins Shinohara Cornblatt Nelson Yegnasubramanian DeWeese 2016 76 2 Abstract Epigenetic silencing of glutathione  GSTP1 is a hallmark of transformation from normal prostatic epithelium to adenocarcinoma of the prostate The functional significance of this loss is incompletely understood The present study explores the effects of restored GSTP1 expression on glutathione levels accumulation of oxidative DNA damage and prostate cancer cell survival following oxidative stress induced by protracted low dose rate ionizing radiation LDR protein expression was stably restored in LNCaP prostate cancer cells The effect of GSTP1 restoration on protracted oxidative DNA damage was measured by quantitation of modified bases Reduced and oxidized glutathione levels were measured in control and GSTP1 expressing populations Clonogenic survival studies of transfected LNCaP cells after exposure to protracted LDR were performed Global gene expression profiling and pathway analysis were expressing cells accumulated less oxidized DNA base damage and exhibited decreased survival compared to control cells following oxidative injury induced by protracted LDR Restoration of GSTP1 expression resulted in changes in modified glutathione levels that correlated with GSTP1 protein levels in response to protracted oxidative stress Survival differences were not attributable to depletion of cellular glutathione stores Gene expression profiling and pathway analysis following GSTP1 restoration suggests this protein plays a key role in regulating prostate cancer cell ubiquitous epigenetic silencing of GSTP1 in prostate cancer results in enhanced survival and accumulation of potentially promutagenic DNA adducts following exposure of cells to protracted oxidative injury suggesting a protective function of GSTP1 The present work provides mechanistic backing to the tumor suppressor function of GSTP1 and its role in prostate carcinogenesis Prostate 2015 Wiley Periodicals View details for DOI View details for Web of Science ID 000368810600007 View details for PubMedID 26447830 Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective Canary PASS Cohort JOURNAL OF UROLOGY Newcomb Thompson Boyer Brooks Carroll Cooperberg Dash Ellis Fazli Feng Gleave Kunju Lance McKenney Meng Nicolas Sanda Simko So Tretiakova Troyer True Virgin Wagner A Wei Zheng Nelson Lin 2016 195 2 Abstract Active surveillance represents a strategy to address the overtreatment of prostate cancer yet uncertainty regarding individual patient outcomes remains a concern We evaluated outcomes in a prospective study of active studied 905 men in the prospective Canary Prostate cancer Active Surveillance Study PASS enrolled between 2008 to 2013 We collected clinical data at study entry and at intervals and determined associations with adverse reclassification defined as increased Gleason grade or greater cancer volume on biopsy We also evaluated the relationships of clinical parameters with pathology findings in participants who underwent surgery after a period of active a median of 28 months 24 of participants experienced adverse reclassification of whom 53 underwent treatment while 31 continued active surveillance Overall 19 of participants received treatment 68 with adverse reclassification while 32 opted for treatment without disease reclassification In multivariate Cox proportional hazards modeling percent of biopsy cores with cancer BMI and PSA density were associated with adverse reclassification P Of 103 participants subsequently treated by radical prostatectomy 34 had adverse pathology defined as primary pattern or confined disease including two with positive lymph nodes with no significant relationship between risk category at diagnosis and findings at surgery P men remain on active surveillance at five years without adverse reclassification or adverse pathology at surgery However clinical factors had only modest association with disease reclassification supporting the need for approaches that improve prediction of this outcome View details for DOI View details for Web of Science ID 000368054800023 Reply to being a widower may be an indication for routine antigen screening above age 69 years which the American Urological Association recommends as a cutoff point Cancer Gomez Martnez Brooks Cheng Lichtensztajn Murphy 2016 View details for PubMedID 27286520 New Paradigms for Outcomes Research in Electronic Medical Records An Example of Detecting Urinary Incontinence Following Prostatectomy EGEMS Washington DC Tamang Blayney Brooks Shah 2016 4 3 Abstract National initiatives to develop quality metrics emphasize the need to include outcomes outcomes are complex require documentation of patient communications and have not been routinely collected by healthcare providers The widespread implementation of electronic medical records EHR offers opportunities to assess outcomes within the routine healthcare delivery system The objective of this study was to test the feasibility and accuracy of identifying patient centered outcomes within the from patients with localized prostate cancer undergoing prostatectomy were used to develop and test algorithms to accurately identify outcomes in EHRs we used urinary incontinence as the use case Standard data mining techniques were used to extract and annotate free text and structured data to assess urinary incontinence recorded within the total prostate cancer patients were identified in our between Among these EHRs had a text mention of urinary incontinence within 90 days compared to less than with a structured data field for urinary incontinence code Our workflow had good precision and recall for urinary incontinence positive predictive value and sensitivity data indicate that important outcomes such as urinary incontinence are being captured in EHRs as free text and highlight the importance of accurate clinician documentation Standard data mining algorithms can accurately and efficiently identify these outcomes in existing EHRs the complete assessment of these outcomes is essential to move practice into the realm of healthcare View details for DOI View details for PubMedID 27347492 Accuracy of Antigen Values in Prostate Cancer Registries Journal of clinical oncology official journal of the American Society of Clinical Oncology Mittakanti Thomas Shelton J Makarov Skolarus Cooperberg Chung Sonn Brooks Leppert 2016 View details for PubMedID 27458297 Precision Medicine in Active Surveillance for Prostate Cancer Development of the Detection Research Network Active Surveillance Biopsy Risk Calculator EUROPEAN UROLOGY Ankerst Xia Thompson Hoefler Newcomb Brooks Carroll Ellis Gleave Lance Nelson Wagner A Wei Etzioni Lin 2015 68 6 Abstract Men on active surveillance AS face repeated biopsies Most biopsy specimens will not show disease progression or change management Such biopsies do not contribute to patient management and are potentially morbid and use a contemporary AS prospective trial to develop a tool to predict AS biopsy samples median 2 range per patient from 859 men participating in the Canary Prostate Active Surveillance Study and with Gleason 6 prostate cancer median mo range mo were regression was used to predict progression defined as an increase in Gleason score from to or increase in percentage of cores positive for cancer from 34 to Fivefold internal was performed to evaluate the area under the receiver operating characteristic curve AUC significant risk factors for progression on biopsy were antigen odds ratio OR 95 confidence interval CI percentage of cores positive for cancer on most recent biopsy OR 95 CI and history of at least one prior negative biopsy OR 95 CI A multivariable predictive model incorporating these factors plus age and number of months since last biopsy achieved an AUC of combination of readily available clinical measures can stratify patients considering AS prostate biopsy Risk of progression or upgrade can be estimated and incorporated into clinical Detection Research Network Active Surveillance Biopsy Risk Calculator an online tool can be used to guide patient decision making regarding prostate biopsy View details for DOI View details for PubMedID 25819722 The Radiogenomic Risk Score Construction of a Prognostic Quantitative Noninvasive Molecular Assay for Renal Cell Carcinoma RADIOLOGY Jamshidi Jonasch Zapala Korn Aganovic Zhao Sitaram Tibshirani Banerjee Brooks Ljungberg Kuo 2015 277 1 Abstract Purpose To evaluate the feasibility of constructing surrogates of molecular assays SOMAs in patients with renal cell carcinoma CCRCC by using data extracted from a single computed tomographic CT image Materials and Methods In this institutional review board approved study gene expression profile data and contrast CT images from 70 patients with CCRCC in a training set were independently assessed by two radiologists for a set of predefined imaging features A SOMA for a previously validated supervised principal component SPC risk score prognostic gene signature was constructed and termed the radiogenomic risk score RRS It uses the microarray data and a image array to evaluate each CT image with multiple regression of gene expression analysis The predictive power of the RRS SOMA was then prospectively validated in an independent dataset to confirm its relationship to the SPC gene signature n 70 and determination of patient outcome n 77 Data were analyzed by using multivariate linear methods and Cox regression modeling and significance was assessed with receiver operator characteristic curves and survival analysis Results Our SOMA faithfully represents the molecular assay it models The RRS scaled with the SPC gene signature R P classification accuracy P and predicted survival log rank P Independent validation confirmed the relationship between the RRS and the SPC gene signature R P classification accuracy P and survival P and that it was independent of stage grade and performance status multivariate Cox model P P Conclusion A SOMA for the SPC prognostic gene signature that is predictive of survival and independent of stage was constructed and validated confirming that SOMA construction is feasible RSNA 2015 Online supplemental material is available for this article An earlier incorrect version of this article appeared online This article was corrected on August 24 2015 View details for DOI View details for Web of Science ID 000368434000014 A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer PROSTATE Troyer Jamaspishvili Wei Feng Good Hawley Fazli McKenney Simko Carroll Gleave Lance Lin Nelson Thompson True Brooks Squire J A 2015 75 11 Abstract Loss of the phosphatase and tensin homolog PTEN tumor suppressor gene is a promising marker of aggressive prostate cancer Active surveillance and watchful waiting are increasingly recommended to patients with small tumors felt to be low risk highlighting the difficulties of Gleason scoring in this setting There is an urgent need for predictive biomarkers that can be rapidly deployed to aid in clinical Our objectives were to assess the incidence and ability of PTEN alterations to predict aggressive disease in a multicenter used recently developed probes optimized for sensitivity and specificity in a FISH deletion assay to study the Canary Retrospective multicenter Prostate Cancer Tissue Microarray TMA This TMA was constructed specifically for biomarker validation from radical prostatectomy specimens and is accompanied by detailed clinical information with 612 prostate cancers the overall rate of PTEN deletion was 112 Hemizygous PTEN losses were present in of cancers whereas homozygous PTEN deletion was observed in of tumors Significant associations were found between PTEN status and pathologic stage P seminal vesicle invasion P extracapsular extension P and Gleason score P In logistic regression analysis of clinical and pathological variables PTEN deletion was significantly associated with extracapsular extension seminal vesicle involvement and higher Gleason score In the 406 patients in which clinical information was available PTEN homozygous P deletion was associated with worse survival number of events 189 prostate specific antigen PSA P and pathologic stage P status assessed by FISH is an independent predictor for survival in multivariate models as were seminal vesicle invasion extracapsular extension and Gleason score and preoperative PSA Furthermore these data demonstrate that the assay can be readily introduced at first diagnosis in a cost effective manner analogous to the use of FISH for analysis of status in breast cancer Combined with published research beginning 17 years ago both the data and tools now exist to implement a PTEN assay in the clinic Prostate 75 2015 2015 The Authors The Prostate published by Wiley Periodicals View details for DOI View details for PubMedID 25939393 quantitative analysis of protein glycoforms in human prostate cancer plasma Totten Kulloli Tanimoto Brooks Pitteri AMER ASSOC CANCER RESEARCH 2015 View details for DOI View details for Web of Science ID 000371578503320 Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Radical Prostatectomy Cohort of 1067 Patients PLOS ONE Brooks Wei Hawley Auman Newcomb Boyer Fazli Simko Troyer Carroll Gleave Lance Lin Nelson Thompson True Feng McKenney 2015 10 7 Abstract Distinguishing between patients with early stage screen detected prostate cancer who must be treated from those that can be safely watched has become a major issue in prostate cancer care Identification of molecular subtypes of prostate cancer has opened the opportunity for testing whether biomarkers that characterize these subtypes can be used as biomarkers of prognosis Two established molecular subtypes are identified by high expression of the ERG oncoprotein due to structural DNA alterations that encode for fusion transcripts in approximately  of prostate cancers and of SPINK1 which is purportedly found only in tumors We used a prostate cancer tissue microarray constructed from radical prostatectomy samples with associated detailed clinical data and with rigorous selection of recurrent and cases to test the prognostic value of immunohistochemistry staining results for the ERG and SPINK1 proteins In univariate analysis ERG positive cases 39 were associated with lower patient age serum PSA levels lower Gleason scores and improved recurrence free survival RFS On multivariate analysis ERG status was not correlated with RFS disease specific survival DSS or overall survival OS SPINK1 protein expression cases 3 was associated with improved RFS on univariate and multivariate Cox regression analysis of either protein was not associated with clinical outcome While expression of ERG and SPINK1 proteins was inversely correlated it was not mutually exclusive since 3 cases showed high expression of both While ERG and SPINK1 appear to identify discrete molecular subtypes of prostate cancer only high expression of SPINK1 was associated with improved clinical outcome However by themselves neither ERG nor SPINK1 appear to be useful biomarkers for prognostication of early stage prostate cancer View details for DOI View details for Web of Science ID 000358194900044 View details for PubMedCentralID PMC4501723 The impact of robotic surgery on the surgical management of prostate cancer in the USA BJU INTERNATIONAL Chang Kibel Brooks Chung I 2015 115 6 Abstract To describe the surgeon characteristics associated with RARP adoption and determine the possible impact of this adoption on practice patterns and retrospective cohort study with a weighted sample size of men who underwent open or laparoscopic radical prostatectomy RP or RARP in the United States from 2003 to 2010 was performed We evaluated predictors for RARP adoption defined as performing 50 of annual RP with the robotic approach Additionally we identified the resulting changes in prostate cancer surgery practice patterns and 2003 to 2010 RARP adoption increased from to 42 of surgeons performing RP surgeons defined as performing 24 RP annually had statically significantly higher odds of adopting RARP throughout the study period From 2005 to 2007 adoption was more common among surgeons at teaching OR 95 CI beds OR 95 CI and hospitals beds OR 95 CI after 2007 adoption was more common among surgeons at urban hospitals OR 95 CI to RARP adoption was generally associated with increased RP volume greatest for surgeons and least for surgeons 5 RP annually The annual number of surgeons performing RP decreased from approximately to with the proportion of cases performed by surgeons increasing from 10 to 45 RARP was more costly disproportionally contributing to the 40 increase in annual prostate cancer surgery expenditures RARP costs generally decreased plateauing at over while costs increased to nearly by the end of the was widespread RARP adoption in the United States between 2003 and 2010 particularly among surgeons The diffusion of RARP was associated with a centralization of care and an increased economic burden for prostate cancer surgery View details for DOI View details for Web of Science ID 000355275600019 View details for PubMedID 24958338 Re Nationwide prevalence of lymph node metastases in Gleason score 3 3 6 prostate cancer authors reply Pathology Sieh Lichtensztajn Gomez Liu Chung Cheng Brooks 2015 47 4 View details for DOI View details for PubMedID 25938367 Increased Risk of Cancer in Infertile Men Analysis of US Claims Data JOURNAL OF UROLOGY Eisenberg Li Brooks Cullen Baker 2015 193 5 Abstract Aberrations in reproductive fitness may be a harbinger of medical diseases in men Data suggest a higher risk of testicular cancer in infertile men However the relationship between infertility and other cancers remains analyzed subjects from the Truven Health claims database from 2001 to 2009 Infertile men were identified through diagnosis and treatment codes Comparison groups were created of men who underwent vasectomy and a control cohort of men who were not infertile and had not undergone vasectomy The incidence of cancer was compared to national estimates Infertile men were also compared to men who underwent vasectomy and the control cohort using a Cox regression total of infertile men were identified with an average age of years Overall men who underwent vasectomy and control men were assembled Compared to age adjusted national averages infertile vasectomy and control subjects in the study cohorts had higher rates of all cancers and many individual cancers In time to event analysis infertile men had a higher risk of cancer than those who underwent vasectomy or controls Infertile men had a higher risk of testis cancer nonHodgkin lymphoma and all cancers than the vasectomy and control with prior reports we identified an increased risk of testicular cancer in infertile men The current data also suggest that infertile men are at a mildly increased risk of all cancers in the years after infertility evaluation Future research should focus on confirming these associations and elucidating pathways between infertility and cancer View details for DOI View details for Web of Science ID 000353113200052 View details for PubMedID 25463997 NUSAP1 expression is upregulated by loss of RB1 in prostate cancer cells Prostate Gordon Gulzar Brooks 2015 75 5 Abstract Overexpression of NUSAP1 is associated with poor prognosis in prostate cancer but little is known about what leads to its overexpression Based on previous observations that NUSAP1 expression is enhanced by E2F1 we hypothesized that NUSAP1 expression is regulated at least in part by loss of RB1 via the Significance Analysis of Microarrays we examined RB1 E2F1 and NUSAP1 transcript levels in prostate cancer gene expression datasets We compared NUSAP1 expression levels in DU145 LNCaP and prostate cancer cell lines via use of cDNA microarray data and Western blots In addition we used lentiviral expression constructs to knockdown RB1 in prostate cancer cell lines and transient transfections to knockdown E2F1 and investigated RB1 E2F1 and NUSAP1 expression levels with and Western blots Finally in DU145 cells or cells that stably underexpress RB1 we used proliferation and invasion assays to assess whether NUSAP1 knockdown affects proliferation or transcript levels are positively correlated with E2F1 and negatively correlated with RB1 transcript levels in prostate cancer microarray datasets NUSAP1 expression is elevated in the DU145 prostate cancer cell line as opposed to LNCaP and cell lines Furthermore NUSAP1 expression increases upon knockdown of RB1 in prostate cancer cell lines LNCaP and and decreases after knockdown of E2F1 Lastly knockdown of NUSAP1 in DU145 cells or cells with stable knockdown of RB1 decreases proliferation and invasion of these studies support the notion that NUSAP1 expression is upregulated by loss of RB1 via the axis in prostate cancer cells Such upregulation may promote prostate cancer progression by increasing proliferation and invasion of prostate cancer cells NUSAP1 may thus represent a novel therapeutic target Prostate 75 2015 2015 Wiley Periodicals View details for DOI View details for PubMedID 25585568 Biologic Differences Between Peripheral and Transition Zone Prostate Cancer PROSTATE Lee Thomas Nolley Ferrari Brooks Leppert 2015 75 2 Abstract Prostate cancer arises in the transition zone TZ in approximately of cases Modern biopsy and surveillance protocols and advances in prostate cancer imaging have renewed interest in TZ prostate cancers We compared TZ and PZ prostate cancer to determine if cancer location is independently associated with better evaluated an expanded cohort of 1354 men who underwent radical prostatectomy between 1983 and 2003 with updated clinical Regression models were used to compare the volume of Gleason 4 or 5 cancer and total cancer volume by location and logistic regression models tested the associations between cancer location and adverse pathologic features Multivariable proportional hazard models were fit to examine cancer with TZ cancer presented with higher serum PSA values and larger total cancer volume cc Patients with TZ cancer had decreased odds of seminal vesicle invasion OR 95 CI extension OR 95 CI and lymphovascular invasion OR 95 CI in multivariable models TZ cancers were independently associated with decreased hazard of tumor recurrence HR 95 CI cancer prostate is associated with favorable pathologic features and better survival despite being diagnosed with larger cancers and higher PSA values Tumor location should be taken into account when stratifying patient risk before and after prostatectomy particularly with the evolving role of imaging in prostate cancer management Prostate 2015 2014 Wiley Periodicals View details for DOI View details for PubMedID 25327466 PTEN Status Determination in Prostate Cancer Comparison of IHC and FISH in a Large Cohort Lotan Moray Wei Troyer Jamaspishvili McKenney Simko Brooks Squire J NATURE PUBLISHING GROUP 2015 241A View details for Web of Science ID 000348948001466 A Magnetic Sensor for the Quantification of Multiple Prostate Cancer Biomarkers PloS one Jokerst Chen Xu Nolley Chang Mitchell Brooks Gambhir 2015 10 9 e0139484 Abstract Novel biomarker assays and upgraded analytical tools are urgently needed to accurately discriminate benign prostatic hypertrophy BPH from prostate cancer CaP To address this unmet clinical need we report a assay to quantitate prostate specific antigen PSA free and total prostatic acid phosphatase carbonic anhydrase 1 CA1 osteonectin soluble receptor and We used the sensor to measure these seven proteins in serum samples from 120 benign prostate hypertrophy patients and 100 Gleason score 6 and 7 CaP using serum samples previously collected and banked The results were analyzed with receiver operator characteristic curve analysis There were significant differences between BPH and CaP patients in the PSA CA1 and assays The highest AUC discrimination was achieved with a OR PSA area under the curve was with a p value below Some of these data seem to contradict previous reports and highlight the importance of sample selection and proper assay building in the development of biomarker measurement schemes This system offers important advantages in assay building including low cost high throughput and rapid identification of an optimal matched antibody pair View details for DOI View details for PubMedID 26421725 View details for PubMedCentralID PMC4589536 Novel Fusion Transcripts Associate with Progressive Prostate Cancer AMERICAN JOURNAL OF PATHOLOGY Yu Ding Chen Liu Michalopoulos Chen Gulzar Yang Cieply Luvison Ren Brooks Jarrard Nelson J Michalopoulos Tseng Luo J 2014 184 10 Abstract The mechanisms underlying the potential for aggressive behavior of prostate cancer PCa remain elusive In this study whole genome transcriptome sequencing was performed on 19 specimens of PCa matched adjacent benign prostate tissues matched blood specimens and organ donor prostates A set of novel fusion transcripts was discovered in PCa Eight of these fusion transcripts were validated through multiple approaches The occurrence of these fusion transcripts was then analyzed in 289 prostate samples from three institutes with clinical ranging from 1 to 15 years The analyses indicated that most patients 69 91 of 76 positive for any of these fusion transcripts and experienced PCa recurrence metastases death after radical prostatectomy These outcomes occurred in only 37 of patients without carrying those fusion transcripts Three fusion transcripts occurred exclusively in PCa samples from patients who experienced recurrence or death The formation of these fusion transcripts may be the result of genome recombination A combination of these fusion transcripts in PCa with Gleason grading or with nomogram significantly improves the prediction rate of PCa recurrence Our analyses suggest that formation of these fusion transcripts may underlie the aggressive behavior of PCa View details for DOI View details for Web of Science ID 000342276800023 Higher rates of upgrading and upstaging in older patients undergoing radical prostatectomy and qualifying for active surveillance BJU INTERNATIONAL Busch Magheli Leva Ferrari Kramer Klopf Kempkensteffen Miller Brooks Gonzalgo 2014 114 4 View details for DOI View details for Web of Science ID 000343007100012 The feasibility of assessing amino acid metabolism in cellular models of prostate cancer with hyperpolarized 13 C Magnetic resonance imaging Billingsley Park Josan Hurd Mayer Nishimura Brooks Spielman 2014 32 7 Abstract Recent advancements in the field of hyperpolarized 13 C magnetic resonance spectroscopy MRS have yielded powerful techniques capable of analysis of metabolic pathways These methods have increasingly shown application in impacting disease diagnosis and have further been employed in mechanistic studies of disease onset and progression Our goals were to investigate aminotransferase BCAT activity in prostate cancer with a novel molecular probe hyperpolarized 13 C 13 C and explore the potential of amino acid BCAA metabolism to serve as a biomarker Using traditional spectrophotometric assays BCAT enzymatic activities were determined in vitro for various sources of prostate cancer human transgenic adenocarcinoma of the mouse prostate TRAMP mouse and human cell lines These preliminary studies indicated that low levels of BCAT activity were present in all models of prostate cancer but enzymatic levels are altered significantly in prostate cancer relative to healthy tissue The MR spectroscopic studies were conducted with two cellular models and that exhibited levels of BCAA metabolism comparable to the human disease state Hyperpolarized 13 C was administered to prostate cancer cell lines and the conversion of 13 C to the metabolic product 13 C 13 C could be monitored via hyperpolarized 13 C View details for DOI View details for PubMedID 24907854 View details for PubMedCentralID PMC4099288 Increased Expression of GCNT1 is Associated With Altered of PSA PAP and MUC1 in Human Prostate Cancers PROSTATE Chen Gulzar St Hill Walcheck Brooks 2014 74 10 Abstract Protein glycosylation is a common posttranslational modification and glycan structural changes have been observed in several malignancies including prostate cancer We hypothesized that altered glycosylation could be related to differences in gene expression levels of glycoprotein synthetic enzymes between normal and malignant prostate interrogated prostate cancer gene expression data for reproducible changes in expression of glycoprotein synthetic enzymes of GCNT1 was validated in prostate samples using ELISA was used to measure core 2 glycan sialyl Lewis X sLe x of prostate specific antigen PSA Mucin1 MUC1 and prostatic acidic phosphatase PAP key glycosyltransferase GCNT1 was consistently in several prostate cancer gene expression datasets confirmed increased transcript levels in cancer samples compared to normal prostate tissue in prostate tissue samples ELISA using PSA PAP and MUC1 capture antibodies and a specific core 2 sLe x detection antibody demonstrated elevation of this glycan structure in cancer compared to normal tissues for MUC1 P PSA P and near significant differences in PAP sLe x levels P MUC1 PSA and PAP protein levels alone were not significantly different between paired normal and malignant prostate is in prostate cancer and is associated with higher levels of core 2 x in PSA PAP and MUC1 proteins Alterations of glycosylation could be important in prostate cancer biology and could provide a new avenue for development of prostate cancer specific glycoprotein biomarkers Prostate 2014 Wiley Periodicals View details for DOI View details for Web of Science ID 000338039500007 View details for PubMedID 24854630 Measurement of urinary incontinence after prostate surgery from electronic health records EHR Tamang Brooks Blayney Shah AMER SOC CLINICAL ONCOLOGY 2014 View details for Web of Science ID 000358613203796 Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era International journal of cancer Journal international du cancer Conti Thomas Hagedorn Chung Chertow Wagner Brooks Srinivas Leppert 2014 134 9 Abstract We sought to analyze utilization and survival outcomes of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma RCC before and after introduction of targeted therapy We identified patients with metastatic RCC between 1993 and 2010 in the SEER registry and examined temporal trends in utilization We performed a joinpoint regression to determine when changes in utilization of cytoreductive nephrectomy occurred We fitted multivariable proportional hazard models in full and propensity cohorts We performed a analysis to compare survival outcomes before and after introduction of targeted therapy The proportion of patients undergoing cytoreductive nephrectomy increased from 1993 to 2004 from 29 to 39 We identified a primary joinpoint of 2004 just prior to the introduction of targeted therapy Beginning in 2005 there was a modest decrease in utilization of cytoreductive nephrectomy Cytoreductive nephrectomy was associated with a lower adjusted relative hazard 95 confidence interval to Median survival among patients receiving cytoreductive nephrectomy increased in the targeted therapy era 19 versus 13 months while median survival among patients not receiving cytoreductive nephrectomy increased only slightly 4 versus 3 months analysis showed a significant decrease in hazard of death among patients who received cytoreductive nephrectomy in the targeted therapy era Despite decreased utilization in the targeted therapy era cytoreductive nephrectomy remains associated with improved survival Prospective randomized trials are needed to confirm the benefit of cytoreductive nephrectomy among patients with metastatic RCC treated with novel targeted therapies 2013 Wiley Periodicals View details for PubMedID 24135850 Prostate cancer risk profiles of men disentangling the effects of immigration status and journal of urology Lichtensztajn Gomez Sieh Chung Cheng Brooks 2014 191 4 Abstract men with prostate cancer have been reported to present with higher grade and later stage disease than White Americans However Asian Americans comprise a heterogeneous population with distinct health outcomes We compared prostate cancer risk profiles among the diverse racial and ethnic groups in used data from the California Cancer Registry for White Black and men diagnosed with prostate cancer between 2004 and 2010 Patients were categorized into low intermediate or groups based on clinical stage Gleason score and PSA value at diagnosis Using polytomous logistic regression we estimated adjusted odds ratios for the association of and nativity with risk addition to Blacks six groups Chinese Chinese Japanese Japanese Filipino and Vietnamese were more likely to have an unfavorable risk profile compared to Whites The odds ratios for high disease ranged from 95 CI for Japanese to 95 CI for Filipinos These associations appeared to be driven by higher grade and PSA values rather than advanced clinical stage at this large ethnically diverse cohort we found that men were more likely to have unfavorable risk profiles at diagnosis This association varied by group and nativity and was not attributable to later stage at diagnosis suggesting that Asian men may have biological differences that predispose to the development of more severe disease View details for DOI View details for PubMedID 24513166 Reply Urology Leppert Hanley Wagner Chung Brooks Srinivas Chertow Saigal 2014 83 4 View details for DOI View details for PubMedID 24529590 Utilization of renal mass biopsy in patients with renal cell carcinoma Urology Leppert Hanley Wagner Chung Srinivas Chertow Brooks Saigal 2014 83 4 Abstract To examine the patient tumor and temporal factors associated with receipt of renal mass biopsy RMB in a contemporary nationally representative queried the Surveillance Epidemiology and End data set for incident cases of renal cell carcinoma diagnosed between 1992 and 2007 We tested for associations among receipt of RMB and patient and tumor characteristics type of therapy and procedure type Temporal trends in receipt of RMB were characterized over the study 1 in 5 patients diagnosed with renal cell carcinoma n underwent RMB before instituting therapy There was a steady and modest increase in RMB utilization with the highest utilization 30 occurring in the final study year Of patients who underwent radical n or partial n 2211 nephrectomy 17 and 20 respectively underwent RMB in advance of surgery percent of patients who underwent ablation n 314 underwent RMB before or in conjunction with the procedure Roughly half of patients treated with systemic therapy alone underwent RMB Factors independently associated with use of RMB included younger age black race Hispanic ethnicity tumor size 7 cm and metastatic disease at present most patients who eventually undergo radical or partial nephrectomy do not undergo RMB whereas most patients who eventually undergo ablation or systemic therapy do The optimal use of RMB in the evaluation of kidney tumors has yet to be determined View details for DOI View details for PubMedID 24529579 DNA methylation profiling reveals novel diagnostic biomarkers in renal cell carcinoma BMC medicine Lasseigne Burwell Patil Absher Brooks Myers 2014 12 1 235 Abstract BackgroundRenal cell carcinoma RCC is the tenth most commonly diagnosed cancer in the United States While it is usually lethal when metastatic RCC is successfully treated with surgery when tumors are confined to the kidney and have low tumor volume Because most early stage renal tumors do not result in symptoms there is a strong need for biomarkers that can be used to detect the presence of the cancer as well as to monitor patients during and after examined DNA methylation alterations in renal cell carcinomas of diverse histologies and benign adjacent kidney tissues from 96 observed widespread methylation differences between tumors and benign adjacent tissues particularly in coupled and genes Additionally we identified a single panel of DNA methylation biomarkers that reliably distinguishes tumor from benign adjacent tissue in all of the most common kidney cancer histologic subtypes and a second panel does the same specifically for clear cell renal cell carcinoma tumors This set of biomarkers were validated independently with excellent performance characteristics in more than tissues in The Cancer Genome Atlas clear cell papillary and chromophobe renal cell carcinoma DNA methylation profiles provide insights into the etiology of renal cell carcinoma and most importantly demonstrate clinically applicable biomarkers for use in early detection of kidney cancer View details for PubMedID 25472429 View details for PubMedCentralID PMC4265327 proteomic profiling to define diagnostic signatures and biomarkers of therapeutic activity in patients with RCC Leppert Fan Metzner Liliental Xu Thong Yost Yaghi Brooks Harshman Sabatti Srinivas Felsher 2013 14 View details for Web of Science ID 000325992100025 Identification and Characterization of 2 Testicular Germ Cell Markers Glut3 and CyclinA2 APPLIED IMMUNOHISTOCHEMISTRY MOLECULAR MORPHOLOGY Howitt Brooks Jones Higgins 2013 21 5 Abstract Testicular germ cell tumors TGCT are the most common type of testicular tumor and encompass different histologic types that greatly influence treatment and prognosis Immunohistochemical studies may be required for accurate classification particularly when these tumors present at extragonadal sites and to aid in distinguishing histologic types Traditional markers for identifying and distinguishing TGCT include PLAP CD117 AFP and CD30 More recently the addition of and SALL4 has increased sensitivity for immunohistochemical detection of germ cell tumors We examined gene expression data from a previously published microarray study that compared normal testis mRNA expression to various TGCT We also performed a search of the literature to identify less markers Glut3 and cyclinA2 showed promise as TGCT markers Therefore we evaluated expression of glut3 and cyclinA2 by immunohistochemistry using tissue microarrays TMAs Of 66 seminomas included in the TMA 64 97 showed positive nuclear staining for cyclinA2 and 58 88 were strongly positive Strong positive staining for cyclinA2 was also seen in the spermatocytic seminoma All 20 of the embryonal carcinomas stained positively with cyclinA2 and 19 95 displayed strong nuclear staining for cyclinA2 Twenty of the 20 embryonal carcinomas stained for glut3 in a strong membranous pattern Of 8 yolk sac tumors 100 stained with glut3 We also evaluated glut3 and cyclinA2 staining on a general TMA containing 486 samples representing 156 different tumors CyclinA2 stained a number of other tumor types but the majority of these were weak or focal staining Glut3 was rarely positive in other tumors interestingly most of these were of ovarian origin We conclude that glut3 is a sensitive 96 and specific 92 marker for embryonal carcinomas and yolk sac tumors Although cyclinA2 is a sensitive marker of seminomas and embryonal carcinomas 98 its specificity is lower if focal and weak staining of nongerm cell tumors is considered positive The sensitivity and specificity of glut3 are comparable with that seen for SALL4 View details for DOI View details for Web of Science ID 000324837800004 View details for PubMedID 23343953 Smoking and adverse outcomes at radical prostatectomy UROLOGIC AND ORIGINAL INVESTIGATIONS Ngo Lee Brooks Nolley Ferrari Presti 2013 31 6 Abstract Multiple large epidemiologic studies have examined the relationship between smoking and prostate cancer incidence and mortality only to arrive at contradictory results In this series we studied the effect of smoking on pathologic outcomes and biochemical recurrence in a cohort of men undergoing radical identified 630 men who underwent radical prostatectomy between 1989 and 2005 who had detailed smoking histories There were 321 smokers and 309 nonsmokers Pathologic outcomes included prostate weight volume of cancer volume of high grade cancer margin status seminal vesicle involvement extraprostatic extension perineural invasion angiolymphatic invasion and the presence of nodal metastasis Biochemical recurrence was defined as a postoperative PSA Univariate analysis and multivariate linear and Cox regression were used to study the impact of smoking on these volume of cancer ml P and the volume of high grade cancer ml P were greater in smokers compared with nonsmokers Smoking independently predicted greater volumes of cancer and high grade cancer in multivariate analysis Heavy smokers history had a greater risk of biochemical recurrence on univariate survival analysis Smoking also predicted a greater risk of biochemical recurrence on Cox regression the magnitude of which was approximately 1 per is associated with adverse pathologic features and a higher risk of biochemical recurrence in men undergoing radical prostatectomy If confirmed by additional studies smoking history may need to be included into risk assessment models View details for DOI View details for Web of Science ID 000322681800006 View details for PubMedID 21824793 Evaluation of Expression in Testicular Germ Cell Tumors A Tissue Microarray Study of 127 Cases Applied immunohistochemistry molecular morphology Sangoi McKenney Brooks Higgins 2013 21 4 Abstract Differentiating testicular germ cell tumors from stromal tumors can be difficult in certain cases because of overlapping morphologic features an absence of clinically apparent hormonal symptoms Immunohistochemistry may be needed as an ancillary diagnostic tool in this differential diagnostic setting Steroidogenic is a nuclear transcription factor controlling steroidogenesis and is expressed in developing Sertoli and Leydig cells Although 1 recent study has reported nuclear immunoreactivity in testicular stromal tumors the specificity for this marker in germ cell tumors has not been evaluated After encountering several problematic cases including some on testicular biopsy we sought to determine the diagnostic specificity of in a large series of germ cell tumors Nuclear immunohistochemical expression of was evaluated in 127 germ cell tumors using tissue microarray technology with 23 cell tumor tissues as positive internal controls No nuclear expression was identified in any of the 127 germ cell tumors including choriocarcinoma 3 embryonal carcinoma 25 epidermal inclusion cyst 1 intratubular germ cell neoplasia unclassified 4 seminoma 72 spermatocytic seminoma 2 teratoma 8 and yolk sac tumor 12 All 23 cell tumor tissues showed strong nuclear expression in Sertoli Leydig cells including testicular atrophy 10 cryptorchidism 2 normal testis 4 hypospermatogenesis 1 immature testis 1 intratubular large cell calcifying Sertoli cell tumor 1 Leydig cell tumor 3 and Sertoli only 1 This study documents the absence of expression in testicular germ cell tumors and supports its specificity for stromal lesions in this diagnostic context View details for DOI View details for PubMedID 23165333 Epigenetic changes in histologically normal prostate tissues journal of urology Brooks 2013 189 6 View details for DOI View details for PubMedID 23465550 Comprehensive gene expression changes associated with mouse postnatal kidney development journal of urology Wu Sahoo Brooks 2013 189 6 Abstract To provide a portrait of the molecular alterations in renal growth that occur in mice postnatally we performed gene expression profiling at discrete time points during the first 5 weeks of were harvested from mice at embryonic day and postnatal days 1 3 5 7 10 14 21 28 and 35 Total RNA was extracted and gene expression profiling was done using microarrays Agilent Technologies Santa Clara California Transcripts whose expression levels changed during the study course were identified using StepMiner software http Biological functions of the modulated genes were identified using kidney growth and development are associated with widespread changes in gene expression with transcripts significantly and during the first 5 weeks of life Pathway analysis showed progressive of pathways associated with cell growth and embryonic development postnatal days 5 to 7 This was followed by increased expression of transcripts associated with metabolism and molecular transport postnatal days 10 to 14 and of genes related to DNA replication cell cycle tissue development protein trafficking and cell morphology postnatal days 14 to 21 our knowledge we report the most comprehensive temporal survey of postnatal kidney development to date This data set provides a framework for interpreting nephropathy such as that induced by congenital obstruction View details for DOI View details for PubMedID 23220383 Liquid assays to monitor residual disease in cancer Mei Sebisanovic Mir Gulzar Brooks Jeffrey Talasaz AMER SOC CLINICAL ONCOLOGY 2013 View details for Web of Science ID 000335419600513 The impact of reducing the frequency of prostate specific antigen PSA testing among men on active surveillance for prostate cancer Cooperberg Newcomb Brown Zhao Feng Brooks Lin Canary PASS Investigators AMER SOC CLINICAL ONCOLOGY 2013 View details for Web of Science ID 000335419602015 Urinary TMPRSS2 ERG and PCA3 in an Active Surveillance Cohort Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study CLINICAL CANCER RESEARCH Lin Newcomb Brown Brooks Carroll Feng Gleave Lance Sanda Thompson Wei Nelson 2013 19 9 Abstract Active surveillance is used to manage prostate cancer Both PCA3 and TMPRSS2 ERG are promising biomarkers that may be associated with aggressive disease This study examines the correlation of these biomarkers with higher cancer volume and grade determined at the time of biopsy in an active surveillance was collected after digital rectal examination prospectively as part of the Canary Prostate Active Surveillance Study PASS PCA3 and TMPRSS2 ERG levels were analyzed in urine collected at study entry Biomarker scores were correlated to clinical and pathologic 387 men both PCA3 and TMPRSS2 ERG scores were significantly associated with higher volume disease For a negative repeat biopsy and 1 to 10 11 to 33 34 or more positive cores median PCA3 and TMPRSS2 ERG scores increased incrementally P Both PCA3 and TMPRSS2 ERG scores were also significantly associated with the presence of disease For a negative repeat biopsy Gleason 6 and Gleason cancers the median PCA3 and TMPRSS2 ERG scores also increased incrementally P and P respectively Using the marker scores as continuous variables the ORs for a biopsy in which cancer was detected versus a negative repeat biopsy ref on modeling was 95 CI P for PCA3 and 95 CI P for TMPRSS2 men on active surveillance both PCA3 and TMPRSS2 ERG seem to stratify the risk of having aggressive cancer as defined by tumor volume or Gleason score View details for DOI View details for Web of Science ID 000318361900018 View details for PubMedID 23515404 View details for PubMedCentralID PMC3674574 PROTEOMIC PROFILING TO DEFINE DIAGNOSTIC SIGNATURES AND BIOMARKERS OF THERAPEUTIC ACTIVITY IN RCC Leppert Fan Liliental Xu Thong Yost Yaghi Metzner Brooks Harshman Sabatti Srinivas Felsher ELSEVIER SCIENCE 2013 View details for DOI View details for Web of Science ID 000320281600603 Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1 ONCOGENE Gulzar McKenney Brooks 2013 32 1 Abstract Increasing evidence suggests that prostate cancer is overdiagnosed and overtreated and prognostic biomarkers would aid in treatment selection To define prognostic biomarkers for aggressive prostate cancer we carried out profiling of 98 prostate tumors and 52 benign adjacent prostate tissue samples with detailed clinical annotation We identified 28 transcripts significantly associated with recurrence after radical prostatectomy including NuSAP a protein that binds DNA to the mitotic spindle Elevated NuSAP transcript levels were associated with poor outcome in two independent prostate cancer datasets To characterize the role and regulation of NuSAP in prostate cancer we studied the expression of NuSAP in the LNCaP and PC3 human prostate cancer cell lines Posttranscriptional silencing of the NuSAP gene severely hampered the ability of PC3 to invade and proliferate in vitro The promoter region of the NuSAP gene contains two CCAAT boxes and binding sites for E2F Transient transfection of an E2F1 cDNA and 431 bp of the NuSAP promoter demonstrated E2F1 as an important regulator of expression Deletion of the site at nucleotide negated the effects of E2F1 on NuSAP expression Electrophoretic mobility shift assays demonstrated that nuclear extracts of cells overexpressing E2F1 bound directly to the site in the NuSAP promoter region Finally immunohistochemistry showed a strong correlation between E2F1 and NuSAP expression in human prostate cancer samples NuSAP is a novel biomarker for prostate cancer recurrence after surgery and its overexpression appears to be driven in part by E2F1 activation View details for DOI View details for Web of Science ID 000313029500007 View details for PubMedID 22349817 View details for PubMedCentralID PMC3360134 Treatment and Mortality in Men with Localized Prostate Cancer A Study in California The open prostate cancer journal Sieh Lichtensztajn Nelson Cockburn West Brooks Chang 2013 6 Abstract To provide patients and physicians with estimates of mortality from prostate cancer or other causes depending upon the primary treatment modality stratified by patient age tumor stage and conducted a analysis of men diagnosed with clinically localized T1 or T2 prostate cancer in California during Information on patient characteristics primary treatment and cause of death was obtained from the California Cancer this cohort the most common primary treatment was surgery followed by radiotherapy conservative management and androgen deprivation therapy ADT monotherapy Prostate cancer mortality differed significantly p across treatment groups among patients 80 years at diagnosis with moderately or poorly differentiated disease the mortality rates were generally highest for men treated with ADT monotherapy range 95 to 95 intermediate for men treated with conservative management range 95 to 95 or radiotherapy range 95 to 95 and lowest for men treated with surgery range 95 to 95 mortality estimates provided by this observational study can help patients and physicians better understand the expected outcomes of localized prostate cancer given the initial treatment choice and practice patterns in the general population View details for PubMedID 23997838 Managing localized prostate cancer in the era of antigen screening Cancer Brooks 2013 View details for PubMedID 24006273 View details for PubMedCentralID PMC3875624 Differential DNA methylation with age displays both common and dynamic features across human tissues that are influenced by CpG landscape GENOME BIOLOGY Day Waite West Bamman Brooks Myers Absher 2013 14 9 Abstract DNA methylation is an epigenetic modification that changes with age in human tissues although the mechanisms and specificity of this process are still poorly understood We compared CpG methylation changes with age across 283 human blood brain kidney and skeletal muscle samples using methylation arrays to identify age found CpGs ageCGs that are both and common across tissues ageCGs are frequently located outside CpG islands with decreased methylation and common ageCGs show the opposite trend AgeCGs are significantly associated with poorly expressed genes but those with decreasing methylation are linked with higher expression levels compared with increasing methylation Therefore gene expression may protect against common methylation Distinguished from other tissues skeletal muscle ageCGs are more associated with expression enriched near genes related to myofiber contraction and closer to CTCF binding sites ageCGs are more increasingly methylated compared to other tissues as measured by affiliation with expressed genes Underlying chromatin features also mark common and age effects reflective of poised and active chromatin states respectively In contrast with decreasingly methylated ageCGs increasingly methylated ageCGs are also generally further from CTCF binding sites and enriched within lamina associated data identified common and DNA methylation changes with age that are reflective of CpG landscape and suggests both common and unique alterations within human tissues Our findings also indicate that a simple epigenetic drift model is insufficient to explain all changes in DNA methylation View details for DOI View details for Web of Science ID 000328195700008 View details for PubMedID 24034465 A Model for the Design and Construction of a Resource for the Validation of Prognostic Prostate Cancer Biomarkers The Canary Prostate Cancer Tissue Microarray ADVANCES IN ANATOMIC PATHOLOGY Hawley Fazli McKenney Simko Troyer Nicolas Newcomb Cowan Crouch Ferrari Hernandez Kuchinsky Liew Smith Tenggara Zhang Carroll Chan Gleave Lance Lin Nelson Thompson Feng True Brooks 2013 20 1 Abstract Tissue microarrays TMAs provide unique resources for rapid evaluation and validation of tissue biomarkers The Canary Foundation Retrospective Prostate Tissue Microarray Resource used a rigorous statistical design quota sampling a variation of the study to select patients for inclusion in a multicenter retrospective prostate cancer TMA cohort The study is designed to definitively validate tissue biomarkers of prostate cancer recurrence after radical prostatectomy Tissue samples from over 1000 participants treated for prostate cancer with radical prostatectomy between 1995 and 2004 were selected at 6 participating institutions in the United States and Canada This design captured the heterogeneity of screening and clinical practices in the contemporary North American population Standardized clinical data were collected in a centralized database The project has been informative in several respects The scale and complexity of assembling TMAs with over 200 cases at each of 6 sites involved unanticipated levels of effort and time Our statistical design promises to provide a model for studies where tissue localization methods are applied to TMAs View details for DOI View details for Web of Science ID 000312346800005 View details for PubMedID 23232570 View details for PubMedCentralID PMC3535290 of Single Prostate Cancer Circulating Tumor Cells Reveals Recapitulation of Gene Expression and Pathways Found in Prostate Cancer PLOS ONE Cann Gulzar Cooper Li Luo Tat Stuart Schroth Srinivas Ronaghi Brooks Talasaz 2012 7 11 Abstract Circulating tumor cells CTC mediate metastatic spread of many solid tumors and enumeration of CTCs is currently used as a prognostic indicator of survival in metastatic prostate cancer patients Some evidence suggests that it is possible to derive additional information about tumors from expression analysis of CTCs but the technical difficulty of isolating and analyzing individual CTCs has limited progress in this area To assess the ability of a new generation of MagSweeper to isolate intact CTCs for downstream analysis we performed on single CTCs isolated from the blood of patients with metastatic prostate cancer and on single prostate cancer cell line LNCaP cells spiked into the blood of healthy donors We found that the MagSweeper effectively isolated CTCs with a capture efficiency that matched the CellSearch platform However unlike CellSearch the MagSweeper facilitates isolation of individual live CTCs without contaminating leukocytes Importantly analysis showed that the MagSweeper isolation process did not have a discernible impact on the transcriptional profile of single LNCaPs isolated from spiked human blood suggesting that any perturbations caused by the MagSweeper process on the transcriptional signature of isolated cells are modest Although the RNA from patient CTCs showed signs of significant degradation consistent with reports of short and apoptosis amongst CTCs transcriptional signatures of prostate tissue and of cancer were readily detectable with single CTC These results demonstrate that the MagSweeper provides access to intact CTCs and that these CTCs can potentially supply clinically relevant information View details for DOI View details for Web of Science ID 000311935800219 View details for PubMedID 23145101 View details for PubMedCentralID PMC3492322 Evaluation of Putative Renal Cell Carcinoma Markers and in Germ Cell Tumors A Tissue Microarray Study of 100 Cases APPLIED IMMUNOHISTOCHEMISTRY MOLECULAR MORPHOLOGY Sangoi McKenney Brooks Bonventre Higgins 2012 20 5 Abstract In a subset of cases metastatic renal cell carcinoma can demonstrate significant morphologic overlap with germ cell neoplasms making accurate diagnosis challenging In such cases immunohistochemistry is often used as an adjunct diagnostic tool Expression of the putative renal cell carcinoma markers and has been reported in a small series of certain germ cell tumors raising doubt about their specificity for renal cell carcinoma To further characterize these markers we evaluated and staining in 100 germ cell tumors using tissue microarrays and staining was identified in 50 and 25 of yolk sac tumors respectively with staining identified in 48 of embryonal carcinomas and 50 of yolk sac tumors All other germ tumor cells notably including 62 seminomas were negative for all 3 markers in contrast to prior reports of reactivity in seminoma This study indicates that and should be used cautiously in distinguishing renal cell carcinoma from nonseminomatous germ cell neoplasia and also adds to the growing list of nonrenal tumors that express these 3 markers View details for DOI View details for Web of Science ID 000309551700003 View details for PubMedID 22495365 Gene Expression Changes Induced by Unilateral Ureteral Obstruction in Mice JOURNAL OF UROLOGY Wu Brooks 2012 188 3 Abstract Loss of renal function is often the impetus for operative intervention in renal obstruction cases Obstructive nephropathy is characterized by discrete morphological and physiological changes including tubular dilatation apoptosis and atrophy as well as interstitial cellular infiltration and progressive interstitial fibrosis We hypothesized that gene expression alterations correlate with obstructive nephropathy and could serve as biomarkers for early mice were subjected to unilateral ureteral obstruction or sham surgery at postnatal day 21 Kidneys were harvested 1 2 5 and 9 days postoperatively RNA was extracted from kidneys and comprehensive gene expression profiling was performed with microarrays pathway analysis software was used to analyze the biological function and gene networks of gene expression analysis revealed more than transcripts that were or during days 1 through 9 after obstruction including many previously reported transcripts FOS CD44 CLU SPP1 and EGF Pathway analysis showed significant enrichment of transcripts in cell responses cell cycle metabolic process and transport Network analysis using IPA showed that transcriptional regulatory pathways involving CEBPB and HNF4A are involved in obstructive data set provides a foundation for development of biomarkers for obstructive nephropathy View details for DOI View details for Web of Science ID 000307551200115 View details for PubMedID 22819101 Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness ONCOGENE Huang Gulzar Salari Lapointe Brooks Pollack 2012 31 37 Abstract Though prostate cancer is often indolent it is nonetheless a leading cause of cancer death Defining the underlying molecular genetic alterations may lead to new strategies for prevention or treatment Towards this goal we performed comparative genomic hybridization CGH on 86 primary prostate tumors Among the most frequent alterations not associated with a known cancer gene we identified focal deletions within 5q21 in 15 out of 86 17 cases By tiling array CGH the smallest common deletion targeted just one gene the chromatin remodeler chromodomain helicase protein 1 CHD1 Expression of CHD1 was significantly reduced in tumors with deletion and compared with normal prostate Exon sequencing analysis also uncovered nonsynonymous mutations in 1 out of 7 14 cell lines LAPC4 and in 1 out of 24 4 prostate tumors surveyed RNA knockdown of CHD1 in two nontumorigenic prostate epithelial cell lines OPCN2 and did not alter cell growth but promoted cell invasiveness and in cell clonogenicity Taken together our findings suggest that CHD1 deletion may underlie cell invasiveness in a subset of prostate cancers and indicate a possible novel role of altered chromatin remodeling in prostate tumorigenesis View details for DOI View details for Web of Science ID 000308688900008 View details for PubMedID 22179824 Methods for registration of magnetic resonance images of ex vivo prostate specimens with histology JOURNAL OF MAGNETIC RESONANCE IMAGING Kimm Tarin Lee Hu Jensen Nishimura Brooks 2012 36 1 Abstract To evaluate two methods of scanning and tissue processing to achieve accurate magnetic resonance MR correlation in human prostate prostates had acrylic paint markers injected to define the plane of imaging and serve as internal fiducials Each was placed on a polycarbonate device PFD which was adjusted to align the imaging and cutting planes Three prostates were aligned by use of a plane finder key PFK a polycarbonate plate that locks the specimen in a cylindrical carrier Markers were injected for registration analysis Prostates were imaged then sectioned Imaging software was used to create registration maps of the MR and histology images Measurements between control points were made and correlation was achieved between MR and histologic images The mean displacement MD between the corresponding registration points using the PFD technique ranged from mm for each section The MD for all sections was mm The MD using the PFK technique ranged from mm for each section and the MD across all sections for the PFK was describe two methods that can achieve accurate reproducible correlation between MR imaging and histologic sections in human prostatectomy specimens View details for DOI View details for PubMedID 22359365 Evaluation of Expression in Testicular Germ Cell Tumors A Tissue Microarray Study of 100 Cases Sangoi McKenney Brooks Higgins OXFORD UNIV PRESS 2012 A355 View details for DOI View details for Web of Science ID 000209848700315 homeobox 1 is frequently hypermethylated in prostate cancer and predicts PSA recurrence BRITISH JOURNAL OF CANCER Truong Yang Wagner Kobayashi Rajamanickam Brooks Jarrard 2012 107 1 Abstract DNA methylation is an important epigenetic mechanism in prostate cancer PCa progression Given the role of homeobox 1 EVX1 in the regulation of multiple genes during embryogenesis we postulated that EVX1 methylation is altered in PCa sequencing and quantitative MethyLight were used to assess methylation in human prostate epithelial cells four PCa cell lines liver lung spleen kidney 35 paired tumour and benign tissues and 11 normal prostate tissues Prostate cancer cell lines were treated with AzaC or trichostatin A TSA and expression of EVX1 transcript and variants was assessed by qPCR Hypermethylation was compared with clinicopathological features in a validation set of 58 patients using homeobox 1 hypermethylation was observed in all four PCa cell lines and 57 of tumours tumours exhibited increased methylation compared with tumours homeobox 1 expression was induced in PCa cell lines after treatment with AzaC or TSA In the validation set 83 of tumours were hypermethylated and hypermethylation was associated with worse this first evaluation of EVX1 methylation in human cancer EVX1 is one of the most commonly hypermethylated genes observed in PCa and predicted treatment failure in moderate risk patients View details for DOI View details for Web of Science ID 000305888400015 View details for PubMedID 22596233 View details for PubMedCentralID PMC3389415 Performance Characteristics of Antigen in Patients Undergoing Radical Prostatectomy UROLOGY Liu Ferrari Nolley Brooks Presti 2012 79 6 Abstract To assess the performance characteristics of antigen PSA for predicting the volume of total or cancer in men undergoing radical prostatectomy It is known that the performance characteristics of PSA are improved for predicting the presence of prostate identified 1459 patients from the Stanford Radical Prostatectomy Database with clinical Stage T1c n 783 and T2 n 676 disease who underwent surgery from 1988 to 2003 with detailed morphometric mapping We generated receiver operating characteristic curves for PSA levels according to the total and Gleason score 4 or 5 cancer volume and compared the areas under the curve AUC for the various total and cancer patients with Stage T1c disease the AUC for the PSA ROC curve increased in a stepwise fashion as both the total cancer volume and the cancer volume increased Significant differences between the AUCs for low and high volumes of total and disease were observed For T2 disease the AUCs for predicting cancer volume were generally greater than the corresponding AUCs for T1c disease although no incremental increase was patients with Stage T1c disease in whom the PSA level was the driving force for biopsy the PSA performance improved in a stepwise fashion with greater total and cancer volumes as evidenced by improved ROC Previous studies have shown that PSA performs better for detecting the presence of disease We have shown that PSA performs better in predicting greater volumes of disease in radical prostatectomy specimens View details for DOI View details for Web of Science ID 000304720600046 View details for PubMedID 22516358 Use of assay to generate rapid quantitative nanoscale proteomic profiling of the hypoxia pathway in renal cell carcinoma clinical specimens Fan Banerjee Leppert Harshman Sabatti Brooks Felsher AMER SOC CLINICAL ONCOLOGY 2012 View details for Web of Science ID 000318009801088 Deficiency in Mammalian Histone H2B Ubiquitin Ligase Bre1 Leads to Replication Stress and Chromosomal Instability CANCER RESEARCH Chernikova Razorenova Higgins Sishc Nicolau Dorth J Chernikova Kwok Brooks Bailey Game Brown 2012 72 8 Abstract Mammalian Bre1 complexes in humans and in mice function similarly to their yeast homolog Bre1 as ubiquitin ligases in monoubiquitination of histone H2B This ubiquitination facilitates methylation of histone H3 at K4 and K79 and accounts for the roles of Bre1 and its homologs in transcriptional regulation Recent studies by others suggested that Bre1 acts as a tumor suppressor augmenting expression of select tumor suppressor genes and suppressing select oncogenes In this study we present an additional mechanism of tumor suppression by Bre1 through maintenance of genomic stability We track the evolution of genomic instability in cells from breaks DSB to specific genomic rearrangements that explain a rapid increase in DNA content and trigger cycles We show that aberrant structures constitute a significant source of DSBs in cells Combined with a previously reported defect in homologous recombination generation of is a likely initiator of replication stress and genomic instability in cells We propose that genomic instability triggered by Bre1 deficiency may be an important early step that precedes acquisition of an invasive phenotype as we find decreased levels of and dimethylated H3K79 in testicular seminoma and in the premalignant lesion in situ carcinoma View details for DOI View details for Web of Science ID 000302905700022 View details for PubMedID 22354749 View details for PubMedCentralID PMC3328627 Treatment and mortality in men with localized prostate cancer A study in California Sieh Lichtensztajn Nelson Cockburn West Brooks Chang AMER ASSOC CANCER RESEARCH 2012 View details for DOI View details for Web of Science ID 000209701602175 Urinary TMPRSS2 Use of ERG and PCA3 to predict tumor volume and Gleason grade in an active surveillance from the Prostate Active Surveillance Study Lin Newcomb Brown Brooks Carroll Feng Gleave Lance Sanda Thompson Wei Nelson AMER SOC CLINICAL ONCOLOGY 2012 View details for DOI View details for Web of Science ID 000208892400004 OUTCOMES FROM A PROSPECTIVE TRIAL OF STEREOTACTIC BODY RADIOTHERAPY FOR PROSTATE CANCER 52nd Annual Meeting of the ASTRO King Brooks Gill Presti ELSEVIER SCIENCE 2012 Abstract Hypofractionated radiotherapy has an intrinsically different normal tissue and tumor radiobiology The results of a prospective trial of stereotactic body radiotherapy SBRT for prostate cancer with toxicity and tumor control rates are 2003 through 2009 67 patients with clinically localized prostate cancer were enrolled Treatment consisted of Gy in 5 fractions using SBRT with the CyberKnife as the delivery technology No patient received hormone therapy Patient bladder and rectal toxicities were graded on the Radiation Therapy Oncology Group scale RTOG was years There were no grade 4 toxicities Radiation Therapy Oncology Group Grade 3 2 and 1 bladder toxicities were seen in 3 2 patients 5 3 patients and 23 13 patients respectively Dysuria exacerbated by urologic instrumentation accounted for both patients with Grade 3 toxicity Urinary incontinence complete obstruction or persistent hematuria was not observed Rectal Grade 3 2 and 1 toxicities were seen in 0 2 1 patient and 7 patients respectively Persistent rectal bleeding was not observed toxicities were substantially less frequent with QOD QD dose regimen p for gastrointestinal and p for genitourinary There were two antigen PSA failures with negative metastatic workup Median PSA at was The PSA survival was 94 95 confidence interval 85 late bladder and rectal toxicities from SBRT for prostate cancer are infrequent PSA survival compares favorably with other definitive treatments The current evidence supports consideration of stereotactic body radiotherapy among the therapeutic options for localized prostate cancer View details for DOI View details for Web of Science ID 000299239900063 View details for PubMedID 21300474 Translational genomics The challenge of developing cancer biomarkers GENOME RESEARCH Brooks 2012 22 2 Abstract Early detection and definitive treatment of cancer have been shown to decrease death and suffering in epidemiologic and intervention studies Application of genomic approaches to many malignancies has produced thousands of candidate biomarkers for detection and prognostication yet very few have become established in clinical practice Fundamental issues related to tumor heterogeneity cancer progression natural history and biomarker performance have provided challenges to biomarker development Technical issues in biomarker assay detection limits specificity clinical deployment and regulation have also slowed progress The recent emergence of biomarkers and molecular imaging strategies for treatment selection and monitoring demonstrates the promise of cancer biomarkers Organized efforts by interdisciplinary teams will spur progress in cancer diagnostics View details for DOI View details for Web of Science ID 000299606400002 View details for PubMedID 22301132 View details for PubMedCentralID PMC3266026 PIVOT and the challenges of localized prostate cancer care Translational andrology and urology Weinberg Brooks 2012 1 3 View details for PubMedID 26816701 View details for PubMedCentralID PMC4708249 The Potential Impact of Reproducibility of Gleason Grading in Men With Early Stage Prostate Cancer Managed by Active Surveillance A Study JOURNAL OF UROLOGY McKenney Simko Bonham True Troyer Hawley Newcomb Fazli Kunju Nicolas Zhang Carroll Brooks 2011 186 2 Abstract We evaluated the reproducibility of Gleason grading as relevant to the clinical treatment of men on active sets of digital images of prostatic adenocarcinoma in biopsies were reviewed and assigned Gleason scores by a total of 11 pathologists from 7 institutions Interobserver and reproducibility were assessed for assignment of the highest Gleason pattern 3 vs 4 or higher We also identified 97 consecutive patients on active surveillance Prostate biopsy glass slides from 82 of the patients were available for and the frequency of carcinoma requiring the distinction of tangentially sectioned Gleason pattern 3 from 4 was reproducibility for classic Gleason patterns was substantial Light  Interobserver reproducibility for the histological distinction of tangentially sectioned Gleason pattern 3 from Gleason pattern 4 was only fair Light  reproducibility ranged from 65 to 100 mean Of the 82 patients on active surveillance 61 had carcinoma and 15 had a set of biopsies with at least 1 focus in which the distinction between tangentially sectioned Gleason pattern 3 and poorly formed pattern 4 glands had to be reproducibility of grading classic Gleason patterns is high However variability in grading occurred when distinguishing between tangentially sectioned pattern 3 glands and the poorly formed gland subset of pattern 4 Developing universally accepted histological molecular criteria to distinguish these patterns and subsequently characterizing their natural history would be useful when treating patients on active surveillance View details for DOI View details for Web of Science ID 000292545100030 View details for PubMedID 21679996 DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer GENOME RESEARCH Kobayashi Absher Gulzar Young McKenney Peehl Brooks Myers Sherlock 2011 21 7 Abstract Candidate studies have identified a handful of aberrant CpG DNA methylation events in prostate cancer However DNA methylation profiles have not been compared on a large scale between prostate tumor and normal prostate and the mechanisms behind these alterations are unknown In this study we quantitatively profiled 95 primary prostate tumors and 86 benign adjacent prostate tissue samples for their DNA methylation levels at CpGs representing gene promoters by using the Illumina HumanMethylation27 platform A Significance Analysis of this data set revealed 5912 CpG sites with increased DNA methylation and 2151 CpG sites with decreased DNA methylation in tumors FDR Prediction Analysis of this data set identified 87 CpGs that are the most predictive diagnostic methylation biomarkers of prostate cancer By integrating available clinical data we also identified 69 prognostic DNA methylation alterations that correlate with biochemical recurrence of the tumor To identify the mechanisms responsible for these DNA methylation alterations we measured the gene expression levels of several DNA methyltransferases DNMTs and their interacting proteins by TaqMan qPCR and observed increased expression of DNMT3A2 DNMT3B and EZH2 in tumors Subsequent transient transfection assays in cultured primary prostate cells revealed that DNMT3B1 and DNMT3B2 overexpression resulted in increased methylation of a substantial subset of CpG sites that showed increased methylation View details for DOI View details for Web of Science ID 000292298000003 View details for PubMedID 21521786 View details for PubMedCentralID PMC3129245 Integrated genomic analyses of ovarian carcinoma NATURE Bell Berchuck Birrer Chien Cramer Dao Dhir Disaia Gabra Glenn Godwin GROSS Hartmann Huang Huntsman Iacocca Imielinski Kalloger Karlan Levine Mills Morrison Mutch Olvera Orsulic Park Petrelli Rabeno Rader Sikic Sood Bowtell PENNY Testa Chang Dinh Drummond J Fowler Gunaratne Hawes Kovar Lewis Morgan Newsham Santibanez Reid Trevino Wu Wang Muzny Wheeler Gibbs Getz Lawrence Cibulskis Sivachenko Sougnez VOET Wilkinson Bloom Ardlie Fennell Baldwin Gabriel Lander Ding Fulton Koboldt McLellan Wylie Walker Dooling Fulton Abbott Dees Zhang Kandoth Wendl Schierding Shen Harris Schmidt Kalicki Delehaunty Fronick Demeter Cook Wallis Lin Magrini Hodges ELDRED Smith Pohl Vandin Raphael Weinstock Mardis Wilson Meyerson Winckler Getz Verhaak Carter Mermel Saksena Nguyen Onofrio Lawrence Hubbard Gupta Crenshaw RAMOS Ardlie Chin Protopopov Zhang Kim Perna Xiao Zhang Ren Sathiamoorthy Park Lee Park Kucherlapati Absher Waite Sherlock Brooks Li J Xu Myers Laird Cope Herman Shen Weisenberger Noushmehr Pan Triche Berman Van den Berg Buckley BAYLIN Spellman Purdom Neuvial Bengtsson Jakkula Durinck Han Dorton Marr Choi Wang Wang Ngai Conboy Parvin Feiler Speed Gray Levine Socci Liang Taylor Schultz Borsu Lash Brennan Viale Sander Ladanyi Hoadley Meng Du Shi Li Turman Zang Helms Balu Zhou Wu Topal Hayes Perou Getz VOET Saksena Zhang Zhang Wu Shukla Cibulskis Lawrence Sivachenko Jing Park Liu Park Noble Chin Carter Kim Karchin Spellman Purdom Neuvial Bengtsson Durinck Han Korkola Heiser Cho Hu Parvin Speed Gray Schultz Cerami Taylor Olshen Reva Antipin Shen Mankoo Sheridan Ciriello Chang Bernanke J Borsu Levine Ladanyi Sander Haussler Benz Stuart Benz Sanborn J Vaske Zhu Szeto Scott Yau Hoadley Du Balu Hayes Perou Wilkerson Zhang Akbani Baggerly YUNG Mills Weinstein PENNY Shelton Grimm Hatfield Morris Yena Rhodes Sherman Paulauskis Millis Kahn Greene Sfeir Jensen Chen Whitmore Alonso Jordan Chu Zhang Barker Compton Eley Ferguson Fielding Gerhard Myles Schaefer Shaw Vaught Vockley J Good Guyer Ozenberger Peterson Thomson 2011 474 7353 Abstract A catalogue of molecular aberrations that cause ovarian cancer is critical for developing and deploying therapies that will improve patients lives The Cancer Genome Atlas project has analysed messenger RNA expression microRNA expression promoter methylation and DNA copy number in 489 serous ovarian adenocarcinomas and the DNA sequences of exons from coding genes in 316 of these tumours Here we report that serous ovarian cancer is characterized by TP53 mutations in almost all tumours 96 low prevalence but statistically recurrent somatic mutations in nine further genes including NF1 BRCA1 BRCA2 RB1 and CDK12 113 significant focal DNA copy number aberrations and promoter methylation events involving 168 genes Analyses delineated four ovarian cancer transcriptional subtypes three microRNA subtypes four promoter methylation subtypes and a transcriptional signature associated with survival duration and shed new light on the impact that tumours with BRCA1 or BRCA2 and CCNE1 aberrations have on survival Pathway analyses suggested that homologous recombination is defective in about half of the tumours analysed and that NOTCH and FOXM1 signalling are involved in serous ovarian cancer pathophysiology View details for DOI View details for Web of Science ID 000292204300032 View details for PubMedID 21720365 View details for PubMedCentralID PMC3163504 Small Prostate Size and High Grade or Artifact JOURNAL OF UROLOGY Liu Brooks Ferrari Nolley Presti 2011 185 6 Abstract Prior radical prostatectomy series have shown an inverse association between prostate size and high grade cancer It has been suggested that smaller size prostates arise in a low androgen environment enabling development of more aggressive cancer We propose that this observation is the result of ascertainment bias driven by prostate specific antigen identified patients from the Stanford Radical Prostatectomy Database with clinical stage T1c 723 and T2 681 disease who underwent surgery between 1988 and 2002 and underwent detailed morphometric mapping by a single pathologist Multivariate linear regression was performed to assess for the effects of age prostate weight and prostate specific antigen on total and high grade Gleason grade cancer volume and percentage of high grade patients who underwent biopsy due to abnormal prostate specific antigen stage T1c prostate weight was negatively associated p with total cancer volume volume of high grade disease and percentage of high grade disease For patients who underwent biopsy based on abnormal digital rectal examination stage T2 these associations were not prostate specific antigen performance for high grade disease results in ascertainment bias in patients with T1c disease Thus the association between prostate size and high grade disease may be a consequence of grade dependent performance of prostate specific antigen rather than true tumor biology View details for DOI View details for Web of Science ID 000290389600027 View details for PubMedID 21496855 A Proliferation Index Predicts Biochemical Recurrence after Surgery for Prostate Cancer PLOS ONE Malhotra Lapointe Salari Higgins Ferrari Montgomery van de Rijn Brooks Pollack 2011 6 5 Abstract Prostate cancer exhibits tremendous variability in clinical behavior ranging from indolent to lethal disease Better prognostic markers are needed to stratify patients for appropriately aggressive therapy By expression profiling we can identify a proliferation signature variably expressed in prostate cancers Here we asked whether one or more tissue biomarkers might capture that information and provide prognostic utility We assayed three proliferation signature genes MKI67 also a classic proliferation biomarker TOP2A DNA topoisomerase II alpha and E2F1 E2F transcription factor 1 Immunohistochemical staining was evaluable on 139 radical prostatectomy cases in tissue microarray format with a median clinical of eight years Each of the three proliferation markers was by itself prognostic Notably combining the three markers together as a proliferation index 0 or 1 2 or 3 positive markers provided superior prognostic performance hazard ratio 95 CI P In a multivariate analysis that included preoperative serum prostate specific antigen PSA levels Gleason grade and pathologic tumor stage the composite proliferation index remained a significant predictor P Analysis of characteristic ROC curves confirmed the improved prognostication afforded by incorporating the proliferation index compared to the clinicopathologic data alone Our findings highlight the potential value of a diagnostic and define a proliferation index with possible utility for improved prognostication and treatment stratification in prostate cancer View details for DOI View details for PubMedID 21629784 Comparison of prostate cancer tumor volume and percent cancer in prediction of biochemical recurrence and cancer specific survival 103rd Annual Meeting of the Chung Tarin Ferrari Brooks ELSEVIER SCIENCE 2011 Abstract Tumor volume and percent cancer ratio of tumor volume have been proposed as predictors of biochemical recurrence and cancer specific survival after radical prostatectomy However their relative merits as prognosticators have not been tested We therefore evaluated and compared tumor volume and percent cancer as independent predictors of biochemical recurrence and prostate cancer specific death after radical retrospective review of 739 patients who underwent radical prostatectomy for prostate cancer between 1984 and 2004 was conducted Median was months and 22 patients died of prostate cancer Univariate and multivariate analysis evaluated the following factors in predicting biochemical recurrence and prostate cancer specific death tumor volume prostate volume percent cancer Gleason score percentage of Gleason grade margin status capsular invasion status seminal vesicle invasion status preoperative PSA and lymph node univariate analysis both tumor volume P and percent cancer P significantly correlated with biochemical recurrence Since they are highly correlated they did not predict outcome independently when included in the same model however both were highly predictive for biochemical recurrence in separate multivariate models for both Both also correlated with cancer specific survival as single variables however in separate multivariate models only tumor volume predicted death while percent cancer did not volume and percent cancer are independent predictors of recurrence after radical prostatectomy However in our series tumor volume predicted cancer specific death better than percent cancer Therefore accurate determination of tumor volume along with other accepted pathologic indices is sufficient and preferred over percent cancer for prognostication after radical prostatectomy View details for DOI View details for Web of Science ID 000290779400016 View details for PubMedID 19837617 Transcriptome sequencing of circulating tumor cells reveals their heterogeneity Cann Gulzar Tat Li Stuart Khrebtukova Luo Bentley Ronaghi Brooks Talasaz AMER ASSOC CANCER RESEARCH 2011 View details for DOI View details for Web of Science ID 000209701403435 Length of positive surgical margins as a risk factor for biochemical recurrence following radical prostatectomy INTERNATIONAL JOURNAL OF UROLOGY Hsu Chang Ferrari Nolley Presti Brooks 2011 18 4 View details for DOI View details for Web of Science ID 000288901000003 INCREASED EXPRESSION OF NUSAP GENE IN RECURRENT PROSTATE CANCER IS MEDIATED BY E2F Gulzar Brooks ELSEVIER SCIENCE 2011 E647 View details for DOI View details for Web of Science ID 000209830101377 Specificity of brachyury in the distinction of chordoma from clear cell renal cell carcinoma and germ cell tumors a study of 305 cases MODERN PATHOLOGY Sangoi Karamchandani Lane Higgins Rouse Brooks McKenney 2011 24 3 Abstract Brachyury is recognized as a specific marker for tissues and neoplasms and has become a defining immunohistochemical feature of chordoma The main differential diagnostic consideration for chordoma is chondrosarcoma which is known to lack brachyury expression However within the spectrum of genitourinary neoplasia metastatic germ cell tumors and clear cell renal cell carcinoma may also be close morphological mimics of chordoma particularly given the increasing prevalence of small tissue samples from biopsies Although immunoreactivity for brachyury has been reported in a few germ cell tumors a thorough characterization of staining by specific subtype has not been performed in a large series Additionally brachyury expression in clear cell renal cell carcinoma has not been well studied In this study immunohistochemical expression with the brachyury antibody was evaluated in 111 germ cell tumors 30 and neoplastic cell testicular tissues and 184 metastatic clear cell renal cell carcinomas using tissue microarray technology In addition immunoreactivity for and was evaluated in 12 chordomas on whole section No nuclear brachyury expression was identified in any of the 101 germ cell tumors within the tissue microarray including choriocarcinoma 1 embryonal carcinoma 20 intratubular germ cell neoplasia unclassified 2 seminoma 64 spermatocytic seminoma 1 teratoma 5 and yolk sac tumor 8 in any of the 30 and neoplastic cell testicular tissues or in any of the 10 seminomas All 184 metastatic clear cell renal cell carcinomas were also for brachyury All 12 chordomas showed strong nuclear immunoreactivity for brachyury but no expression of In all 1 of 12 chordoma cases showed patchy nuclear immunoreactivity for This study confirms the specificity of brachyury for chordoma in the differential diagnostic distinction from the potential genitourinary mimics germ cell tumors and metastatic clear cell renal cell carcinoma View details for DOI View details for Web of Science ID 000287986600010 View details for PubMedID 21102418 Evaluation of Putative Renal Cell Carcinoma Markers and in Germ Cell Tumors GCT A Tissue Microarray Study of 100 Cases Sangoi Higgins Brooks Bonventre McKenney I NATURE PUBLISHING GROUP 2011 222A View details for Web of Science ID 000291285000377 The distribution of immunoreactivity in the prostate gland seminal vesicle and ejaculatory duct comparison with prostatic adenocarcinoma and discussion of prostatic zonal embryogenesis HUMAN PATHOLOGY Quick Gokden Sangoi Brooks McKenney 2010 41 8 Abstract is a homeogene strongly expressed during development of the genitourinary tract including the kidney and both and tissues Expression of by immunohistochemistry has been studied mainly in renal epithelial neoplasms with little attention to the lower male genitourinary tract We studied expression in epithelium of normal seminal vesicle normal ejaculatory duct normal prostatic secretory epithelium and prostatic adenocarcinoma to define its immunoreactivity pattern throughout the prostate gland and to evaluate its potential diagnostic role in the discrimination of seminal duct epithelium from prostatic adenocarcinoma In addition given that is highly expressed in tissues of wolffian duct embryologic origin we also sought to confirm the divergent embryogenesis of the central zone seminal vesicle and ejaculatory duct from other regions of the prostate Prostatectomy specimens from 12 patients were reviewed to identify blocks containing seminal vesicle ejaculatory duct periurethral glands benign prostatic glands and prostatic acinar adenocarcinoma A total of 35 blocks from the 12 patients were evaluated In addition 2 tissue microarrays representing 15 additional seminal vesicles and 45 prostatic adenocarcinomas 7 whole sections from prostatic adenocarcinomas of the central zone and 5 core needle biopsies of seminal vesicle were also evaluated with antibody In the 12 radical prostatectomy whole sections nuclear reactivity for was identified in 12 100 of 12 of the seminal vesicle epithelium 9 90 of 10 of the ejaculatory duct epithelium 0 of 12 of the prostatic adenocarcinoma and 0 of 6 of the prostatic intraepithelial neoplasia All 20 total additional seminal vesicles were positive for in the tissue microarray and biopsies and all 52 additional prostatic adenocarcinomas were negative including 7 of central zone origin The staining intensity and percentage of immunoreactive cells in seminal vesicle were both in all cases Although the ejaculatory ducts also showed diffuse staining their staining intensity was less than that in the seminal vesicles particularly in the ejaculatory ducts in the periurethral area The smaller glands surrounding the main seminal vesicle duct also showed less intense staining than the luminal cells of the main duct Of the 19 total cases with evaluable central zone glands 2 had focal nuclear reactivity in normal benign prostatic secretory cells All other benign prostatic secretory epithelia from the peripheral and transition zones were negative for In conclusion nuclear immunoreactivity is typical in epithelium of the seminal vesicle and ejaculatory duct but the intensity of staining is less in the ejaculatory duct No reactivity for was seen in prostatic adenocarcinoma or prostatic intraepithelial neoplasia has diagnostic utility as a positive immunohistochemical marker of seminal vesicle and ejaculatory duct epithelium In addition these data add further support to the proposed embryogenesis of the prostatic central zone seminal vesicle and ejaculatory ducts from the wolffian system View details for DOI View details for Web of Science ID 000280128300011 View details for PubMedID 20413145 Canary Prostate Active Surveillance Study Design of a Active Surveillance Cohort and Biorepository UROLOGY Newcomb Brooks Carroll Feng Gleave Nelson Thompson Lin 2010 75 2 Abstract Active surveillance is a management plan for localized prostate cancer that offers selective delayed intervention on indication of disease progression allowing patients to delay or avoid treatment and associated Outcomes from centers that promote active surveillance are favorable with high rates of survival However there remains a need for prognostic variables or biomarkers that distinguish with high specificity the aggressive cancers that progress on surveillance from the indolent cancers The Canary Prostate Active Surveillance Study is a multicenter study and a biorepository that will discover and confirm biomarkers of aggressive disease as defined by histologic antigen or clinical criteria View details for DOI View details for Web of Science ID 000274393300051 View details for PubMedID 19758683 Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns Genes cancer Brannon Reddy Seiler Arreola Moore Pruthi Wallen Nielsen Liu Nathanson Ljungberg Zhao Brooks Ganesan Bhanot Rathmell 2010 1 2 Abstract Clear cell renal cell carcinoma ccRCC is the predominant RCC subtype but even within this classification the natural history is heterogeneous and difficult to predict A sophisticated understanding of the molecular features most discriminatory for the underlying tumor heterogeneity should be predicated on identifiable and biologically meaningful patterns of gene expression Gene expression microarray data were analyzed using software that implements iterative unsupervised consensus clustering algorithms to identify the optimal molecular subclasses without clinical or other classifying information ConsensusCluster analysis identified two distinct subtypes of ccRCC within the training set designated clear cell type A ccA and B ccB Based on the core tumors or most arrays in each subtype logical analysis of data LAD defined a small highly predictive gene set that could then be used to classify additional tumors individually The subclasses were corroborated in a validation data set of 177 tumors and analyzed for clinical outcome Based on individual tumor assignment tumors designated ccA have markedly improved survival compared to ccB median survival of vs years P Analyzed by both univariate and multivariate analysis the classification schema was independently associated with survival Using patterns of gene expression based on a defined gene set ccRCC was classified into two robust subclasses based on inherent molecular features that ultimately correspond to marked differences in clinical outcome This classification schema thus provides a molecular stratification applicable to individual tumors that has implications to influence treatment decisions define biological mechanisms involved in ccRCC tumor progression and direct future drug discovery View details for DOI View details for PubMedID 20871783 View details for PubMedCentralID PMC2943630 Gene expression changes induced by genistein in the prostate cancer cell line LNCaP The Open Prostate Cancer Journal Bhamre S Sahoo D Tibshirani R Dill DL Brooks JD 2010 3 Adjuvant docetaxel and abbreviated androgen deprivation therapy in patients with high risk prostate cancer The Open Prostate Cancer Journal Bazan JG King CR Brooks JD Srinivas S 2010 3 Prognostic significance of prostate cancer originating from the transition zone UROLOGIC AND ORIGINAL INVESTIGATIONS King Ferrari Brooks 2009 27 6 Abstract Transition zone TZ cancers are reported to have better biochemical survival bRFS after radical prostatectomy RP than cancers from the peripheral zone PZ To understand the influence of tumor location we compared bRFS for TZ and PZ cancers stratified for risk using known clinical and pathological prognostic surgical pathology and outcomes of 494 patients were reviewed Cancers originating from the TZ and PZ were identified from step sectioning of surgical specimens and tumor mapping Univariate and multivariate analyses of bRFS after RP were cancers were present in 89 18 patients On univariate analysis most factors predicted bRFS although cancer location did not bRFS was 85 for TZ 77 for PZ P However on multivariate analysis all factors except SV involvement were significant including TZ cancer location P HR Interestingly TZ location was correlated with improved bRFS for cancers 2 cc 81 for TZ 65 for PZ P for preop PSA 10 80 for TZ 59 for PZ P and for PSAV 2 85 for TZ 66 for PZ P However TZ cancers showed no difference in outcome for small volumes low preop PSA low PSAV or high Gleason cancers that are large with high preop PSA low Gleason scores and high PSAV show better outcomes than their PZ counterparts However cancer tumor location had no apparent influence on outcome Tumor location could be considered in subsets for optimal prognostication View details for DOI View details for Web of Science ID 000271801200003 View details for PubMedID 18799332 Disorders of sex development expose transcriptional autonomy of genetic sex and hormonal sex in human blood leukocytes BMC GENOMICS Holterhus Bebermeier Werner Demeter Cario Appari Siebert Riepe Brooks Hiort O 2009 10 Abstract Gender appears to be determined by independent programs controlled by the and by programming during embryonic development To enable experimental dissection of these components in the human we performed profiling of the transcriptomes of peripheral blood mononuclear cells PBMC in patients with rare defined disorders of sex development DSD 46 due to defective androgen biosynthesis compared to normal 46 and 46 discrete set of transcripts was directly correlated with XY or XX genotypes in all individuals independent of male or female phenotype of the external genitalia However a significantly larger gene set in the PBMC only reflected the degree of external genital masculinization independent of the sex chromosomes and independent of concurrent sex steroid hormone levels Consequently the architecture of the transcriptional sexes was either male female or even intersex with a discordant alignment of the DSD individuals genetic and hormonal sex significant fraction of gene expression differences between males and females in the human appears to have its roots in early embryogenesis and is not only caused by sex chromosomes but also by hormonal programming due to presence or absence of androgen during the time of external genital masculinization Genetic sex and the androgen milieu during embryonic development might therefore independently modulate functional traits phenotype and diseases associated with male or female gender as well as with DSD conditions View details for DOI View details for Web of Science ID 000268754800001 View details for PubMedID 19570224 Alteration of Gene Expression Signatures of Cortical Differentiation and Wound Response in Lethal Clear Cell Renal Cell Carcinomas PLOS ONE Zhao Ma Tibshirani Higgins Ljungberg Brooks 2009 4 6 Abstract Clear cell renal cell carcinoma ccRCC is the most common malignancy of the adult kidney and displays heterogeneity in clinical outcomes Through comprehensive gene expression profiling we have identified previously a set of transcripts that predict survival following nephrectomy independent of tumor stage grade and performance status These transcripts designated as the SPC supervised principal components gene set show no apparent biological or genetic features that provide insight into renal carcinogenesis or tumor progression We explored the relationship of this gene list to a set of genes expressed in different anatomical segments of the normal kidney including the cortex cortex gene set and the glomerulus glomerulus gene set and a gene set expressed after serum stimulation of quiescent fibroblasts the core serum response or CSR gene set Interestingly the normal cortex glomerulus part of the normal renal cortex and CSR gene sets captured more than of the genes in the highly prognostic SPC gene set Based on gene expression patterns alone the SPC gene set could be used to sort samples from normal adult kidneys by the anatomical regions from which they were dissected Tumors whose gene expression profiles most resembled the normal renal cortex or glomerulus showed better survival than those that did not and those with expression features more similar to CSR showed poorer survival While the cortex glomerulus and CSR signatures predicted survival independent of traditional clinical parameters they were not independent of the SPC gene list Our findings suggest that critical biological features of lethal ccRCC include loss of normal cortical differentiation and activation of programs associated with wound healing View details for DOI View details for Web of Science ID 000267356900003 View details for PubMedID 19557179 View details for PubMedCentralID PMC2698218 Apolipoprotein D APOD is a putative biomarker of androgen receptor function in androgen insensitivity syndrome JOURNAL OF MOLECULAR Appari Werner Wuensch Cario Demeter Hiort Riepe Brooks Holterhus 2009 87 6 Abstract Androgen insensitivity syndrome AIS is the most common cause of disorders of sex development usually caused by mutations in the androgen receptor AR gene AIS is characterized by a poor correlation and many patients with clinically presumed AIS do not seem to have mutations in the AR gene We therefore aimed at identifying a biomarker enabling the assessment of the cellular function of the AR as a transcriptional activator In the first step we used complementary DNA cDNA microarrays for a screen for genes in two normal male primary scrotal skin fibroblast strains compared to two labia majora fibroblast strains from 46 XY females with complete AIS CAIS Apolipoprotein D APOD and two further transcripts were significantly upregulated by dihydrotestosterone DHT in scrotum fibroblasts while CAIS labia majora cells were unresponsive Microarray data were well correlated with quantitative polymerase chain reaction R Subsequently we used in independent new cell cultures and confirmed the significant upregulation of APOD in five normal scrotum strains SD compared with three CAIS strains p t test and six partial androgen insensitivity syndrome strains 2 p t test Moreover two different dehydrogenase III deficiency labia majora strains showed APOD induction in the range of normal scrotum supporting AR specificity Therefore of APOD messenger RNA transcription in primary cultures of labioscrotal skin fibroblasts is a promising tool for assessing AR function potentially allowing a diagnostic evaluation of AIS in the future View details for DOI View details for Web of Science ID 000266475800009 View details for PubMedID 19330472 Prostatic Soy Isoflavone Concentrations Exceed Serum Levels After Dietary Supplementation PROSTATE Gardner Oelrich Liu Feldman Franke A Brooks 2009 69 7 Abstract The effects of soy isoflavones on prostate cancer may be The impact of soy supplementation on isoflavone concentrations in prostate tissues and serum remain assess and compare concentrations of soy isoflavones in prostate tissue and serum among 19 men with prostate cancer who had elected to undergo radical were randomized to receive either daily soy supplements 82 aglycone equivalents or placebos for 2 weeks 14 days prior to surgery Serum samples were obtained at the time of the surgery Isoflavone concentrations were measured by median 25th 75th percentile total isoflavone concentration in the group was in the prostate tissue and in the serum Total isoflavone concentrations in this group were an average of approximately higher in prostate tissue compared to serum the tissue versus serum ratio was significantly lower for genistein than daidzein versus P Tissue and serum levels of isoflavones among the placebo group were negligible with a few findings from the present study suggest that prostate tissue may have the ability to concentrate dietary soy isoflavones to potentially levels View details for DOI View details for Web of Science ID 000265727700004 View details for PubMedID 19180569 View details for PubMedCentralID PMC2734961 Recommendations for the Reporting of Surgically Resected Specimens of Renal Cell Carcinoma AMERICAN JOURNAL OF CLINICAL PATHOLOGY Higgins McKenney Brooks Argani Epstein I 2009 131 5 View details for DOI View details for Web of Science ID 000265264200003 View details for PubMedID 19369620 Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients INTERNATIONAL JOURNAL OF CANCER Swami Krishnan Moreno Bhattacharya Gardner Brooks Peehl Feldman 2009 124 9 Abstract Soy and its constituent isoflavone genistein inhibit the development and progression of prostate cancer PCa Our study in both cultured cells and PCa patients reveals a novel pathway for the actions of genistein namely the inhibition of the synthesis and biological actions of prostaglandins PGs known stimulators of PCa growth In the cell culture experiments genistein decreased mRNA and protein expression in both human PCa cell lines LNCaP and and primary prostate epithelial cells and increased dehydrogenase mRNA levels in primary prostate cells As a result genistein significantly reduced the secretion of PGE 2 by these cells EP4 and FP PG receptor mRNA were also reduced by genistein providing an additional mechanism for the suppression of PG biological effects Further the growth stimulatory effects of both exogenous PGs and endogenous PGs derived from precursor arachidonic acid were attenuated by genistein We also performed a pilot randomised double blind clinical study in which placebo or soy isoflavone supplements were given to PCa patients in the setting for 2 weeks before prostatectomy Gene expression changes were measured in the prostatectomy specimens In PCa patients ingesting isoflavones we observed significant decreases in prostate mRNA and increases in p21 mRNA There were significant correlations between mRNA suppression p21 mRNA stimulation and serum isoflavone levels We propose that the inhibition of the PG pathway contributes to the beneficial effect of soy isoflavones in PCa chemoprevention treatment View details for DOI View details for Web of Science ID 000264647600007 View details for PubMedID 19127598 Recommendations for the reporting of surgically resected specimens of renal cell carcinoma The Association of Directors of Anatomic and Surgical Pathology HUMAN PATHOLOGY Higgins McKenney Brooksd Argani Epstein I 2009 40 4 Abstract A checklist based approach to reporting the relevant pathologic details of renal cell carcinoma resection specimens improves the completeness of the report Karyotypic evaluation of renal neoplasms has refined but also complicated their classification The number of diagnostic possibilities has increased and the importance of distinguishing different tumor types has been underscored by dramatic variation in prognosis and the development of targeted therapies for specific subtypes The increasing number of recognized renal neoplasms has implications for handling renal resection specimens Furthermore the prognostic significance of other features of renal neoplasms related to grade and stage has been demonstrated This guideline for the handling of renal resection specimens will focus on problem areas in the evolving practice of diagnosis grading and staging of renal neoplasms The accompanying checklist will serve to ensure that all necessary details of the renal resection specimen are included in the surgical pathology report View details for DOI View details for Web of Science ID 000264990200002 View details for PubMedID 19289184 STEREOTACTIC BODY RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER INTERIM RESULTS OF A PROSPECTIVE PHASE II CLINICAL TRIAL INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS King Brooks Gill Pawlicki Cotrutz Presti 2009 73 4 Abstract The radiobiology of prostate cancer favors a hypofractionated dose regimen We report results of a prospective Phase II clinical trial of stereotactic body radiotherapy SBRT for localized prostate prostate cancer patients with 6 months minimum received Gy in five fractions of Gy with SBRT alone using the CyberKnife The early 3 months and late 6 months urinary and rectal toxicities were assessed using validated quality of life questionnaires International Prostate Symptom Score Expanded Prostate Cancer Index Composite and the Radiation Therapy Oncology Group RTOG toxicity criteria Patterns of antigen PSA response are median was 33 months There were no RTOG Grade 4 acute or late complications There were 2 patients with RTOG Grade 3 late urinary toxicity and none with RTOG Grade 3 rectal complications A reduced rate of severe rectal toxicities was observed with 5 consecutive days treatment regimen 0 38 p A benign PSA bounce median was observed in 12 patients 29 occurring at 18 months median after treatment At last no patient has had a PSA failure regardless of biochemical failure definition Of 32 patients with 12 months minimum 25 patients 78 achieved a PSA nadir View details for DOI View details for Web of Science ID 000264257400013 View details for PubMedID 18755555 Temporal Changes in Gene Expression Induced by Sulforaphane in Human Prostate Cancer Cells PROSTATE Bhamre Sahoo Tibshirani Dill Brooks 2009 69 2 Abstract Prostate cancer is thought to arise as a result of oxidative stresses and induction of antioxidant electrophile defense phase 2 enzymes has been proposed as a prostate cancer prevention strategy The isothiocyanate sulforaphane derived from cruciferous vegetables like broccoli potently induces surrogate markers of phase 2 enzyme activity in prostate cells in vitro and in vivo To better understand the temporal effects of sulforaphane and broccoli sprouts on gene expression in prostate cells we carried out comprehensive transcriptome analysis using cDNA significantly modulated by sulforaphane over time were identified using StepMiner analysis Ingenuity Pathway Analysis IPA was used to identify biological pathways networks and functions significantly altered by sulforaphane and IPA revealed significant changes in many transcripts associated with cell growth and cell cycle as well as a significant number associated with cellular response to oxidative damage and stress Comparison to an existing dataset suggested that sulforaphane blocked cell growth by inducing arrest Cell growth assays and flow cytometry analysis confirmed that sulforaphane inhibited cell growth and induced cell cycle data suggest that in prostate cells sulforaphane primarily induces cellular defenses and inhibits cell growth by causing phase arrest Furthermore based on the striking similarities in the gene expression patterns induced across experiments in these cells sulforaphane appears to be the primary bioactive compound present in broccoli sprouts suggesting that broccoli sprouts can serve as a suitable source for sulforaphane in intervention trials View details for DOI View details for Web of Science ID 000262701200008 View details for PubMedID 18973173 View details for PubMedCentralID PMC2612096 CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma BMC clinical pathology Williams A Higgins Zhao Ljunberg Brooks 2009 9 Abstract Clear cell renal cell carcinoma ccRCC and chromophobe renal cell carcinoma chRCC can usually be distinguished by histologic characteristics Occasionally diagnosis proves challenging and diagnostic difficulty will likely increase as needle biopsies of renal lesions become more identify markers that aid in differentiating ccRCC from chRCC we used gene expression profiles to identify candidate markers that correlate with histology 39 antisera and antibodies including 35 for transcripts identified from gene expression profiling were evaluated Promising markers were tested on a tissue microarray TMA containing 428 renal neoplasms Strength of staining of each core on the TMA was formally scored and the distribution of staining across different types of renal neoplasms was on results from initial immunohistochemical staining of multitissue titer arrays 23 of the antisera and antibodies were selected for staining of the TMA For 7 of these markers strength of staining of each core on the TMA was formally scored Vimentin positive in ccRCC and CD9 positive in chRCC best distinguished ccRCC from chRCC The combination of vimentin negativity and CD9 positivity was found to distinguish chRCC from ccRCC with a sensitivity of and a specificity of on gene expression analysis we identify CD9 and vimentin as candidate markers for distinguishing between ccRCC and chRCC In difficult cases and particularly when the amount of diagnostic tissue is limited vimentin and CD9 staining could serve as a useful adjunct in the differential diagnosis of ccRCC and chRCC View details for DOI View details for PubMedID 19922654 View details for PubMedCentralID PMC2788570 Comprehensive genomic characterization defines human glioblastoma genes and core pathways NATURE Chin Meyerson Aldape Bigner Mikkelsen VandenBerg Kahn PENNY Ferguson Gerhard Getz Brennan Taylor Winckler Park Ladanyi Hoadley Verhaak Hayes Spellman Absher Weir B Ding Wheeler Lawrence Cibulskis Mardis Zhang Wilson Donehower Wheeler Purdom Wallis Laird Herman Schuebel Weisenberger BAYLIN Schultz Yao Wiedemeyer WEINSTEIN Sander Gibbs Gray Kucherlapati Lander Myers Perou McLendon Friedman Van Meir Brat Mastrogianakis Olson Lehman Yung Bogler Berger Prados Muzny Morgan Scherer Sabo Nazareth Lewis Hall Zhu Ren Alvi Yao Hawes Jhangiani Fowler San Lucas Kovar Cree Dinh Santibanez Joshi Miller Milosavljevic Sougnez Fennell Mahan Wilkinson Ziaugra Onofrio Bloom Nicol Ardlie Baldwin Gabriel Fulton McLellan Larson Shi Abbott Fulton Chen Koboldt Wendl Meyer Tang Lin Osborne Miner Delehaunty Markovic Swift Courtney Pohl Abbott Hawkins Leong Haipek Schmidt Wiechert Vickery Scott Dooling Chinwalla Weinstock Robinson Alexe Beroukhim Carter Chiang Gould Gupta Korn Mermel Mesirov Monti Nguyen Parkin Reich Stransky Garraway Golub Protopopov Perna Aronson Sathiamoorthy Ren Kim Kong Xiao Kohane Seidman Cope Pan Van Den Berg van Neste Yi Li J Southwick Brady Aggarwal Chung Sherlock Brooks Jakkula Lapuk Marr Dorton Choi Han Ray Wang Durinck Robinson Wang Vranizan Peng Van Name Fontenay Ngai Conboy Parvin Feiler Speed Socci Olshen Lash Reva Antipin Stukalov Gross Cerami Wang Qin Seshan Villafania Cavatore Borsu Viale Gerald Topal Qi Balu Shi Wu Bittner Shelton Lenkiewicz Morris Beasley Sanders Sfeir Chen Nassau Feng Hickey Schaefer Madhavan Buetow Barker Vockley Compton Vaught Fielding Collins Good Guyer Ozenberger Peterson Thomson 2008 455 7216 Abstract Human cancer cells typically harbour multiple chromosomal aberrations nucleotide substitutions and epigenetic modifications that drive malignant transformation The Cancer Genome Atlas TCGA pilot project aims to assess the value of analysis of these molecular characteristics in human cancer and to provide the data rapidly to the research community Here we report the interim integrative analysis of DNA copy number gene expression and DNA methylation aberrations in 206 glioblastomas the most common type of adult brain cancer and nucleotide sequence aberrations in 91 of the 206 glioblastomas This analysis provides new insights into the roles of ERBB2 NF1 and TP53 uncovers frequent mutations of the kinase regulatory subunit gene PIK3R1 and provides a network view of the pathways altered in the development of glioblastoma Furthermore integration of mutation DNA methylation and clinical treatment data reveals a link between MGMT promoter methylation and a hypermutator phenotype consequent to mismatch repair deficiency in treated glioblastomas an observation with potential clinical implications Together these findings establish the feasibility and power of TCGA demonstrating that it can rapidly expand knowledge of the molecular basis of cancer View details for DOI View details for Web of Science ID 000260252600035 View details for PubMedID 18772890 Identification of candidate prostate cancer genes through comparative of seminal vesicle PROSTATE Thompson Lapointe Choi Ong Higgins Brooks Pollack 2008 68 11 Abstract Prostate cancer is the most frequently diagnosed cancer among men in the United States In contrast cancer of the seminal vesicle is exceedingly rare despite that the prostate and seminal vesicle share similar histology secretory function androgen dependency blood supply and in part embryonic origin We hypothesized that differences between prostate and seminal vesicle might inform mechanisms underlying the higher incidence of prostate DNA microarrays were used to profile gene expression of 11 normal prostate and 7 seminal vesicle specimens including six matched pairs obtained from radical prostatectomy Supervised analysis was used to identify genes differentially expressed between normal prostate and seminal vesicle and this list was then to genes differentially expressed between normal and cancerous prostate Expression patterns of selected genes were confirmed by immunohistochemistry using a tissue identified 32 genes that displayed a highly statistically significant expression pattern with highest levels in seminal vesicle lower levels in normal prostate and lowest levels in prostate cancer Among these genes was the known candidate prostate tumor suppressor GSTP1 involved in xenobiotic detoxification The expression pattern of GSTP1 and four other genes ABCG2 xenobiotic transport CRABP2 retinoic acid signaling GATA3 transcription and SLPI immune response was confirmed by findings identify candidate prostate cancer genes whose reduced expression in prostate compared to seminal vesicle may be permissive to prostate cancer initiation Such genes and their pathways may inform mechanisms of prostate carcinogenesis and suggest new opportunities for prostate cancer prevention View details for DOI View details for Web of Science ID 000258021300012 View details for PubMedID 18500686 View details for PubMedCentralID PMC2516917 Postoperative antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS King Presti Brooks Gill Spiotto 2008 70 5 Abstract Identification of patients most likely to benefit from salvage radiotherapy RT using postoperative postop antigen PSA 1984 to 2004 81 patients who fit the following criteria formed the study population undetectable PSA after radical prostatectomy RP pathologically negative nodes biochemical relapse defined as a persistently detectable PSA salvage RT and two or more postop PSAs available before salvage RT Salvage RT included the whole pelvic nodes in 55 patients and 4 months of total androgen suppression in 56 patients The median was 5 years All relapses were defined as a persistently detectable PSA and Cox proportional hazards multivariable analysis were performed for all clinical pathological and treatment factors predicting for biochemical survival bRFS were 37 biochemical relapses observed after salvage RT The bRFS after salvage RT for patients with postop antigen velocity or 1 1 was 59 29 p In multivariate analysis only postop PSAV p PSA level or 1 p and 10 months p remained significant whereas pelvic RT hormone therapy and RT dose showed a trend p approximately PSAV but not antigen doubling time predicted successful salvage RT suggesting an association of kinetics with locally recurrent PSA velocity independently predicts for the failure of salvage RT and can be considered in addition to features when selecting patients in need of systemic therapy following biochemical failure after RP For patients salvage RT can achieve high cure rates View details for DOI View details for Web of Science ID 000254660800028 View details for PubMedID 17935902 Do cancer index and tumor volume predict prostate cancer specific death Tarin Chung Brooks ELSEVIER SCIENCE 2008 115 View details for DOI 08 View details for Web of Science ID 000254175300323 expression marks a prostate cancer subtype with favorable clinical behavior and androgen signaling signature AMERICAN JOURNAL OF SURGICAL PATHOLOGY Lapointe Malhotra Higgins Bair Thompson Salari Giacomini Ferrari Montgomery Tibshirani van de Rijn Brooks Pollack 2008 32 2 Abstract Growing evidence suggests that only a fraction of prostate cancers detected clinically are potentially lethal An important clinical issue is identifying men with indolent cancer who might be spared aggressive therapies with associated morbidities Previously using microarray analysis we defined 3 molecular subtypes of prostate cancer with different patterns One displayed features consistent with more indolent behavior where an immunohistochemical marker AZGP1 for predicted favorable outcome after radical prostatectomy Here we characterize a second candidate tissue biomarker expressed in prostate tumors expression assayed by RNA in situ hybridization on a tissue microarray comprising 225 cases was associated with decreased tumor recurrence after radical prostatectomy independent of pathologic tumor stage Gleason grade and preoperative antigen levels Simultaneous assessment of and AZGP1 expression in this tumor set improved outcome prediction We have previously demonstrated that is induced by androgen in prostate cells Extending this finding Gene Set Enrichment Analysis revealed enrichment of genes in tumors Our findings identify as a new biomarker for tumors that improves prognostication and reveal androgen signaling as an important biologic feature of this potentially clinically favorable molecular subtype View details for PubMedID 18223322 The impact of tumor volume on outcomes after radical prostatectomy Implications for prostate cancer screening The Open Prostate Cancer Journal James Brooks Robert Tibshirani Michelle Ferrari Joseph Presti Harcharan Gill Christopher King 2008 1 Editorial comments JOURNAL OF UROLOGY Brooks 2007 178 6 2400 View details for DOI View details for Web of Science ID 000250847900050 Intrinsic gene expression patterns revealed by comparison of genital fibroblasts from normal males and individuals with complete and partial androgen insensitivity syndrome BMC GENOMICS Holterhus Deppe Werner Bebermeier Wuensch Krege Schweikert Demeter Riepe Hiort Brooks 2007 8 Abstract To better understand the molecular programs of normal and abnormal genital development definition of gene expression patterns without the influence of genotype 46 XX 46 XY is warranted Previously we have identified global gene expression profiles in fibroblasts that differ between 46 XY males and 46 XY females with complete androgen insensitivity syndrome CAIS due to inactivating mutations of the androgen receptor AR While these differences could be due to cell autonomous changes in gene expression induced by androgen programming recent work suggests they could also be influenced by the location from which the fibroblasts were harvested topology To minimize the influence of topology we compared gene expression patterns of fibroblasts derived from identical urogenital anlagen the scrotum in normally virilized 46 XY males and the labia majora from completely feminized 46 XY individuals with transcripts representing 440 unique genes differed significantly in expression levels between scrotum and CAIS labia majora suggesting the effects of androgen programming While some genes coincided with those we had identified previously TBX3 IGFBP5 EGFR CSPG2 a significant number did not implying that topology had influenced gene expression in our previous experiments Supervised clustering of gene expression data derived from a large set of fibroblast cultures from individuals with partial AIS revealed that the new topology controlled data set better classified the mutations of the AR in themselves appear to induce lasting changes in gene expression in cultured fibroblasts independent of topology and genotype Genes identified are likely to be relevant candidates to decipher normal and abnormal genital development View details for DOI View details for Web of Science ID 000252779600001 View details for PubMedID 17945006 View details for PubMedCentralID PMC2212662 Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis CANCER RESEARCH Lapointe Li Giacomini Salari Huang Wang Ferrari Brooks Pollack 2007 67 18 Abstract Prostate cancer is clinically heterogeneous ranging from indolent to lethal disease Expression profiling previously defined three subtypes of prostate cancer one linked to clinically favorable behavior and the others and linked with a more aggressive form of the disease To explore disease heterogeneity at the genomic level we carried out comparative genomic hybridization array CGH on 64 prostate tumor specimens including 55 primary tumors and 9 pelvic lymph node metastases Unsupervised cluster analysis of DNA copy number alterations CNA identified recurrent aberrations including a group associated with gene expression patterns and decreased tumor recurrence Supervised analysis further disclosed distinct patterns of CNA among subtypes where tumors exhibited characteristic deletions at 5q21 and 6q15 and cases harbored deletions at 8p21 and 21q22 resulting in fusion Lymph node metastases predominantly displayed overall higher frequencies of CNA and in particular gains at 8q24 MYC and 16p13 and loss at 10q23 PTEN and 16q23 Our findings reveal that prostate cancers develop via a limited number of alternative preferred genetic pathways The resultant molecular genetic subtypes provide a new framework for investigating prostate cancer biology and explain in part the clinical heterogeneity of the disease View details for DOI View details for Web of Science ID 000249679500013 View details for PubMedID 17875689 Placental S100 S100P and GATA3 Markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray AMERICAN JOURNAL OF SURGICAL PATHOLOGY Higgins Kaygusuz Wang Montgomery Mason Zhu Marinelli Presti van de Rijn Brooks 2007 31 5 Abstract The morphologic distinction between prostate and urothelial carcinoma can be difficult To identify novel diagnostic markers that may aid in the differential diagnosis of prostate versus urothelial carcinoma we analyzed expression patterns in prostate and bladder cancer tissues using complementary DNA microarrays Together with our prior studies on renal neoplasms and normal kidney these studies suggested that the gene for placental S100 S100P is specifically expressed in benign and malignant urothelial cells Using tissue microarrays a polyclonal antiserum against S100P protein stained 86 of 295 urothelial carcinomas while only 3 of 260 prostatic adenocarcinomas and 1 of 133 renal cell carcinomas stained A commercially available monoclonal antibody against S100P stained 78 of 300 urothelial carcinomas while only 2 of 256 prostatic adenocarcinomas and none of 137 renal cell carcinomas stained A second gene GATA3 also showed high level expression in urothelial tumors by cDNA array A commercially available monoclonal antibody against GATA3 stained 67 of 308 urothelial carcinomas but none of the prostate or renal carcinomas For comparison staining was also performed for p63 and cytokeratin p63 stained 87 of urothelial carcinomas whereas stained 54 Importantly when S100P and p63 were combined 95 of urothelial carcinomas were labeled by one or both markers We conclude that the detection of S100P and GATA3 protein expression may help distinguish urothelial carcinomas from other genitourinary neoplasms that enter into the differential diagnosis View details for PubMedID 17460449 A promoting role of androgen receptor in and prostate cancer cells NUCLEIC ACIDS RESEARCH Li Zhao Peng Beliakoff Brooks Sun Z 2007 35 8 Abstract Although the vital role of the androgen receptor AR has been well demonstrated in primary prostate cancers its role in the prostate cancers still remains unclear Here we used a small hairpin RNA approach to directly assess AR activity in prostate cancer cells Reduction of AR expression in the two prostate cancer cell lines LNCaP and LAPC4 significantly decreased transcription and cell growth Intriguingly in two prostate cell lines and CWR22Rv1 knockdown of AR expression showed a more pronounced effect on transcription and cell growth than androgen depletion Using cDNA microarrays we also compared the transcriptional profiles induced by either androgen depletion or AR knockdown Although a significant number of transcripts appear to be regulated by both androgen depletion and AR knockdown we observed a subset of transcripts affected only by androgen depletion but not by AR knockdown and vice versa Finally we demonstrated a direct role for AR in promoting tumor formation and growth in a xenograft model Taken together our results elucidate an important role for the AR in prostate cancer cells and suggest that AR can be used as a therapeutic target for prostate cancers View details for DOI View details for Web of Science ID 000247239600029 View details for PubMedID 17426117 View details for PubMedCentralID PMC1885678 A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis MODERN PATHOLOGY Lapointe Kim Miller Li Kaygusuz van de Rijn Huntsman Brooks Pollack 2007 20 4 Abstract Prostate cancer is the most commonly diagnosed cancer among men in the United States Recently fusion of TMPRSS2 with ETS family oncogenic transcription factors has been identified as a common molecular alteration in prostate cancer where most often the rearrangement places ERG under the transcriptional control of TMPRSS2 Here we carried out rapid amplification of cDNA ends RACE on a prostate cancer specimen carrying an atypical aberration discovered by comparative genomic hybridization array CGH suggesting an alternative fusion partner of ERG We identified novel transcribed sequences fused to ERG mapping 4 kb upstream of the TMPRSS2 start site The sequences derive from an apparent second TMPRSS2 isoform which we found also expressed in some prostate tumors suggesting similar control In a reverse chain reaction survey of 63 prostate tumor specimens 54 primary and nine lymph node metastases 44 70 cases expressed either the known or novel variant fusion 28 44 expressed both 10 16 expressed only the known and notably six 10 expressed only the variant isoform fusion In this specimen set the presence of a fusion showed no statistical association with tumor stage Gleason grade or survival Nonetheless the discovery of a novel variant TMPRSS2 fusion adds to the characterization of rearrangements in prostate cancer and has important implications for the accurate molecular diagnosis of fusions View details for DOI View details for PubMedID 17334351 promotes cell survival in renal cell carcinoma through the ETA receptor CANCER LETTERS Pflug Zheng Udan Marshall Brooks Nelson J B 2007 246 Abstract is a potent vasoconstrictor that has been shown to significantly impact many benign and malignant tissues by signaling through its two cognate receptors ET A and ET B As has a role in both normal and diseased kidney we initiated studies to investigate endothelin axis expression and function in renal cell carcinoma RCC In this study relatively high levels of were detected in all six human RCC cell lines investigated and Southern analyses revealed that all six RCC cell lines expressed ET A receptor mRNA while cell lines also expressed ET B mRNA High affinity binding occurred in all but one RCC cell line and quantitative demonstrated ET A mRNA expression in all six cell lines Methylation of the ET B promoter EDNRB in RCC cell lines was observed suggesting a mechanism for repressed ET B expression Moreover methylation occurred in of renal tumors and in of histologically normal adjacent tissue samples studied while no methylation was evident in any normal tissue isolated from nephrectomy or at autopsy Functionally significantly inhibited apoptosis in RCC cells through binding ET A with the signaling mediated via the pathway Collectively these data support the therapeutic targeting of the ET A receptor as a novel treatment strategy for RCC View details for DOI View details for Web of Science ID 000244154900017 View details for PubMedID 16581180 Selenomethionine induced transcriptional programs in human prostate cancer cells JOURNAL OF UROLOGY Zhao Brooks 2007 177 2 Abstract We determined the effects of selenomethionine the major organic selenium containing compound found in the diet and the form of selenium being used in the Selenium and Vitamin E Cancer Prevention Trial on prostate cancer assessed global transcript profiles of selenomethionine treated LNCaP using cDNA microarrays and compared them to those of cells treated with methylselenic acid a direct precursor of methylselenol which is the active form of selenium in treatment with selenomethionine unique genes showed expression changes of at least in at least 3 time points during 48 hours and 366 unique transcripts differed significantly between selenomethionine and methylselenic acid treated LNCaP Approximately half of the 76 cell cycle regulated genes affected by selenomethionine were and enriched for genes associated with the phase Flow cytometry analysis showed that selenomethionine induced arrest in LNCaP at low concentrations Selenomethionine also affected expression levels of 35 known androgen responsive genes and 18 of these transcripts showed changes that were the inverse of those seen after androgen stimulation At high concentrations selenomethionine decreased prostate specific antigen promoter driven luciferase modulates transcript levels of genes involved in a number of biological processes including cell androgen signaling signal transduction and transcriptional regulation Although the pathways affected paralleled in many ways those that are modulated by methylselenic acid distinct differences in transcript patterns and effects on cell cycle regulation suggest that different selenium compounds could exert unique effects in prostate cells View details for DOI View details for Web of Science ID 000243453900074 View details for PubMedID 17222674 View details for PubMedCentralID PMC2729366 Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues JOURNAL OF CELLULAR PHYSIOLOGY Zhao Ramos Brooks Peehl 2007 210 1 Abstract To obtain a comprehensive view of the transcriptional programs in prostatic stromal cells of different origin we profiled 18 adult human stromal cell cultures from normal transition zone TZ normal peripheral zone PZ benign prostatic hyperplasia BPH and prostate cancer CA using cDNA microarrays A hierarchical clustering analysis of 714 named unique genes whose expression varied at least threefold from the overall mean abundance in at least three samples in all 18 samples demonstrated that cells of different origin displayed distinct gene expression profiles Many of the differentially expressed genes are involved in biological processes known to be important in the development of prostatic diseases including cell proliferation and apoptosis cell adhesion and immune response Significance Analysis of Microarrays SAM analysis identified genes that showed differential expression with statistical significance including 24 genes between cells from TZ versus BPH 34 between BPH versus CA and 101 between PZ versus CA S100A4 and SULF1 the most and downregulated genes in BPH versus TZ respectively showed expression at the protein level consistent with microarray analysis In addition sulfatase assay showed that BPH cells have lower SULF1 activity compared to TZ cells Quantitative polymerase chain reaction analysis confirmed differential expression of and six other genes between PZ versus CA as well as differential expression of six genes between BPH versus CA Our results support the hypothesis that prostatic stromal cells of different origin have unique transcriptional programs and point towards genes involved in actions of stromal cells in BPH and CA View details for DOI View details for Web of Science ID 000242568200012 View details for PubMedID 17044071 View details for PubMedCentralID PMC2732006 and signatures of androgen transcription JOURNAL OF MOLECULAR Bebermeier Brooks DePrimo Werner Deppe Demeter Hiort Holterhus 2006 84 11 Abstract Normal genital skin fibroblasts GSF and the human prostate carcinoma cell line LNCaP have been used widely as cell culture models of genital origin to study androgen receptor AR signaling We demonstrate that LNCaP shows a reproducible response to androgens as assessed using representing approximately unique human genes whereas several independent GSF strains are virtually unresponsive We show that LNCaP cells express markedly higher AR protein levels likely contributing to the observed differences of androgen responsiveness However previous data suggested that levels alone do not determine androgen responsiveness of human GSF compared to LNCaP We hypothesized that differences in expression levels of AR coregulators might contribute to differences in androgen responsiveness and might be found by comparing LNCaP and GSFs Using the Canadian of AR coregulators http we identified 61 genes represented by 282 transcripts on our microarray platform that was used to measure transcript profiles of LNCaP and GSF cells Baseline expression levels of 48 transcripts representing 33 distinct genes showed significant differences between GSF and LNCaP four of which we confirmed by reverse transcriptase polymerase chain reaction Compared to LNCaP GSFs displayed significant upregulation of AR coregulators that can function as repressors of such as caveolin 1 Analysis of a recently published comprehensive dataset of 115 microarrays representing 35 different human tissues revealed signatures of AR coregulators that segregated with ontogenetically related groups of tissues lymphatic system and genital tissues brain Our data demonstrate the existence of and expression patterns of molecules with documented AR coregulatory functions Therefore differential expression patterns of AR coregulators could modify and diversity of androgen actions in development physiology and disease View details for DOI View details for Web of Science ID 000241589100005 View details for PubMedID 16932916 Natural history of positive urinary cytology after radical cystectomy Editorial comment JOURNAL OF UROLOGY Brooks 2006 176 5 2005 View details for DOI View details for Web of Science ID 000241273100032 Application of genomic technologies to human prostate cancer JOURNAL OF INTEGRATIVE BIOLOGY Li Bhamre Lapointe Pollack Brooks 2006 10 3 Abstract Prostate cancer is the most commonly diagnosed malignancy in males and has a broad spectrum of clinical behavior ranging from indolent to lethal Microarray technology has provided unprecedented opportunity to explore the genetic processes underlying prostate cancer by providing a comprehensive survey of a cell transcriptional landscape Prostate cancer however has posed significant challenges that have contributed to inconsistent results between studies and difficulty replicating findings Despite these challenges several important insights have been gained along with new clinical biomarkers of diagnosis and prognosis Continued improvements in methods of tissue preparation microarray technology and data analysis will overcome existing challenges and fuel future discoveries View details for Web of Science ID 000241666200002 View details for PubMedID 17069507 Reliability of small amounts of cancer in prostate biopsies to reveal pathologic grade UROLOGY King McNeal Gill Brooks Srinivas Presti 2006 67 6 Abstract To examine grade reliability when biopsies contain very small amounts of prostate cancer Prostate biopsy findings are known to undergrade prostate cancer compared with the pathologic specimens yet remain the only grade guiding disease presence of a clinically significant grade change from biopsy cores to matched prostatectomy specimens was examined in 371 patients The biopsies were characterized for primary and secondary Gleason grade number of positive cores and total linear length of cancer The pathologic specimens were characterized for cancer volume and relative percentage by grade The rates of upgrading or downgrading were tested against all clinical and biopsy information for any significant predictive overall rate of upgrading was and downgrading was Upgrading was constant and independent of any clinical or biopsy tumor volume indexes Specifically when cancer was present in only one biopsy core and measured 2 mm or less n 48 it was just as predictive of the pathologic grade as that from any greater number of positive cores and any greater extent of cancer length present Downgrading was less frequent for biopsies with small amounts of grading from small amounts of cancer in prostate biopsies is reliable and not more prone to grading errors A repeat biopsy for these patients may not be indicated View details for DOI View details for PubMedID 16765184 Refractory hematuria from amyloidosis successfully treated by splenectomy UROLOGY Ma Coutre Curet Brooks 2006 67 5 Abstract Systemic amyloidosis can result in a coagulopathy that is associated with low levels of factor X We present a case of intractable hematuria that was successfully managed with activated recombinant human factor VII and splenectomy View details for DOI View details for Web of Science ID 000238390800059 View details for PubMedID 16698382 The application of genomic and proteomic approaches to human prostate cancer in developing diagnostic and prognostic markers UROLOGIC AND ORIGINAL INVESTIGATIONS Brooks 2006 24 3 View details for DOI View details for Web of Science ID 000237944800009 Modest induction of phase 2 enzyme activity in the rat prostate BMC CANCER Jones Brooks 2006 6 Abstract Prostate cancer is the most commonly diagnosed malignancy in men and is thought to arise as a result of endogenous oxidative stress in the face of compromised carcinogen defenses We tested whether carcinogen defense phase 2 enzymes could be induced in the prostate tissues of rats after oral feeding of candidate phase 2 enzyme inducing F344 rats were gavage fed sulforaphane curcumin dimethyl fumarate or vehicle control over five days and on the sixth day prostate liver kidney and bladder tissues were harvested Cytosolic enzyme activities of nicotinamide quinone oxidoreductase NQO1 total glutathione transferase using DCNB and glutathione transferase using CDNB were determined in the treated and control animals and prostatic tissues sulforaphane produced modest but significant increases in the enzymatic activities of NQO1 total GST and compared to control animals significantly increased NQO1 and activities and curcumin increased total GST and enzymatic activities Dimethyl fumarate did not significantly increase prostatic phase 2 enzyme activity Compared to control animals sulforaphane also significantly induced NQO1 or total GST enzyme activity in the liver kidney and most significantly in the bladder tissues All compounds were well tolerated over the course of the gavage administered compounds will induce modestly phase 2 enzyme activity in the prostate although the significance of this degree of induction is unknown The 4 different compounds also altered phase 2 enzyme activity to different degrees in different tissue types Orally administered sulforaphane potently induces phase 2 enzymes in bladder tissues and should be investigated as a bladder cancer preventive agent View details for DOI View details for Web of Science ID 000236547000001 View details for PubMedID 16539699 View details for PubMedCentralID PMC1421427 Gene expression profiling predicts survival in conventional renal cell carcinoma PLOS MEDICINE Zhao Ljungberg Grankvist Rasmuson Tibshirani Brooks 2006 3 1 Abstract Conventional renal cell carcinoma cRCC accounts for most of the deaths due to kidney cancer Tumor stage grade and patient performance status are used currently to predict survival after surgery Our goal was to identify gene expression features using comprehensive gene expression profiling that correlate with expression profiles were determined in 177 primary cRCCs using DNA microarrays Unsupervised hierarchical clustering analysis segregated cRCC into five gene expression subgroups Expression subgroup was correlated with survival in and was independent of grade stage and performance status The tumors were then divided evenly into training and test sets that were balanced for grade stage performance status and length of A semisupervised learning algorithm supervised principal components analysis was applied to identify transcripts whose expression was associated with survival in the training set and the performance of this gene survival predictor was assessed using the test set With this method we identified 259 genes that accurately predicted survival among patients in the independent validation group p In multivariate analysis the gene expression predictor was a strong predictor of survival independent of tumor stage grade and performance status p displays molecular heterogeneity and can be separated into gene expression subgroups that correlate with survival after surgery We have identified a set of 259 genes that predict survival after surgery independent of clinical prognostic factors View details for DOI View details for Web of Science ID 000236342700020 View details for PubMedID 16318415 View details for PubMedCentralID PMC1298943 S100p A marker for transitional epithelium and urothelial carcinoma Higgins Kaygusuz Wang Montgomery Mason Brooks van de Rijn NATURE PUBLISHING GROUP 2006 142A View details for Web of Science ID 000234094501089 The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer CANCER RESEARCH Kim Lapointe Kaygusuz Ong Li van de Rijn Brooks Pollack 2005 65 18 Abstract Prostate cancer is the most common cancer among men in the United States and aberrant DNA methylation is known to be an early molecular event in its development Here we have used expression profiling to identify novel hypermethylated genes whose expression is induced by treatment of prostate cancer cell lines with the DNA methyltransferase inhibitor Of the 271 genes that were induced by treatment 25 also displayed reduced expression in primary prostate tumors compared with normal prostate tissue and the decreased expression of only one gene aldehyde dehydrogenase 1 family member A2 ALDH1a2 was also associated with shorter survival ALDH1a2 encodes an enzyme responsible for synthesis of retinoic acid RA a compound with prodifferentiation properties By immunohistochemistry we observed that ALDH1a2 was expressed in epithelia from normal prostate but not prostate cancer Using bisulfite sequencing we determined that the ALDH1a2 promoter region was significantly hypermethylated in primary prostate tumors compared with normal prostate specimens P Finally reexpression of ALDH1a2 but not a presumptive catalytically dead mutant in the prostate cancer cell line DU145 resulted in decreased colony growth P comparable with treatment with either or RA Taken together our findings implicate ALDH1a2 as a candidate tumor suppressor gene in prostate cancer and further support a role of retinoids in the prevention or treatment of prostate cancer View details for DOI View details for PubMedID 16166285 Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy JOURNAL OF CLINICAL ONCOLOGY Patel Presti McNeal Gill Brooks King 2005 23 25 Abstract Preoperative antigen PSA velocity PSAV or the rate of PSA rise before diagnosis predicts for risk of cancer death after radical prostatectomy RP We evaluated the relative merit of established preoperative factors including biopsy indices and preoperative PSAV for their impact on relapse after outcomes of 202 men who underwent RP were reviewed Biopsies were characterized for grade percentage positive cores and total linear tumor length Surgical specimens were characterized for cancer volume relative percentage by grade extracapsular extension and margin status Univariate and multivariate analyses were performed with respect to survival after patients relapsed after RP defined as PSA or with a median time to failure of 16 months Median was 48 months survival at 5 years was 89 compared with 73 for PSAV or 2 v 2 P On multivariate analysis only the biopsy Gleason sum P relative risk and the preoperative PSAV P relative risk to remained significant Patients with a PSAV of 2 were more likely to be pT3 P have positive margins P have tumors 1 mL P and possess 10 grade tumors P preoperative PSAV is a significant independent clinical factor predicting for relapse after RP and also predicts for larger more aggressive and more locally advanced tumors Its inclusion will be useful in risk stratification evaluation for alternatives to surgery and patient selection for neoadjuvant or adjuvant therapies as part of randomized clinical trials View details for DOI View details for Web of Science ID 000231606300041 View details for PubMedID 16135482 characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines PROSTATE Zhao Kim Wang Lapointe Tibshirani Pollack Brooks 2005 63 2 Abstract The aim of this study was to characterize gene expression and DNA copy number profiles in androgen sensitive AS and androgen insensitive AI prostate cancer cell lines on a expression profiles and DNA copy number changes were examined using DNA microarrays in eight commonly used prostate cancer cell lines Chromosomal regions with DNA copy number changes were identified using cluster along chromosome CLAC were discrete differences in gene expression patterns between AS and AI cells that were not limited to genes AI cells displayed more DNA copy number changes especially amplifications than AS cells The gene expression profiles of cell lines showed limited similarities to prostate tumors harvested at and AI cell lines are different in their transcriptional programs and degree of DNA copy number alterations This dataset provides a context for the use of prostate cancer cell lines as models for clinical cancers View details for DOI View details for PubMedID 15486987 Juvenile posttraumatic priapism current management dilemmas JOURNAL OF PEDIATRIC SURGERY Marotte J Brooks Sze Kennedy A 2005 40 4 Abstract priapism results from disruption of the intercavernosal artery resulting in an arteriocavernosal fistula and is rarely encountered in the pediatric and adolescent population Clinically it manifests as a painless prolonged erection after perineal trauma Treatment has ranged from expectant management to open surgical exploration with vessel ligation Internal pudendal arteriogram and superselective embolization with autologous blood clot has emerged as a safe and effective treatment modality in the young male population Here the authors present 3 patients with priapism and discuss management of this rare clinical entity View details for DOI View details for Web of Science ID 000229359300042 View details for PubMedID 15852259 Reg IV A promising marker of hormone refractory metastatic prostate cancer CLINICAL CANCER RESEARCH Gu Rubin Yang DePrimo Zhao Horvath Brooks Loda Reiter 2005 11 6 Abstract The diagnosis and management of prostate cancer is hampered by the absence of markers capable of identifying patients with metastatic disease In order to identify potential new markers for prostate cancer we compared gene expression signatures of matched and hormone refractory prostate cancer xenografts One candidate gene overexpressed in a hormone refractory xenograft was homologous to the regenerating protein gene family a group of secreted proteins expressed in the gastrointestinal tract and overexpressed in inflammatory bowel disease and cancer This gene Reg IV was confirmed to be differentially expressed in the hormone refractory xenograft Consistent with its in a hormone refractory xenograft it is expressed in several prostate tumors after neoadjuvant hormone ablation therapy As predicted by its sequence homology it is secreted from transiently transfected cells It is also expressed strongly in a majority of hormone refractory metastases represented on two tissue microarrays In comparison it is not expressed by any normal prostate specimens and only at low levels in approximately 40 of primary tumors These data support Reg IV as a candidate marker for hormone refractory metastatic prostate cancer View details for Web of Science ID 000227770000019 View details for PubMedID 15788672 gene expression profiles in human prostate cancer cells CANCER EPIDEMIOLOGY BIOMARKERS PREVENTION Jones DePrimo Whitfield Brooks 2005 14 3 Abstract The transhydroxystilbene resveratrol is found at high levels in red wine and grapes and red wine consumption may be inversely associated with prostate cancer risk To gain insights into the possible mechanisms of action of resveratrol in human prostate cancer we did DNA microarray analysis of the temporal transcriptional program induced by treatment of the human prostate cancer cell line LNCaP with DNA microarrays containing over elements were used to obtain a global view of the effects of resveratrol on gene expression antigen PSA and androgen receptor AR expression were determined by Northern blot and immunoblot analyses Cell proliferation was determined by the 4 bromide assay and cell cycle analysis by flow observed expression changes in transcripts as early as 6 hours after treatment with resveratrol Most striking was the modulation of a number of important genes in the androgen pathway including PSA and AR Resveratrol also expression of cell cycle and genes involved in all phases of the cell cycle induced negative regulators of proliferation caused accumulation of cells at the and S phases of the cell cycle and inhibited cell proliferation in a and produces gene expression changes in the androgen axis and cell cycle regulators that may underlie its putative anticancer activities in prostate cancer View details for Web of Science ID 000227545900011 View details for PubMedID 15767336 Molecular targets of Doxazosin in human prostatic stromal cells PROSTATE Zhao Lai Nonn Brooks Peehl 2005 62 4 Abstract We used cDNA microarray analysis to obtain insights into the mechanisms of action of doxazosin an alpha 1 receptor antagonist used to treat benign prostatic hyperplasia BPH clustering analysis and significance analysis of microarray SAM were performed to identify genes differentially expressed between untreated stromal cells cultured from normal tissue and BPH and changes in gene expression induced by doxazosin Transcript levels of selected genes were validated by polymerase chain reaction clustering analyses separated untreated normal and BPH cells genes whose expression varied at least twofold after doxazosin treatment in both normal and BPH cells were identified as were 93 genes differentially regulated in normal versus BPH cells Molecular targets consistent with tumor necrosis factor TNF activity were versus BPH stromal cells differ in global gene transcription Doxazosin induced gene expression changes relevant to immune defense transduction and transcriptional regulation View details for DOI View details for Web of Science ID 000226991500011 View details for PubMedID 15378519 Positive family history of prostate cancer not associated with worse outcomes after radical prostatectomy UROLOGY Lee Marotte J Ferrari McNeal Brooks Presti 2005 65 2 Abstract To determine the clinical outcomes in men with FH and without NFH a family history of prostate cancer after radical performed a retrospective analysis of 557 men with localized prostate cancer treated by radical prostatectomy between 1989 and 2000 We defined a positive FH as having one or more relatives such as a father or brother with prostate cancer The clinical and pathologic features as well as biochemical survival defined as an undetectable antigen level less than were compared between the FH and NFH with the NFH group the FH men were younger at surgery median 62 years versus 64 years P had a lower median preoperative antigen level versus P and were more likely to have only disease at the final pathologic evaluation versus P At a median of years mean years 17 of the FH group had biochemical disease recurrence compared with 30 in the NFH group The actuarial survival rate at 5 and 10 years for the two groups was 86 and 80 compared with 73 and 66 respectively P When controlled for pathologic variables in a multivariate analysis FH was not an independent predictor of association of improved survival in the FH patients may have been driven by an earlier age at diagnosis and more favorable pathologic features View details for DOI View details for Web of Science ID 000227307000021 View details for PubMedID 15708044 Microarray Data Mining for Potential Selenium Targets in Chemoprevention of Prostate Cancer Cancer genomics proteomics Zhang Dong Zhao Brooks Hawthorn Nowak Marshall Gao Ip 2005 2 2 Abstract BACKGROUND A previous clinical trial showed that selenium supplementation significantly reduced the incidence of prostate cancer We report here a bioinformatics approach to gain new insights into selenium molecular targets that might be relevant to prostate cancer chemoprevention MATERIALS AND METHODS We first performed data mining analysis to identify genes which are consistently dysregulated in prostate cancer using published datasets from gene expression profiling of clinical prostate specimens We then devised a method to systematically analyze three selenium microarray datasets from the LNCaP human prostate cancer cells and to match the analysis to the cohort of genes implicated in prostate carcinogenesis Moreover we compared the selenium datasets with two datasets obtained from expression profiling of LNCaP cells RESULTS We found that selenium reverses the expression of genes implicated in prostate carcinogenesis In addition we found that selenium could counteract the effect of androgen on the expression of a subset obtained from genes CONCLUSIONS The above information provides us with a treasure of new clues to investigate the mechanism of selenium chemoprevention of prostate cancer Furthermore these selenium target genes could also serve as biomarkers in future clinical trials to gauge the efficacy of selenium intervention View details for PubMedID 18548127 View details for PubMedCentralID PMC2424238 A transcriptional profile of aging in the human kidney PLOS BIOLOGY Rodwell Sonu Zahn Lund Wilhelmy Wang Xiao Mindrinos Crane Segal Myers Brooks Davis Higgins Owen A Kim 2004 2 12 Abstract In this study we found 985 genes that change expression in the cortex and the medulla of the kidney with age Some of the genes whose transcripts increase in abundance with age are known to be specifically expressed in immune cells suggesting that immune surveillance or inflammation increases with age The genes show a similar aging profile in the cortex and the medulla suggesting a common underlying mechanism for aging Expression profiles of these genes mark not only age but also the relative health and physiology of the kidney in older individuals Finally the set of kidney genes suggests specific mechanisms and pathways that may play a role in kidney degeneration with age View details for DOI View details for PubMedID 15562319 Vascular invasion predicts recurrence after radical prostatectomy Stratification of risk based on pathologic variables UROLOGY Ferrari McNeal Malhotra Brooks 2004 64 4 Abstract To determine whether vascular invasion VI is an independent predictor of prostate cancer recurrence survival and to stratify risk of recurrence in patients with invasion status was documented in 620 radical prostatectomy specimens with an average of years of The relationship between VI and other clinical and pathologic features was tested Vascular invasion as an independent predictor of recurrence was investigated by logistic regression analysis Survival analyses and stratification of VI patients was developed with survival invasion was identified in 110 patients 18 and correlated significantly P with high Gleason grade extracapsular extension EPE seminal vesicle invasion increasing cancer volumes positive margins and elevated preoperative antigen PSA levels Logistic regression analysis demonstrated that VI was a strong and independent predictor for disease recurrence when considered with grade EPE seminal vesicle invasion lymph node involvement cancer volume preoperative PSA levels and positive margins At 12 years after radical prostatectomy patients with VI demonstrated significantly lower survival P Among patients with VI stratification of grade EPE and the number of VI foci identified three significantly different prognostic VI was a significant predictor of prostate cancer recurrence and death after radical prostatectomy In patients with VI high Gleason grade EPE and more than five foci of VI are associated with poor prognosis View details for DOI View details for Web of Science ID 000224680300030 View details for PubMedID 15491714 Molecular activity of in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY Peehl Shinghal Nonn Seto Krishnan Brooks Feldman 2004 92 3 Abstract D 3 OH 2 D 3 exerts differentiating and apoptotic effects on prostatic cells These activities in addition to epidemiologic findings that link Vitamin D to prostate cancer risk support the use of OH 2 D 3 for prevention or therapy of prostate cancer The molecular mechanisms by which OH 2 D 3 exerts antitumor effects on prostatic cells are not In addition there is heterogeneity among the responses of various prostate cell lines and primary cultures to OH 2 D 3 with regard to growth inhibition differentiation and apoptosis To understand the basis of these differential responses and to develop a better model of Vitamin D action in the prostate we performed cDNA microarray analyses of primary cultures of normal and malignant human prostatic epithelial cells treated with 50 nM of OH 2 D 3 for 6 and 24 CYP24 D 3 was the most highly upregulated gene Significant and early upregulation of dual specificity phosphatase 10 DUSP10 validated in five additional primary cultures points to inhibition of members of the protein kinase MAPK superfamily as a key event mediating activity of OH 2 D 3 in prostatic epithelial cells The functions of other regulated genes suggest protection by OH 2 D 3 from oxidative stress Overall these results provide new insights into the molecular basis of antitumor activities of Vitamin D in prostate cells View details for DOI View details for Web of Science ID 000226009000003 View details for PubMedID 15555907 Lower body mass index is associated with a higher prostate cancer detection rate and less favorable pathological features in a biopsy population JOURNAL OF UROLOGY Presti Lee Brooks Terris 2004 171 6 Abstract Body mass index BMI calculated as weight in kg divided by the square of height in m is used as an indicator of obesity We assessed the relationship between BMI and prostate cancer detection rates and biopsy features in a referral based biopsy total of 787 consecutive patients referred for abnormal digital rectal examination prostate specific antigen PSA greater than 4 underwent systematic prostate biopsy Three standard categories of BMI were considered namely than 25 to and or greater The presence or absence of cancer percent of core involvement and tumor grade were correlated with BMI Additional analyses controlled for patient age PSA and prostate the entire population detection rates were highest in the normal BMI group compared to the overweight or obese group 52 vs 37 vs 42 p When stratified by age this observation was true for men younger than 70 years 49 vs 32 vs 37 p but not for men 70 years or older When only patients with PSA 10 or less were considered detection rates were highest in the normal BMI group 44 vs 28 vs 36 p This observation also persisted in patients younger than 70 years with PSA 10 or less or when only patients younger than 70 years with a total prostate volume of less than 50 cc were included Of patients with cancer those with a normal BMI had a greater length of needle core involvement on BMI correlates with a higher cancer detection rate and larger cancers in men undergoing prostate biopsy View details for DOI View details for Web of Science ID 000221510300018 View details for PubMedID 15126785 Radiotherapy after radical prostatectomy Does transient androgen suppression improve outcomes 44th Annual Meeting of the King Presti Gill Brooks Hancock ELSEVIER SCIENCE 2004 Abstract The biochemical survival and overall survival were compared for patients receiving either radiotherapy RT alone or radiotherapy combined with a of total androgen suppression for failure after radical 1985 and 2001 a total of 122 patients received RT after radical prostatectomy at our institution of these patients received a of total androgen suppression TAS 2 months before and 2 months concurrent with RT with a nonsteroidal antiandrogen and an luteinizing hormone LHRH agonist combined therapy group the remaining 69 patients received RT alone Treatment failure was defined after postoperative RT as a detectable PSA Clinical and treatment variables examined included presurgical PSA clinical T stage pathologic Gleason sum pGS seminal vesicle SV involvement lymph node involvement surgical margins PSA prostate dose pelvic irradiation indication for postoperative RT salvage or adjuvant and time interval between surgery and RT Minimum after postoperative RT was 1 year and median was years maximum 14 years for patients receiving RT alone and years maximum 11 years for patients receiving RT with TAS combined therapy group analysis was performed for PSA survival bNED and for overall survival OS Cox proportional hazards multivariable analysis examined the influence all clinical and treatment variables predicting for bNED and median time to PSA failure after postoperative RT was years for the combined therapy group and years for the RT alone group p with no failures beyond 5 years At 5 years the actuarial bNED rates were 57 for the combined therapy group compared with 31 for the RT alone group p Overall survival rates at 5 years were 100 for the combined therapy group compared with 87 for the RT alone group p For pGS the bNED rates were 65 for combined therapy and 17 for RT alone p The OS rates for pGS was 100 for combined therapy and 54 for RT alone p On multivariable analysis only SV involvement p and the addition of TAS to postoperative RT p were significant covariates predicting for bNED and similarly approached significance for overall survival p and p respectively combined with a TAS after radical prostatectomy appears to confer a PSA survival advantage and possibly an overall survival advantage when compared with RT alone The hypothesis that a transient course of androgen suppression with salvage or adjuvant RT after prostatectomy improves outcomes will need to be tested in a randomized trial View details for DOI View details for Web of Science ID 000221440800002 View details for PubMedID 15145146 Analysis of vitamin gene expression in LNCaP human prostate cancer cells using cDNA microarrays PROSTATE Krishnan Shinghal Raghavachari Brooks Peehl Feldman 2004 59 3 Abstract D 3 OH 2D3 exerts growth inhibitory and effects on prostate cells To better understand the molecular mechanisms underlying these actions we employed cDNA microarrays to study OH gene expression in the LNCaP human prostate cancer isolated from LNCaP cells treated with vehicle or 50 nM OH 2D3 for various lengths of time were hybridized to microarrays carrying approximately genes Some of the putative target genes revealed by the microarray analysis were verified by PCR OH 2D3 most substantially increased the expression of the growth factor binding gene Our analysis also revealed several novel OH genes Interestingly some of the key genes regulated by OH 2D3 are also genes OH 2D3 also genes that mediate androgen putative OH 2D3 target genes appear to be involved in a variety of cellular functions including growth regulation differentiation membrane transport and interactions DNA repair and inhibition of metastasis The of gene has been shown to be crucial in OH inhibition of LNCaP cell growth OH 2D3 regulation of genes as well as genes involved in androgen catabolism suggests that there are interactions between OH 2D3 and androgen signaling pathways in LNCaP cells Further studies on the role of these genes and others in mediating the effects of OH 2D3 may lead to better approaches to the prevention and treatment of prostate cancer View details for DOI View details for Web of Science ID 000220910600003 View details for PubMedID 15042599 Time trends in pathologic features of radical prostatectomy impact of family history UROLOGIC AND ORIGINAL INVESTIGATIONS Marotte J Ferrari McNeal Brooks Presti 2004 22 3 Abstract We investigated whether the clinical or pathological features of patients with a family history of prostate cancer treated by radical prostatectomy differ from patients without a family history A retrospective analysis of patients treated by radical prostatectomy between 1989 through 2000 was performed The clinical and pathologic features of patients with a family history defined as at least one relative with prostate cancer N 103 were compared with those with no family history N 456 In addition the patients were stratified into two groups those treated from 1989 through 1992 and those treated after 1992 In the entire cohort from 1989 through 2000 patients with a family history had a greater proportion of tumors than the NFH group P From 1989 to 1992 there was no statistical difference between patients with a family history FH and those without a family history NFH with respect to age prostate specific antigen PSA PSA density clinical or pathologic stage Gleason grade or total tumor volume However after 1992 the FH group tended to be younger than the NFH group P and have a lower PSA P at the time of diagnosis We believe these differences are predominantly driven by more aggressive screening in patients with a family history of prostate cancer rather than any true genetic differences View details for DOI View details for Web of Science ID 000223195600002 View details for PubMedID 15271309 Prognostic significance of vascular invasion A of 621 radical prostatectomy patients Ferrari Malhotra McNeal Brooks LIPPINCOTT WILLIAMS WILKINS 2004 222 View details for Web of Science ID 000220495500841 Normal body mass index is associated with a higher prostate cancer detection rate and less favorable pathologic features in a biopsy population Presti Lee Brooks Terris LIPPINCOTT WILLIAMS WILKINS 2004 122 View details for Web of Science ID 000220495500459 Biochemical remission after resection of prostate cancer lung metastasis UROLOGY Chao Higgins Brooks 2004 63 3 Abstract Once metastatic prostate cancer was regarded as a systemic disease that is not amenable to surgical therapy We present a case of a solitary pulmonary recurrence of prostate cancer after radical prostatectomy that was resected resulting in 12 years of biochemical remission without additional therapy View details for DOI View details for Web of Science ID 000220223500041 View details for PubMedID 15028469 Gene expression in the normal adult human kidney assessed by complementary DNA microarray MOLECULAR BIOLOGY OF THE CELL Higgins Wang Kambham Montgomery Mason Vogelmann Lemley Brown Brooks van de Rijn 2004 15 2 Abstract The kidney is a highly specialized organ with a complex stereotyped architecture and a great diversity of functions and cell types Because the microscopic organization of the nephron the functional unit of the kidney has a consistent relationship to the macroscopic anatomy of the kidney knowledge of the characteristic patterns of gene expression in different compartments of the kidney could provide insight into the functions and functional organization of the normal nephron We studied gene expression in dissected renal lobes of five adult human kidneys using cDNA microarrays representing approximately different human genes Total RNA was isolated from sections of the inner and outer cortex inner and outer medulla papillary tips and renal pelvis and from glomeruli isolated by sieving The results revealed unique and highly distinctive patterns of gene expression for glomeruli cortex medulla papillary tips and pelvic samples Immunohistochemical staining using selected antisera confirmed differential expression of several cognate proteins and provided histological localization of expression within the nephron The distinctive patterns of gene expression in discrete portions of the kidney may serve as a resource for further understanding of renal physiology and the molecular and cellular organization of the nephron View details for DOI View details for PubMedID 14657249 Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells MOLECULAR BIOLOGY OF THE CELL Zhao Whitfield Xu Botstein Brooks 2004 15 2 Abstract Methylseleninic acid MSA has been shown to have potent anticancer activity and is an excellent compound for studying the anticancer effects of selenium in vitro To gain insights into the effects of MSA in prostate cancer we characterized the global transcriptional response of LNCaP an human prostate cancer cell line to MSA by using cDNA microarrays We identified 951 genes whose expression shows striking and changes in response to microM MSA over the time course of 48 Transcript levels of many cell genes change in response to MSA suggesting that MSA inhibits proliferation Consistent with these gene expression changes cell proliferation monitored by carboxyfluoroscein succinimidyl ester staining was decreased after MSA treatment and an accumulation of cells at phase was detected by flow cytometry Surprisingly MSA also modulated expression of many genes suppressed androgen receptor AR expression at both mRNA and protein level and decreased levels of prostate specific antigen secreted into the medium Low concentrations of MSA also induced significant increases in transcript levels of phase 2 detoxification enzymes and induced NADPH dehydrogenase quinone 1 enzymatic activity a surrogate marker of global phase 2 enzyme activity Our results suggest that MSA may protect against prostate cancer by inhibiting cell proliferation by modulating the expression of AR and genes and by inducing carcinogen defenses View details for DOI View details for Web of Science ID 000188718900012 View details for PubMedID 14617803 View details for PubMedCentralID PMC329225 Gene expression profiling identifies clinically relevant subtypes of prostate cancer PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA Lapointe Li Higgins van de Rijn Bair Montgomery Ferrari Egevad Rayford Bergerheim Ekman DeMarzo Tibshirani Botstein Brown Brooks Pollack 2004 101 3 Abstract Prostate cancer a leading cause of cancer death displays a broad range of clinical behavior from relatively indolent to aggressive metastatic disease To explore potential molecular variation underlying this clinical heterogeneity we profiled gene expression in 62 primary prostate tumors as well as 41 normal prostate specimens and nine lymph node metastases using cDNA microarrays containing approximately genes Unsupervised hierarchical clustering readily distinguished tumors from normal samples and further identified three subclasses of prostate tumors based on distinct patterns of gene expression and advanced stage tumors as well as tumors associated with recurrence were disproportionately represented among two of the three subtypes one of which also included most lymph node metastases To further characterize the clinical relevance of tumor subtypes we evaluated as surrogate markers two genes differentially expressed among tumor subgroups by using immunohistochemistry on tissue microarrays representing an independent set of 225 prostate tumors Positive staining for MUC1 a gene highly expressed in the subgroups with aggressive clinicopathological features was associated with an elevated risk of recurrence P whereas strong staining for AZGP1 a gene highly expressed in the other subgroup was associated with a decreased risk of recurrence P In multivariate analysis MUC1 and AZGP1 staining were strong predictors of tumor recurrence independent of tumor grade stage and preoperative antigen levels Our results suggest that prostate tumors can be usefully classified according to their gene expression patterns and these tumor subtypes may provide a basis for improved prognostication and treatment stratification View details for DOI View details for PubMedID 14711987 Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA Sperger Chen Draper Antosiewicz Chon Jones Brooks Andrews Brown Thomson J A 2003 100 23 Abstract Remarkably little is known about the transcriptional profiles of human embryonic stem ES cells or the molecular mechanisms that underlie their pluripotency To identify commonalties among the transcriptional profiles of different human pluripotent cells and to search for clues into the genesis of human germ cell tumors we compared the expression profiles of human ES cell lines human germ cell tumor cell lines and tumor samples somatic cell lines and testicular tissue samples by using cDNA microarray analysis Hierarchical cluster analysis of gene expression profiles showed that the five independent human ES cell lines clustered tightly together reflecting highly similar expression profiles The gene expression patterns of human ES cell lines showed many similarities with the human embryonal carcinoma cell samples and more distantly with the seminoma samples We identified 895 genes that were expressed at significantly greater levels in human ES and embryonal carcinoma cell lines than in control samples These genes are candidates for involvement in the maintenance of a pluripotent undifferentiated phenotype View details for DOI View details for Web of Science ID 000186573700044 View details for PubMedID 14595015 View details for PubMedCentralID PMC263817 Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray AMERICAN JOURNAL OF PATHOLOGY Higgins Shinghal Gill Reese Terris Cohen Fero Pollack van de Rijn Brooks 2003 162 3 Abstract Renal cell carcinoma comprises several histological types with different clinical behavior Accurate pathological characterization is important in the clinical management of these tumors We describe gene expression profiles in 41 renal tumors determined by using DNA microarrays containing unique cDNAs representing different UniGene Clusters including 7230 characterized human genes Differences in the patterns of gene expression among the different tumor types were readily apparent hierarchical cluster analysis of the tumor samples segregated histologically distinct tumor types solely based on their gene expression patterns Conventional renal cell carcinomas with clear cells showed a highly distinctive pattern of gene expression Papillary carcinomas formed a tightly clustered group as did tumors arising from the distal nephron and the normal kidney samples Surprisingly conventional renal cell carcinomas with granular cytoplasm were heterogeneous and did not resemble any of the conventional carcinomas with clear cytoplasm in their pattern of gene expression Characterization of renal cell carcinomas based on gene expression patterns provides a revised classification of these tumors and has the potential to supply significant biological and clinical insights View details for PubMedID 12598325 Biochemical recurrence without PSA progression characterizes a subset of patients after radical prostatectomy UROLOGY Shinghal Yemoto McNeal Brooks 2003 61 2 View details for DOI 02 View details for Web of Science ID 000181157600026 Differential patterns in genital fibroblasts of normal males and 46 XY females with androgen insensitivity syndrome evidence for early programming involving the androgen receptor GENOME BIOLOGY Holterhus Hiort Demeter Brown Brooks 2003 4 6 Abstract Androgen insensitivity syndrome AIS comprises a range of phenotypes from male infertility to complete feminization Most individuals with AIS carry germline mutations of the androgen receptor AR that interfere with or ablate its function As genital fibroblasts retain expression of the AR in vitro we used genital skin fibroblasts from normal males and 46 XY females with complete AIS due to known AR mutations to gain insights into the role of the AR in human genital DNA microarrays representing different genes we identified 404 transcripts with significant differences in transcription levels between genital skin fibroblasts cultured from normal and individuals analyses uncovered coordinated expression of genes involved in key processes of morphogenesis On the basis of animal studies and human genetic syndromes several of these genes are known to have specific roles in genital differentiation Remarkably genital fibroblasts from both normal and individuals showed no transcriptional response to dihydrotestosterone treatment despite expression of the results suggest that in addition to differences in the anatomic origin of the cells androgen signaling during prenatal development contributes to setting transcriptional programs in genital fibroblasts Our findings have broad implications in understanding the establishment and the stability of sexual dimorphism in human genital development View details for Web of Science ID 000183720100007 View details for PubMedID 12801411 Gene expression in the normal adult human kidney assessed by complementary DNA microarray Higgins Wang Kambham Montgomery Vogelmann Lemley Pollack van de Rijn Brooks LIPPINCOTT WILLIAMS WILKINS 2003 266A View details for Web of Science ID 000180720101226 Expression of FKBP12 in benign and malignant vascular endothelium An immunohistochemical study on conventional sections and tissue microarrays AMERICAN JOURNAL OF SURGICAL PATHOLOGY Higgins Montgomery Wang Domanay Warnke Brooks van de Rijn 2003 27 1 Abstract FKBP12 is a cytosolic FK506 binding protein that interacts with calcineurin and thereby mediates the immunosuppressive effects of FK506 Because initial immunohistochemical staining showed abundant expression of FKBP12 in vascular endothelial cells we evaluated whether it could serve as a marker for vascular neoplasms We performed immunohistochemical staining of conventional sections from tissue from 59 benign and malignant vascular neoplasms using a polyclonal rabbit antiserum against FKBP12 Western blot analysis of tissue from 6 angiosarcomas showed a single band at 12 kD consistent with the published molecular weight for the FKBP12 protein Together CD31 CD34 and FKBP12 identified all 59 vascular neoplasms in this study Specificity of immunohistochemical staining was assessed on tissues represented on 7 tissue microarrays All proteins were occasionally expressed in tissue Six of 8 vascular neoplasms represented on the arrays stained for FKBP12 as did normal vessels in numerous cores The polyclonal antiserum shows comparable sensitivity and specificity to CD34 and CD31 and may be a useful additional marker for vascular differentiation Because we have evaluated a large number of tissues by tissue microarray we anticipate that our estimate of the specificity of immunostaining for FKBP12 as a marker for vascular endothelium will be accurate In addition our findings may explain the toxic effects of FK506 on vascular endothelium of the kidney View details for PubMedID 12502928 Identification of potential prostate cancer preventive agents through induction of quinone reductase in vitro CANCER EPIDEMIOLOGY BIOMARKERS PREVENTION Brooks Goldberg Nelson Wu Nelson 2002 11 9 Abstract Human prostate cancer is characterized by an early and loss of expression of the phase 2 enzyme glutathione GSTP1 We hypothesize that a prostate cancer preventive strategy could involve induction of phase 2 enzymes within the prostate to compensate for the loss of GSTP1 expression NAD P H oxidoreductase quinone reductase or QR enzymatic activity a surrogate of phase 2 enzyme response was measured after treating the human prostate cancer cell line LNCaP with known phase 2 agents from 10 distinct chemical classes QR enzymatic activity was assayed in microtiter plates using the reduction of tetrazolium dye Degree of induction was expressed as over control and corrected for toxicity Compounds were also tested in an LNCaP subline selected in that expresses GSTP1 and in the human liver cell line HepG2 LNCaP showed robust induction of QR enzymatic activity after treatment with a subset of the phase 2 agents All Michael acceptors were effective at inducing QR activity in LNCaP Some phenolic antioxidants heavy metal salts and quinones also significantly increased QR activity although inducer potency varied widely within these classes of compounds Some of the isothiocyanates mercaptans bifunctional inducers and trivalent arsenicals also produced modest QR induction but peroxides and dithiolethiones were inactive and LNCaP responded similarly to all compounds but the pattern of response for HepG2 differed significantly The differences in QR responsiveness between the prostate cell lines and HepG2 suggest that prostate tissues may have a unique pattern of response to phase agents distinct from other tissue types Our data suggest that measurement of QR induction in prostate cancer cell lines may help identify potential cancer chemopreventive agents effective in the prostate View details for PubMedID 12223431 Polymorphisms in the androgen receptor and type II 5 genes and prostate cancer prognosis PROSTATE Shibata Garcia Cheng Stamey McNeal Brooks Henderson Yemoto Peehl 2002 52 4 Abstract repeat length of the androgen receptor gene and the A49T and V89L polymorphisms of the 5 SRD5A2 gene have been associated with prostate investigated the relationship of the three genetic polymorphisms to tumor grade among 211 men who had undergone radical prostatectomy Subjects had prostate cancer 3 cm 3 with a percentage of cancer represented by Gleason grade 4 or 5 Gleason grade of either or 20 or or 5 We also examined the association between those genetic markers and prostate specific antigen PSA failure among 112 subjects with or 20 Gleason grade analysis none of the polymorphisms was a significant predictor of Gleason grade In longitudinal analysis the LL genotype at the V89L site was associated with statistically significant to sixfold increase in PSA failure risk after adjustment for clinicopathologic observed poorer prognosis among men with the LL genotype at codon 89 of the SRD5A2 gene Lack of consistency between studies must be resolved before clinical utility of this marker is established View details for DOI View details for Web of Science ID 000177541200003 View details for PubMedID 12210487 Microarray analysis in prostate cancer research Current opinion in urology Brooks 2002 12 5 Abstract Microarray technologies are now being used to analyse prostate tumors and to gain insights into prostate cancer biology This review provides a background on microarray technology reviews recent applications of these techniques in prostate cancer research and discusses the potential application of this technology to patient analysis of changes in expression has identified several hundred genes differentially expressed by normal and malignant prostate tissues Some such as hepsin not only show increased expression in cancer but can also provide prognostic information on prostate tumors based on their level of expression Microarrays have also been used to characterize gene expression changes associated with androgen stimulation the activation of EGR1 pathways and prostate epithelial cellular analysis of gene expression in prostate cancer is in its infancy Future work will probably yield new diagnostic and prognostic markers provide insight into prostate cancer biology and aid in identifying new therapeutic strategies View details for PubMedID 12172426 Silencing of glutathione in MDA PCa 2a and MDA PCa 2b cells PROSTATE Vidanes Paton Wallen Peehl Navone Brooks 2002 51 4 Abstract Loss of expression of the glutathione GSTP1 is the most common genetic alteration described in human prostate cancer occurring in virtually all tumors regardless of grade or stage Of the available human prostate cancer cell lines only LNCaP mirrors this phenotype We investigated whether the prostate cancer cell lines MDA PCa 2a and MDA PCa 2b share this protein and mRNA levels were assessed in the MDA PCa 2a and MDA PCa 2b cell lines by Western and Northern blot DNA methylation was evaluated by Southern blot analysis of genomic DNA digested with the restriction enzymes BssHII NotI and SacII of GSTP1 was determined by following treatment with a DNA methyltransferase inhibitor the histone deacetylase inhibitor trichostatin A TSA all human prostatic carcinomas in vivo both the MDA PCa 2a and 2b cell lines lack protein and mRNA expression of GSTP1 This lack of expression is associated with methylation in the GSTP1 gene promoter Treatment with the methyltransferase inhibitor resulted in of GSTP1 By itself TSA did not result in of GSTP1 nor did it augment expression induced by PCa 2a and 2b appear to be useful models of human prostatic carcinoma in that they lack expression of GSTP1 due to gene silencing via promoter methylation Inhibition of histone acetylation does not appear to affect GSTP1 expression View details for DOI View details for Web of Science ID 000175909900001 View details for PubMedID 11987150 Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells JOURNAL OF BIOLOGICAL CHEMISTRY Schwarze DePrimo Grabert Fu Brooks Jarrard 2002 277 17 Abstract Cellular senescence forms a barrier that inhibits the acquisition of an immortal phenotype a critical feature in tumorigenesis The inactivation of multiple pathways that positively regulate senescence are required for immortalization To identify these pathways in an unbiased manner we performed DNA microarray analyses to assess the expression of genes in human prostate epithelial cells HPECs passaged to senescence These gene expression patterns were then compared with those of HPECs immortalized with the human Papillomavirus 16 E7 oncoprotein Senescent cells display gene expression patterns that reflect their nonproliferative differentiated phenotype and express secretory proteases and extracellular matrix components A comparison of genes transcriptionally in senescence to those in which expression is significantly in immortalized HPECs identified three genes the chemokine BRAK DOC1 and a member of the growth factor axis Expression of these genes is found to be uniformly lost in human prostate cancer cell lines and xenografts and previously their inactivation was documented in tumor samples Thus these genes may function in novel pathways that regulate senescence and are inactivated during immortalization These changes may be critical not only in allowing cells to bypass senescence in vitro but in the progression of prostate cancer in vivo View details for DOI View details for Web of Science ID 000175203000068 View details for PubMedID 11836256 systematic biopsy results are the most powerful predictors of cancer volume at radical prostatectomy Presti Brooks Gill Nolley McNeal LIPPINCOTT WILLIAMS WILKINS 2002 226 View details for Web of Science ID 000184566700913 Anatomy of the rectourethralis muscle EUROPEAN UROLOGY Brooks Eggener Chao 2002 41 1 Abstract To define the true anatomic structure of the rectourethralis images of fresh tissues from the Visible Human Data set were reviewed computer reconstructions of the rectourethralis and surrounding structures were generated from these data using a high speed computer and imaging software The structure of rectourethralis was confirmed by dissection of fresh rectourethralis arises deep within the substance of the smooth muscle of the rectal wall as two limbs of muscle which face posterolaterally These limbs fuse into a single thick muscle which inserts into the perineal contrast to all previous descriptions in the literature the rectourethralis is a muscle which arises within the substance of the rectal wall deep to the outer longitudinal smooth muscle This shape is consistent with the muscle embryologic origin Knowledge of the structure of the rectourethralis muscle will help urologists avoid rectal injuries during perineal approaches to the prostate View details for Web of Science ID 000174457200021 View details for PubMedID 11999473 Gene expression profiles in renal cell carcinoma assessed by complementary DNA microarray Higgins Shinghal Reese Terris Cohen Tibshirani Sherlock Fero Pollack Brown Botstein van de Rijn Brooks NATURE PUBLISHING GROUP 2002 164A View details for Web of Science ID 000173388900698 Transcriptional programs activated by exposure of human prostate cancer cells to androgen GENOME BIOLOGY DePrimo Diehn Nelson J Reiter Matese Fero Tibshirani Brown Brooks 2002 3 7 Abstract Androgens are required for both normal prostate development and prostate carcinogenesis We used DNA microarrays representing approximately genes to examine the temporal program of gene expression following treatment of the human prostate cancer cell line LNCaP with a synthetic observed statistically significant changes in levels of transcripts of more than 500 genes Many of these genes were previously reported androgen targets but most were not previously known to be regulated by androgens The expression programs in three additional human prostate cancer cell lines and in four subclones derived from LNCaP shared many features with those observed in LNCaP but some differences were observed A remarkable fraction of the genes induced by androgen appeared to be related to production of seminal fluid and these genes included many with roles in protein folding trafficking and cancer cell lines retain features of androgen responsiveness that reflect normal prostatic physiology These results provide a broad view of the effect of androgen signaling on the transcriptional program in these cancer cells and a foundation for further studies of androgen action View details for Web of Science ID 000207581200008 View details for PubMedID 12184806 Plasma selenium level before diagnosis and the risk of prostate cancer development JOURNAL OF UROLOGY Brooks Metter Chan Sokoll Landis Nelson Muller Andres Carter B 2001 166 6 Abstract Epidemiological studies and a randomized intervention trial suggest that the risk of prostate cancer may be reduced by selenium intake We investigated whether plasma selenium level before diagnosis correlated with the risk of later developing prostate case control study was performed on men from the Baltimore Longitudinal Study of Aging registry including 52 with known prostate cancer and 96 age matched controls with no detectable prostatic disease Plasma selenium was measured at an average time plus or minus standard deviation of years before the diagnosis of prostate cancer by graphite furnace atomic absorption spectrophotometry Adjusted odds ratio and 95 confidence interval were computed with logistic correcting for years before diagnosis body mass index and smoking and alcohol use history higher selenium was associated with a lower risk of prostate cancer Compared with the lowest quartile of selenium range to the odds ratios of the second to third to and fourth to quartiles were 95 confidence interval to to and to respectively p Furthermore plasma selenium decreased significantly with patient age p plasma selenium is associated with a 4 to increased risk of prostate cancer These results support the hypothesis that supplemental selenium may reduce the risk of prostate cancer Because plasma selenium decreases with patient age supplementation may be particularly beneficial to older men View details for PubMedID 11696701 GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells AMERICAN JOURNAL OF PATHOLOGY Lin Tascilar Lee Vles Lee Veeraswamy Asgari Freije Van Rees Gage Bova Isaacs Brooks DeWeese De Marzo Nelson 2001 159 5 Abstract GSTP1 CpG island hypermethylation is the most common somatic genome alteration described for human prostate cancer PCA lack of GSTP1 expression is characteristic of human PCA cells in vivo We report here that loss of GSTP1 function may have been selected during the pathogenesis of human PCA Using a variety of techniques to detect GSTP1 CpG island DNA hypermethylation in PCA DNA we found only hypermethylated GSTP1 alleles in each PCA cell in all but two PCA cases studied In these two cases CpG island hypermethylation was present at only one of two GSTP1 alleles in PCA DNA In one of the cases DNA hypermethylation at one GSTP1 allele and deletion of the other GSTP1 allele were evident In the other case an unmethylated GSTP1 allele was detected accompanied by abundant GSTP1 expression GSTP1 CpG island DNA hypermethylation was responsible for lack of GSTP1 expression by LNCaP PCA cells treatment of the cells with an inhibitor of DNA methyltransferases reversed the GSTP1 promoter DNA hypermethylation activated GSTP1 transcription and restored GSTP1 expression GSTP1 promoter activity assessed via transfection of GSTP1 reporter constructs in LNCaP cells was inhibited by CpG dinucleotide methylation Remarkably although selection for loss of GSTP1 function may be inferred for human PCA GSTP1 did not act like a tumor suppressor gene as LNCaP cells expressing GSTP1 either after treatment or as a consequence of transfection with GSTP1 cDNA grew well in vitro and in vivo Perhaps GSTP1 inactivation may render prostatic cells susceptible to additional genome alterations caused by electrophilic or oxidant carcinogens that provide a selective growth advantage View details for Web of Science ID 000171988000024 View details for PubMedID 11696442 Potent induction of phase 2 enzymes in human prostate cells by sulforaphane CANCER EPIDEMIOLOGY BIOMARKERS PREVENTION Brooks Paton Vidanes 2001 10 9 Abstract Two studies have documented reduced risk of prostate cancer in men who consume cruciferous vegetables Cruciferae contain high levels of the isothiocyanate sulforaphane Sulforaphane is known to bolster the defenses of cells against carcinogens through of enzymes of carcinogen defense phase 2 enzymes Prostate cancer is characterized by an early and near universal loss of expression of the phase 2 enzyme glutathione GST We tested whether sulforaphane may act in prostatic cells by increasing phase 2 enzyme expression The human prostate cancer cell lines LNCaP MDA PCa 2a MDA PCa 2b and were treated with microM sulforaphane in vitro LNCaP was also treated with an aqueous extract of broccoli sprouts Quinone reductase enzymatic activity a surrogate of global phase 2 enzyme activity was assayed by the reduction of tetrazolium dye Expression of and chains and microsomal GST was assessed by Northern blot analysis Sulforaphane and broccoli sprout extract potently induce quinone reductase activity in cultured prostate cells and this induction appears to be mediated by increased transcription of the gene Sulforaphane also induces expression of synthetase light subunit but not the heavy subunit and this induction is associated with moderate increases in intracellular glutathione levels Microsomal and glutathione transferases were also induced transcriptionally Sulforaphane induces phase 2 enzyme expression and activity significantly in human prostatic cells This induction is accompanied by but not because of increased intracellular glutathione synthesis Our findings may help explain the observed inverse correlation between consumption of cruciferae and prostate cancer risk View details for Web of Science ID 000170899000006 View details for PubMedID 11535546 Prevention of prostate cancer CLINICS OF NORTH AMERICA DePrimo Shinghal Vidanes Brooks 2001 15 3 Abstract Strategies for reducing the occurrence of prostate cancers will be critical in limiting the morbidity and mortality of this disease The long latency period of prostate tumors and improved understanding of prostate carcinogenesis suggest opportunities for effective preventive measures Because androgen is integral to prostatic carcinogenesis several preventive strategies under investigation target the androgen axis Epidemiologic and basic studies implicate dietary factors in prostate cancer development and suggest that altering diet may influence prostate cancer risk and progression Many of the micronutrients with preventive potential have antioxidant properties cellular defenses against oxidative stresses are likely to be crucial in reducing prostate carcinogenesis This article summarizes the current status and opportunities in prostate cancer prevention View details for Web of Science ID 000170718000004 View details for PubMedID 11525290 New molecular approaches for identifying novel targets mechanisms and biomarkers for prostate cancer chemopreventive agents Workshop Williams Brooks ELSEVIER SCIENCE 2001 Abstract Recently developed complementary DNA cDNA microarray technology allows simultaneous assessment of expression on many hundreds or thousands of genes simultaneously This technology holds great promise for providing new insights into prostate carcinogenesis that will reveal new targets for preventive intervention strategies In addition this technology will deepen understanding of the means by which putative preventive compounds exert their effects generating molecular genetic biomarkers of treatment efficacy Several putative preventive agents are currently under investigation and development of novel preventive strategies poses significant challenges High throughput approaches such as cDNA microarrays will speed discovery and progress in prostate cancer chemoprevention View details for Web of Science ID 000168170400018 Role of cytologic criteria in the histologic diagnosis of gleason grade 1 prostatic adenocarcinoma HUMAN PATHOLOGY McNeal Cohen Brooks 2001 32 4 Abstract Gleason grade 1 prostatic adenocarcinoma is defined by its gland architecture which resembles that of benign prostate more than any other grade It is characterized by closely spaced glands and expansile tumor border Cytoplasm is clear to pale superficially identical to benign nodular hyperplasia BPH However there is recent evidence that prostatic carcinoma including grade 1 has cytoplasm whose composition is distinctively different from BPH being filled with lipid rather than with the granules that characterize benign secretory cells or the nongranular protein matrix of other prostate cancers We reasoned that grade 1 cancer might also have additional distinctive cellular features we tested this hypothesis by observations on 17 grade 1 carcinoma foci found as components of transition zone cancers Unlike BPH secretory cells cells of grade 1 cancer were uniformly large with even straight borders laterally and luminally Nuclei appeared sometimes benign but were fixed in a basal row dissimilar to the uneven distribution in BPH Nuclear pyknotic foci cytoplasm and abundant dense luminal secretion were distinctively common Immunostain for transferase was negative in grade 1 cancer but lightly positive in BPH secretory cells These cytologic findings were proposed to be useful as diagnostic clues especially in biopsy samples in which architecture may be difficult to interpret HUM PATHOL View details for PubMedID 11331962 Preneoplastic prostate lesions An opportunity for prostate cancer prevention 4th Strang International Cancer Prevention Conference Nelson De Marzo DeWeese Lin Brooks Putzi Nelson Groopman Kensler NEW YORK ACAD SCIENCES 2001 Abstract Environmental factors especially the diet play a prominent role in the epidemic of prostate cancer PCA in the United States Many candidate dietary components have been proposed to influence human prostatic carcinogenesis including fat calories fruits and vegetables and various micronutrients but the specific roles dietary agents play in promoting or preventing PCA remain controversial We have collected evidence to suggest that GSTP1 the gene encoding the glutathione GST may serve a caretaker function for prostatic cells Although GSTP1 can be detected in normal prostatic epithelium in almost all PCA cases PCA cells fail to express GSTP1 polypeptides and lack of GSTP1 expression most often appears to be the result of somatic CpG island DNA methylation changes Loss of GSTP1 function also appears to be characteristic of prostatic epithelial neoplasia PIN lesions thought to represent PCA precursors We have recently learned that a new candidate early PCA precursor lesion proliferative inflammatory atrophy PIA characterized by proliferating prostatic cells juxtaposed to inflammatory cells contains epithelial cells that express high levels of GSTP1 These findings have formed the basis for a new model of prostatic carcinogenesis in which prostatic cells in PIA lesions subjected to a barrage of inflammatory oxidants induce GSTP1 expression as a defense against oxidative genome damage When cells with defective GSTP1 genes appear amongst the PIA cells such cells become vulnerable to oxidants and electrophiles that inflict genome damage that tends to promote neoplastic transformation to PIN and PCA cells Subsequently PIN and PCA cells with defective GSTPI genes remain vulnerable to similar stresses tending to promote malignant progression This new model for prostatic carcinogenesis has implications for the design of new prostate cancer prevention strategies Rational prevention approaches might include i restoration of GSTPI expression via treatment with inhibitors of CpG methylation ii compensation for inadequate GSTPI activity via treatment with inducers of general GST activity and iii abrogation of stresses via avoidance of exogenous carcinogens reduction of endogenous carcinogenic particularly oxidant stresses View details for Web of Science ID 000173778200012 View details for PubMedID 11795433 GSTP1 CpG island DNA hypermethylation in hepatocellular carcinomas INTERNATIONAL JOURNAL OF ONCOLOGY Tchou Lin Freije Isaacs Brooks Rashid De Marzo Kanai Hirohashi Nelson 2000 16 4 Abstract Glutathione enzymes that defend cells against damage mediated by oxidant and electrophilic carcinogens may be critical determinants of cancer pathogenesis We report here that the pathogenesis of hepatocellular carcinoma HCC one of the most common cancers in the world frequently involves an accumulation of somatic DNA methylation changes at GSTP1 the gene encoding the glutathione For our study Hep3B HCC cells and a cohort of 20 HCC tissue specimens were subjected to analysis for GSTP1 expression and for somatic GSTP1 alterations GSTP1 DNA hypermethylation in HCC DNA was assessed by Southern blot analysis via a polymerase chain reaction PCR assay and by using a genomic sequencing approach Hep3B HCC cells failed to express GSTP1 mRNA or GSTP1 polypeptides Similarly HCC cells in 19 of 20 HCC cases were devoid of GSTP1 polypeptides By Southern blot analysis DNA from Hep3B HCC cells displayed abnormal GSTP1 hypermethylation Treatment of Hep3B HCC cells in vitro with the DNA methyltransferase inhibitor both reversed GSTP1 DNA hypermethylation and restored GSTP1 expression Using a PCR assay somatic GSTP1 DNA hypermethylation was also detected in HCC DNA from 17 of 20 HCC cases Genomic sequencing analyses undertaken to map nucleotides located at the GSTP1 transcriptional regulatory region frequently detected somatic DNA hypermethylation near the gene promoter in HCC DNA The data indicate that GSTP1 DNA hypermethylation changes appear frequently in human HCC In addition the data raise the possibility that somatic GSTP1 inactivation via hypermethylation may contribute to the pathogenesis of HCC View details for Web of Science ID 000085926100003 View details for PubMedID 10717233 Absence of HinfI restriction abnormalities in renal oncocytoma mitochondrial DNA MOLECULAR UROLOGY Brooks Marshall Isaacs Johns 1999 3 1 Abstract Renal oncocytomas are characterized by eosinophilic cells with a profusion of mitochondria Previous work has suggested that these tumors possess a mutation in the circular mitochondrial DNA mtDNA manifested by an abnormal restriction fragment pattern after digestion with HinfI Welter et al Genes Chromosomes Cancer 1989 To better characterize this mtDNA abnormality in renal oncocytomas we amplified the entire mitochondrial genome from five paired normal and oncocytoma specimens and subjected the amplified fragments to digestion with the restriction enzyme HinfI No somatically acquired alterations were detected in the mtDNA from any of the five renal oncocytomas One specimen displayed a known HinfI polymorphism in the mtDNA from both the normal and oncocytoma tissues Our data do not support the existence of somatically acquired mitochondrial genome abnormalities in renal oncocytomas View details for Web of Science ID 000079433600001 Partial nephrectomy and caval thrombectomy for renal cell carcinoma in a solitary kidney with an accessory renal vein BJU INTERNATIONAL Pruthi Angell Brooks Gill 1999 83 1 View details for Web of Science ID 000079775000026 View details for PubMedID 10233469 Potent induction of carcinogen defence enzymes with sulforaphane a putative prostate cancer chemopreventive agent Prostate cancer and prostatic diseases Brooks Paton 1999 2 S3 S8 View details for PubMedID 12496788 CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia CANCER EPIDEMIOLOGY BIOMARKERS PREVENTION Brooks WEINSTEIN Lin Sun Pin Bova Epstein Isaacs Nelson 1998 7 6 Abstract Prostate intraepithelial neoplasia PIN is a purported prostate cancer precursor lesion and a candidate biomarker for efficacy assessment in prostate cancer chemoprevention trials Loss of expression of the glutathione enzyme GSTP1 which is associated with the hypermethylation of deoxycytidine residues in the CG island region of the GSTP1 gene is a finding in human prostate cancer GSTP1 expression was assessed by immunohistochemistry in 60 PIN samples adjacent to and distant from prostate adenocarcinoma Whereas abundant enzyme polypeptide expression was evident in all normal prostatic tissues all samples of PIN and adenocarcinoma were completely devoid of GSTP1 DNA from 10 PIN lesions was analyzed for GSTP1 CG island methylation changes using a PCR technique targeting a polymorphic ATAAA n repeat sequence in the promoter region of the GSTP1 gene Somatic GSTP1 CG island methylation changes were detected in DNA from 7 of the 10 PIN lesions Allele discrimination was possible for 5 of the 10 DNA samples 2 of the 5 samples exhibited DNA methylation changes at both alleles whereas 3 samples displayed no DNA methylation changes at either allele GSTP1 CG island methylation changes were present in each of the five homozygous samples Hypermethylation of the region of the GSTP1 gene may serve as an important molecular genetic biomarker for both prostate cancer and PIN The finding of frequent GSTP1 methylation changes in PIN and prostate cancer supports a role for PIN lesions as a prostate cancer precursor and may provide insight to the molecular pathogenesis of prostate cancer View details for Web of Science ID 000074029000013 View details for PubMedID 9641498 Male pelvic anatomy reconstructed from the visible human data set Brooks Chao Kerr LIPPINCOTT WILLIAMS WILKINS 1998 14 View details for Web of Science ID 000073081500054 Male pelvic anatomy reconstructed from the visible human data set JOURNAL OF UROLOGY Brooks Chao Kerr J 1998 159 3 Abstract To improve understanding of the male pelvic anatomy pertinent to urological surgery we performed computer generated reconstruction of the male pelvis from the Visible Human data total of 18 discrete anatomical structures including the prostate bladder urethra rectum and pelvic musculature was segmented from the Visible Human data obtained from the National Library of Medicine Using high speed computing and rendering software models of each structure were generated and assembled into composite reconstructions offer a revised view of pelvic anatomy as it has been traditionally depicted The lateral surfaces of the levator ani muscle are oriented vertically in the pelvis and directly applied to the entire lateral surface of the prostate The bladder rests primarily anterior to the prostate rather than directly above it as has been commonly depicted In the data and reconstructions the trigone and anterior fibromuscular stroma of the prostate appear as a single unit in continuity which may have functional implications for understanding the mechanisms of continence at the bladder neck The striated urethral sphincter appears circular with abundant tissue posteriorly This sphincteric muscle has greater length anteriorly than reconstructions provide unique insights into male pelvic anatomy They are a useful teaching tool for investigation and virtual reality modeling of the male pelvis View details for Web of Science ID 000071913700068 View details for PubMedID 9474171 Differentiation of colonic metaplasia from adenocarcinoma of urinary bladder HUMAN PATHOLOGY JACOBS Brooks Epstein I 1997 28 10 Abstract Colonic metaplasia and primary bladder adenocarcinoma are relatively uncommon entities that can have similar gross clinical appearances Examples of colonic metaplasia histologically mimicking cancer have only rarely been reported We retrospectively analyzed 38 cases of cystitis glandularis 18 cases of colonic metaplasia 12 cases of adenocarcinoma of urinary bladder two WDA and one in situ adenocarcinoma from the surgical pathology files of Johns Hopkins Hospital Nine patients with colonic metaplasia had widespread lesions Two showed superficial muscularis propria involvement mimicking adenocarcinoma one of these cases had been diagnosed as infiltrating WDA at both an academic center and a community hospital Dissecting mucin pools were focally seen in four cases of widespread colonic metaplasia also mimicking cancer One of the nine cases showed minimal cytological atypia but no cases showed mitoses or signet ring cells Distinguishing WDA from colonic metaplasia was the finding in WDA of infiltrative architectural pattern two of two extensive muscle invasion two of two moderate anaplasia one of two mitotic figures two of two and extensive mucinous pools one of two The diagnosis of adenocarcinoma in situ was based on anaplasia Clinically colonic metaplasia may resemble cancer Histologically colonic metaplasia may mimic cancer based on extensive involvement of the lamina propria focal mucinous pools focal muscularis propria involvement focal mild cytological atypia and rare mitoses Despite overlapping features with colonic metaplasia the diagnosis of WDA is based on the greater degree and extent of these atypical findings in cancer View details for Web of Science ID A1997YD80100007 View details for PubMedID 9343322 The Swedish prostate cancer paradox OF THE AMERICAN MEDICAL ASSOCIATION Walsh Brooks 1997 277 6 View details for Web of Science ID A1997WG05400039 View details for PubMedID 9020276 Methylation of the 5 CpG island of the endothelin B receptor gene is common in human prostate cancer CANCER RESEARCH Nelson J Lee Nguyen Jarrard Brooks Magnuson Opgenorth Nelson Bova 1997 57 1 Abstract Production of the potent vasoconstrictor by human prostate cancer cells accompanies prostate cancer progression in vivo The predominant endothelin receptor expressed by normal prostate epithelium ETB is not expressed by any of the established human prostate cancer cell lines and ETB binding is decreased on prostate cancer tissues ETB which may mediate clearance and may inhibit secretion is encoded by a gene that contains a 5 CpG island encompassing the transcriptional regulatory region We examined this regulatory region of the ETB receptor gene EDNRB to determine whether hypermethylation of cytidine nucleotides accompanies decreased ETB expression in human prostate cancer We found somatic methylation of CpG island sequences in EDNRB in 5 of 5 human prostate cancer cell lines 15 of 21 primary prostate cancer tissues and 8 of 14 prostate cancer metastases 70 of samples overall Normal tissues contained only unmethylated EDNRB Treatment of human prostatic carcinoma cell line cultures with induced ETB mRNA expression suggesting that CpG island methylation changes might accompany the apparent transcriptional silencing of EDNRB in vivo View details for Web of Science ID A1997WA69100009 View details for PubMedID 8988036 An uncertain role for p53 gene alterations in human prostate cancers CANCER RESEARCH Brooks Bova Ewing PIANTADOSI Carter Robinson Epstein Isaacs B 1996 56 16 Abstract Inactivation of the p53 gene has been implicated in prostate cancer progression To determine the role of p53 inactivation in the progression of clinical prostatic carcinomas we assessed 67 tumors derived from patients with clinically localized disease for chromosome 17p and p53 gene allelic loss p53 gene mutations using conformational polymorphism and direct sequencing and p53 protein expression using immunohistochemical staining Of 55 informative tumors 10 demonstrated loss of 17p or the p53 gene however only a single tumor had a mutation in its remaining p53 allele Significant p53 overexpression was observed in 2 of 38 tumors and 9 others had faint staining of a few nuclei 1 p53 overexpression occurred in no informative tumor with allelic loss or mutation In a positive immunohistochemical staining did not confer an increased risk of recurrence risk of recurrence P whereas allelic loss of chromosome 17p appeared to be highly correlated with recurrence risk of recurrence P In an unrelated group of 42 patients with metastatic prostate cancer p53 overexpression was found in 26 tumors 62 and 15 36 had high grade staining Neither the presence nor the degree of expression correlated with time to progression or time to death This series suggests that p53 gene inactivation is rare in primary prostatic tumors not essential to the development of prostate cancer metastases and of limited use as a prognostic marker in patients with primary or metastatic disease Another gene or genes on chromosome 17p may be involved in prostate cancer progression View details for Web of Science ID A1996VB98600038 View details for PubMedID 8706029 Epidemiologic and molecular features of prostate carcinogenesis as clues for new prostate cancer prevention strategies Canadian Journal of Urology Brooks JD Lee WH Nelson WG 1996 3 Supplement Molecular staging of prostate cancer Canadian Journal of Urology Lee WH Brooks JD Nelson WG 1996 3 Supplement UPJ obstruction assessing minimally invasive therapies Contemporary urology Moore Brooks 1995 7 12 View details for PubMedID 10172648 COMPARISON OF OPEN AND ENDOUROLOGICAL APPROACHES TO THE OBSTRUCTED URETEROPELVIC JUNCTION UROLOGY Brooks Kavoussi Preminger Schuessler Moore 1995 46 6 Abstract To compare open pyeloplasty with three minimally invasive modalities antegrade endopyelotomy Acucise endopyelotomy Applied Medical Laguna Hills Calif and laparoscopic adult patients with ureteropelvic junction obstruction were managed by one of the above four techniques Success rates analgesic use length of hospital stay recovery time and complications were compared between each of the four relief of obstruction was achieved in 100 of patients undergoing open and laparoscopic dismembered pyeloplasty 78 undergoing Acucise endopyelotomy and 77 undergoing antegrade percutaneous endopyelotomy Acucise endopyelotomy results in shorter convalescence 1 week than antegrade endopyelotomy weeks laparoscopic pyeloplasty weeks or open pyeloplasty weeks Complication rates appear to be similar among all limited data imply that Acucise endopyelotomy offers low morbidity with success rates comparable to antegrade pyeloplasty whereas laparoscopic pyeloplasty is as effective as open pyeloplasty with diminished morbidity View details for Web of Science ID A1995TJ34700007 View details for PubMedID 7502417 AND CHROMOSOMAL ALTERATIONS IN National Conference on Prostate Cancer Isaacs Bova Morton Bussemakers Brooks Ewing 1995 View details for Web of Science ID A1995QP39300040 ALLELIC LOSS OF THE RETINOBLASTOMA GENE IN PRIMARY HUMAN PROSTATIC ADENOCARCINOMAS PROSTATE Brooks Bova Isaacs B 1995 26 1 Abstract Inactivation of the retinoblastoma Rb gene has been implicated in the genesis and progression of a number of tumor types including prostatic adenocarcinomas We have analyzed a series of 46 human prostatic adenocarcinomas for allelic loss of the Rb gene with PCR amplification of a highly polymorphic region of the gene 41 of 46 tumors 89 were informative and 11 of these 27 had lost one Rb allele The relative frequency of this occurrence suggests that inactivation of the retinoblastoma gene may be an important event in prostate carcinogenesis View details for Web of Science ID A1995QE72800007 View details for PubMedID 7845865 FREQUENT LOSS OF CHROMOSOME ARMS 8P AND 13Q IN COLLECTING DUCT CARCINOMA CDC OF THE KIDNEY GENES CHROMOSOMES CANCER Schoenberg Cairns Brooks Marshall Epstein Isaacs Sidransky 1995 12 1 Abstract Collecting duct carcinoma CDC is a malignant renal neoplasm that is believed to arise from the epithelium of the ducts of Bellini in the distal nephron These tumors are clinically aggressive and more often occur in a younger population than is typical of the more common clear cell renal carcinoma RCC Using highly informative polymorphic microsatellite markers on chromosome arms 3p 5q 6q 9p 9q 11p 13q 17p and 18q we analyzed DNA from nonmalignant and tumor tissue in 6 cases of CDC We found no evidence of 3p loss of heterozygosity LOH in these renal tumors by using multiple markers a finding that distinguishes CDC from RCC in which 3p LOH has frequently been observed We found LOH of 8p in 50 of the tumors examined in addition we observed LOH of 13q in 50 of the tumors studied Interestingly 8p LOH may be associated with high stage and poor clinical prognosis These data suggest that the molecular events responsible for the development of CDC differ from those associated with the origin of RCC and that tumor suppressor genes on 8p and 13q may be involved in the pathogenesis of CDC View details for Web of Science ID A1995QU21600014 View details for PubMedID 7534117 OF PROGRESSION CANCER SURVEYS Isaacs Bova Morton Bussemakers Brooks Ewing 1995 23 Abstract A number of genetic changes have been documented in prostate cancer ranging from allelic loss to point mutations and changes in DNA methylation patterns summarized in Fig 1 The most consistent changes seen are those of allelic loss events with the majority of tumours examined showing loss of alleles from at least one chromosomal arm The short arm of chromosome 8 followed by the long arm of chromosome 16 seem to be the most frequent regions of loss suggesting the presence of novel tumour suppressor genes Deletions of one copy of the RB and TP53 genes are less frequent as are mutations of the TP53 gene and accumulating evidence suggests the presence of an additional tumour suppressor gene on chromosome 17p which is frequently inactivated in prostate cancer Alterations in the catenin mediated adhesion mechanism appear to be present in almost half of all prostate cancers and may be critical to the acquisition of metastatic potential of aggressive prostate cancers Finally altered DNA methylation patterns have been found in the majority of prostate cancers examined suggesting widespread alterations in methylation modulated gene expression The presence of multiple changes in these tumours is consistent with the multistep nature of the transformation process Finally efforts to identify prostate cancer susceptibility loci are under way which may elucidate critical early events in prostatic carcinogenesis View details for Web of Science ID A1995RH96200003 View details for PubMedID 7621457 Embryonal adenoma of the kidney case report Journal of Urology Perlman EJ Brooks J Gordon AH Griffin CA Schoenberg M 1995 154 CYTIDINE METHYLATION OF REGULATORY SEQUENCES NEAR THE GENE ACCOMPANIES HUMAN PROSTATIC CARCINOGENESIS PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA Lee Morton Epstein Brooks Campbell Bova Hsieh Isaacs Nelson 1994 91 24 Abstract Hypermethylation of regulatory sequences at the locus of the glutathione gene GSTP1 was detected in 20 of 20 human prostatic carcinoma tissue specimens studied but not in normal tissues or prostatic tissues exhibiting benign hyperplasia In addition a striking decrease in GSTP1 expression was found to accompany human prostatic carcinogenesis Immunohistochemical staining with antibodies failed to detect the enzyme in 88 of 91 prostatic carcinomas analyzed In vitro GSTP1 expression was limited to human prostatic cancer cell lines containing GSTP1 alleles with hypomethylated promoter sequences a human prostatic cancer cell line containing only hypermethylated GSTP1 promoter sequences did not express GSTP1 mRNA or polypeptides Methylation of cytidine nucleotides in GSTP1 regulatory sequences constitutes the most common genomic alteration yet described for human prostate cancer View details for Web of Science ID A1994PU28500092 View details for PubMedID 7972132 OF SEMINARS IN ONCOLOGY Isaacs Bova Morton Bussemakers Brooks Ewing 1994 21 5 Abstract A number of genetic changes have been documented in prostate cancer ranging from allelic loss to point mutations and changes in DNA methylation patterns summarized in Fig 1 To date the most consistent changes are those of allelic loss events with the majority of tumors examined showing loss of alleles from at least one chromosomal arm The short arm of chromosome 8 followed by the long arm of chromosome 16 appear to be the most frequent regions of loss suggesting the presence of novel tumor suppressor genes Deletions of one copy of the Rb and p53 genes are less frequent as are mutations of the p53 gene and accumulating evidence suggests the presence of an additional tumor suppressor gene on chromosome 17p which is frequently inactivated in prostate cancer Alterations in the catenin mediated adhesion mechanism appear to be present in almost half of all prostate cancers and may be critical to the acquisition of metastatic potential of aggressive prostate cancers Finally altered DNA methylation patterns have been found in the majority of prostate cancers examined suggesting widespread alterations in gene expression The presence of multiple changes in these tumors is consistent with the multistep nature of the transformation process Finally efforts to identify prostate cancer susceptibility loci are underway and will hopefully elucidate critical early events in prostatic carcinogenesis View details for Web of Science ID A1994PM94000002 View details for PubMedID 7939745 LAPAROSCOPIC MANAGEMENT OF TESTICULAR PAIN AFTER EMBOLOTHERAPY OF VARICOCELE JOURNAL OF ENDOUROLOGY Brooks Moore Kavoussi 1994 8 5 Abstract We report a patient who underwent embolization of a varicocele for chronic testicular pain with Gianturco coils and developed increased bilateral pain Complete pain relief was achieved by laparoscopic resection of both spermatic cords The case provides insights into the pathophysiology of testicular pain and may suggest alternative therapies for chronic orchialgia View details for Web of Science ID A1994PQ01200010 View details for PubMedID 7858624 Mutations of the VHL tumour suppressor gene in renal carcinoma Nature Genetics Gnarra JR Tory K Weng Y Schmidt L Wei MH Li H Latif F Liu S Chen F Duh FM Lubensky I Duan DR Florence C Pozzatti R Walther MM Bander NH Grossman HB Braunch H Pomer S Brooks JD Isaacs WB Lerman MI Zbar B Linehan WM 1994 7 GENETIC ALTERATIONS IN 59th Cold Spring Harbor Symposium on Quantitative Biology The Molecular Genetics of Cancer Isaacs Bova Morton Bussemakers Brooks Ewing COLD SPRING HARBOR LAB PRESS PUBLICATIONS DEPT 1994 Abstract A number of genetic changes have been documented in prostate cancer ranging from allelic loss to point mutations and changes in DNA methylation patterns summarized in Fig 1 To date the most consistent changes are those of allelic loss events with the majority of tumors examined showing loss of alleles from at least one chromosomal arm The short arm of chromosome 8 followed by the long arm of chromosome 16 appear to be the most frequent regions of loss suggesting the presence of novel tumor suppressor genes Deletions of one copy of the Rb and p53 genes are less frequent as are mutations of the p53 gene and accumulating evidence suggests the presence of an additional tumor suppressor gene on chromosome 17p which is frequently inactivated in prostate cancer Alterations in the adhesion mechanism appear to be present in almost half of all prostate cancers and may be critical to the acquisition of metastatic potential of aggressive prostate cancers Finally altered DNA methylation patterns have been found in the majority of prostate cancers examined suggesting widespread alterations in gene expression The presence of multiple changes in these tumors is consistent with the multistep nature of the transformation process Finally efforts to identify prostate cancer susceptibility loci are under way and may elucidate critical early events in prostatic carcinogenesis View details for Web of Science ID A1994RH96600074 View details for PubMedID 7587126 GENE ALLELIC LOSS IN HUMAN RENAL CANCERS JOURNAL OF UROLOGY Brooks Bova Marshall Isaacs B 1993 150 4 Abstract It is now apparent that multiple genetic alterations including oncogene activation and tumor suppressor gene inactivation are necessary steps in carcinogenesis We have studied this concept in renal cancers by looking at specific tumor suppressor genes implicated in several allelotyping studies Primary predominantly low stage renal tumors of varying grades and histologic subtypes were investigated for allelic loss of 3p 17p and the p53 gene the DCC gene and the Rb gene and its product 3p loss occurred in 47 of tumors studied and was much more common in clear cell cancers 85 17p and p53 gene loss were relatively uncommon events with only 6 of 42 tumors demonstrating loss None of the tumors with typical histologies had allelic loss of the DCC gene though loss did occur in leiomyosarcoma and a collecting duct tumor Allelic loss of the Rb gene occurred in one clear cell tumor the leiomyosarcoma and interestingly in both collecting duct tumors in this series Allelic loss of the Rb gene was correlated with little or no RB protein expression as judged by immunohistochemistry At all loci studied allelic loss did not appear to correlate with tumor grade or stage These results suggest that inactivation of the p53 Rb and DCC genes by allelic loss are uncommon events in the early stages of renal carcinogenesis View details for Web of Science ID A1993LX76200066 View details for PubMedID 8371415 TUBULARIZED NEOURETHRA FOLLOWING RADICAL RETROPUBIC PROSTATECTOMY JOURNAL OF UROLOGY Steiner Burnett Brooks Brendler STUTZMAN Carter B 1993 150 2 Abstract A cm tubularized neourethra was formed using an anterior bladder flap as part of bladder neck reconstruction after radical retropubic prostatectomy in 69 consecutive patients with clinically localized prostate cancer study group Postoperative continence defined as requiring no protection for any activity was assessed by history at 3 months all men and 6 months 45 of 69 men Continence in the study group was compared to that of 45 men with 6 months of followup who underwent radical retropubic prostatectomy without tubularization of the anterior bladder control group At 3 months 38 of 69 men 55 were continent in the study group and 14 of 45 31 were continent in the control group p At 6 months 39 of 45 men 87 were continent in the study group compared to 21 of 45 47 in the control group p Upright cystograms performed on men with and without the tubularized neourethra after radical retropubic prostatectomy suggest that a neourethra proximal to the external sphincter may increase resistance in this area and result in early return of urinary control in men undergoing radical retropubic prostatectomy View details for Web of Science ID A1993LM76500032 View details for PubMedID 8326564 Regional DNA Hypermethylation at D17S5 precedes 17p structural changes in the progression of renal tumors Cancer Research Makos M Nelkin BD Reiter RE Gnarra JR Brooks J Isaacs W Linehan M Baylin SB 1993 53 Genetic alterations in prostate cancer prognostic implications Akteulle Onkologie Isaacs WB Bova GS Brooks JD Ewing CM Morton RA Robinson JC 1993 78 DOPAMINE UPTAKE BLOCKERS PROTECT AGAINST THE DOPAMINE DEPLETING EFFECT OF MPTP IN THE MOUSE STRIATUM NEUROSCIENCE LETTERS Ricaurte Langston DeLanney Irwin Brooks 1985 59 3 Abstract MPTP a recently described neurotoxin produces a marked dopamine DA depletion in the mouse striatum In this study a series of DA uptake blockers was tested for their ability to prevent this effect of MPTP The agents tested amfonelic acid benztropine bupropion and mazindol completely protected against DA depletion in the mouse striatum when given before doses of MPTP were administered whereas atropine and trihexyphenidyl which were employed for comparative purposes did not DA uptake blocking agents appear to represent a second general class of compounds monoamine oxidase inhibitors being the first which protect against the biologic effects of MPTP in the mouse View details for Web of Science ID A1985ASY5800005 View details for PubMedID 3932903 Report Accessibility Issues Powered By CAP Network Stanford University SU Home Maps Directions Search Stanford Terms of Use Copyright Complaints Stanford University Stanford California 94305
https://profiles.stanford.edu/james-brooks